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 CHAPTER 1 
Literature review 
1. Environmental contamination and human health 
1.1 Introduction 
 “De aere, aquis et locis” from Hippocrates (460-377 BC) is the earliest human 
ecology study which recognized the relationship between environmental pollution and 
human health and which reported on the influence of nutrition, occupation and climate 
in causing diseases. Likewise, Ancient Roman writers such as Vitruvius, Plutarch and 
Pliny the Elder reported the toxic effects of mercury, lead and zinc towards workers in 
industrial sites such as mines and smelters (Vitruvius, 25BC). Recent reports suggest 
that about one quarter to one third of the human diseases in the world can be directly 
attributed to environmental factors (EEA, 2003). Therefore, a lot of attention has been 
payed by international institutions such as the World Health Organization (WHO), the 
Organization of Econonomic Cooperation and Development (OECD), Environmental 
Protection Agency (EPA) and the European Centre For Ecotoxicology and Toxicology 
of Chemicals (ECETOC) since the 1990s to the development of Human Health Risk 
Assessment (HHRA) and Environmental Risk Assessment (ERA) studies. Although the 
cause-effect relationship from pure chemicals is reasonably understood, the actual 
health consequences from these compounds when present in environmental matrices 
or mixed with other contaminants, are difficult to assess. Additionally, the complexity of 
environmental pollution phenomena is ever increasing, showing the importance and 
relevance to investigate, clarify and identify the relationship between environmental 
pollution and human or environmental health. The complexity of the exposure 
pathways of environmental contaminants towards human or ecological receptors can 
be observed from the multitude of processes that determine the environmental fate 
and concentrations of contaminants in the four main environmental compartments: air, 
water, soil and biomass (Figure 1.1).  
 
A domain of risk assessment which needs further attention is the human exposure 
to soil-bound contaminants by ingestion. A first issue is that chemicals may have 
different degrees of binding to soil, nutrition or liquid matrices, thus changing their 
availability for uptake by the human body. This results in different degrees of internal 
exposure to the chemical, depending on the compound, the matrix or other 
environmental factors. Those processes that precede this biological availability or in 
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short, bioavailability, are currently not well understood. Scientific research will allow to 
develop better methods by which a more accurate prediction of the bioavailable 
fraction of ingested contaminants may be obtained.  
Secondly, there is increasing concern about the behavior of ingested contaminants 
in the gastrointestinal tract with respect to their biological activity. Although the 
bioactivation or inactivation of chemicals by human biotransformation enzymes is 
extensively studied and well understood by environmental scientists, pharmacologists 
and toxicologists, there is only limited knowledge on the biotransformation potency 
from the vast microbial community residing in the human large intestine. It is believed 
that the microbial metabolic potency may be as diverse as the human 
biotransformation processes. This may have considerable consequences when 
assessing the health risks from ingested contaminants, since the toxicity of 
bioavailable chemicals largely depends on their degree of metabolization. 
 
 
Figure 1.1 Important pathways for the transfer of chemical substances between several 
compartments of the natural and man-made environment. (Source:  EEA, 1999) 
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1.2 Human health risk assessment 
1.2.1 Risk management process 
The 1990s have brought considerable activity in the field of risk assessment. With 
regards to environmental pollution, regulatory decisions that are issued by international 
and national environmental institutes, are based upon risk assessment studies. The 
objective of human health risk assessment is to determine the likelihood that exposure 
to a toxic chemical will have adverse effects on human health and to quantitatively 
estimate the magnitude of the effects. Human health risk assessment is not only a 
central theme in the management of environmental pollution hazards, but also in the 
control of chemicals that are brought on the market. In essence, the process of 
managing health risks consists of the risk assessment step and the risk management 
step. The assessment of risks towards human health can basically be split up in four 
major components (Figure 1.2) (NRC, 2003): hazard identification, exposure 
assessment, dose-response assessment and risk characterization. 
Hazard identification
Dose-response 
assessment Exposure assessment 
Risk characterization
Risk classification 
Risk-benefit analysis 
Risk reduction
Monitoring 
 
Figure 1.2  Steps in the risk assessment and risk management process 
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i) The hazard identification process is a systematic planning stage that identifies the 
important points that need to be covered by all subsequent steps in the HHRA. It 
identifies the adverse effects, inherently associated with environmental contaminants, 
it gathers and evaluates the data that describe whether the possibility of direct or 
indirect human exposure exists, and it points towards the possible health effects 
following exposure.  
ii) Exposure assessment estimates the magnitude of actual or potential human 
exposure to a contaminant of concern, the frequency of this exposure and its duration. 
It is probably the most uncertain part of risk assessment because of the lack of 
information on emission factors during the production of chemicals (point-source 
emission) and about the use of chemicals in various products and their emissions 
(diffuse sources of pollution). The number of exposure pathways from environmental 
contaminants to the human body is numerous and variable. The routes of exposure 
are more easily distinguished: dermal contact, inhalation and ingestion. An important 
output of the exposure assessment step is the determination of the PEC, or predicted 
environmental concentration, which is used to estimate the total daily intake.  
iii) Dose-response assessment characterizes the relation between the dose of an 
agent administered or received and the incidence of an adverse health effect. This 
step estimates the probability that an individual will experience negative health effects 
upon exposure to a chemical or a contaminated matrix. Data are usually obtained from 
animal laboratory studies, experimental field studies or less frequently from 
epidemiological studies of human populations. For most chemicals, laboratory derived 
no effect levels (NEL) are converted into predicted NELs or PNELs. Often, predicted 
no effect concentrations (PNEC) are derived. Another frequently used parameter in 
dose-response assessment is the No Observable (adverse) Effect Level (NOEL). 
iv) Risk characterization integrates the exposure assessment and dose-response 
assessment into a quantitative and qualitative expression of risk. Basically, the PEC 
and the PNEC from the exposure and dose-response assessment respectively are 
integrated to give a risk quotient. This risk quotient will eventually serve as a basic 
parameter for the risk characterization.  
These four corner stones form the basis for the risk management step. The 
subsequent step is the risk classification which is used to validate whether risk 
reduction is required. Decisions about risk classification are always related to decision 
about what risk level is acceptable. In order to obtain some kind of risk acceptability 
classification, two levels are distinguished: the maximum permissible level (MPL) and 
the negligible level (NL). An important differentiation should be made for compounds 
which do not have a treshold levels, such as carcinogens and mutagens. For these 
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compounds, a linear relationship is assumed between exposure (dose) and effect 
(incidence of cancer). Statistically, effects can therefore always occur. In such cases, 
the risk number is expressed as “maximal tolerable risk” or “negligible risk” and it 
represents the probability of additional cancer cases occurring. Once the risk 
classification process is completed, the risk-benefit analysis is carried out, which is 
basically a cost-benefit analysis. This step is multifactorial, since it needs to consider 
the technical feasibility of future risk reduction steps, the financial costs, social factors, 
legislative factors and multidisciplinary research. The outcome of the risk-benefit 
analysis leads to decisions about what risk reduction measures are taken to protect 
humans from the identified risks. With respect to chemicals that pose a threat to the 
environment or human health in particular, classification and labeling chemicals is 
required on the basis of their intrinsic properties. If it concerns contaminated sites or 
specific pathways of exposure, the operator, manufacturer or user is responsible for 
lowering the risk level to as low as reasonably achievable (ALARA). Safety and quality 
standards comprise guidelines, objectives and standards which assist in the risk 
reduction process. Well-known examples of these standards are Threshold Limit 
Values (TLV) and Acceptable Daily Intake (ADI).  
 
1.3 Exposure routes for soil contaminants 
Chemicals may reach the human body through soil, water, and air. These media 
serve as vehicles that carry chemicals to potential receptors. For soil contaminants 
specifically, the most important exposure pathways are direct soil contact, groundwater 
exposure and occupational exposure (e.g. construction workers). Besides these 
exposure pathways three direct exposure routes can be distinguished which refer to 
the ways that chemicals are transferred from environmental media into the body: 
inhalation, dermal contact and ingestion. For soil contamination in particular, all three 
routes are relevant but dermal contact and ingestion are the most likely exposure 
routes.  
Inhalation 
Human exposure to soil-borne contaminants by inhalation is less frequent than 
dermal contact or ingestion, but may occur when the chemical volatilizes from the soil 
(for example organic compounds) and is inhaled in the vapor phase, or when soil 
particles as such, containing the chemical, are respired (NRC, 2003). When 
contaminants as such or their particulate carriers are inhaled and pass the 
nose/mouth, they reach the pulmonary tract which consists out of an upper part, the 
tracheobronchial region, and a lower part, the alveolar region. The tracheobronchial 
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region is composed of a layer of cilia and mucus and an epithelium of 50 µm thick, 
followed by the blood capillaries. The rate of contaminant absorption in this part of the 
pulmonary tract is low since it takes more time for the contaminants to cross the thick 
epithelium. This longer residence time however also allows for the metabolism of 
inhaled chemicals and is responsible for the fact that 95% of all lung cancers are 
located in this region of the lungs. The alveolar region with the alveoli contains an 
epithelium which is only 5 µm thick and which is followed by the blood capillaries. This 
thin epithelium causes contaminants to be rapidly absorbed across the epithelium 
upon which they reach the blood stream through the capillaries. 
Soil-bound contaminants which have a low vapor pressure may volatilize from the 
soil or groundwater by desorption of the chemical from the soil matrix, movement from 
the soil pores to the soil surface and mixing with the atmosphere. This process is 
largely dependent on the contaminant vapor pressure, the concentration of the 
contaminant in the soil with depth and the interaction of the compound with the soil 
matrix by sorption (Cockerham and Shane, 1994). Best known examples are the BTEX 
compounds (benzene, toluene, ethylbenzene, xylene) and other volatile organic 
compounds. If contaminants are inhaled as vapors, they are assumed to be 100% 
bioavailable. 
Respirable particles are considered to be smaller than 10 µm and have been 
estimated to make up 30 to 50% of the total suspended air particles (Paustenbach, 
1988). About 50% of these particulates may be deposited in the tracheobronchial 
region. Subsequently, they move upwards by mucociliary activity and are eventually 
swallowed and taken up in the gastrointestinal tract. Exposure of these initially inhaled 
particles is therefore occurring through the gastrointestinal tract. The remaining 
particles may reach the alveoli. Particulate material can be divided in to PM-2.5 
particles, fine particles smaller than 2.5 µm in diameter, and PM-10 particles, coarse 
particles smaller than 10 µm in diameter. Combustion products from motor vehicles, 
the industry and residential fireplaces usually give rise to fine particles, whereas 
coarse particles arise from traffic, construction sites, wind erosion and material 
handling. In general, the inhalation of particles is fairly relevant for organic compounds 
with low vapor pressures such as polychlorinated biphenyls (PCB) and polycyclic 
aromatic hydrocarbons (PAH) (NEPI, 2000).  
Dermal contact 
The skin protects the human body from external influences by an outer epidermis 
which consists of a non-viable cell layer, the stratum corneum and an inner layer 
consisting of viable cells which have a metabolic capability. The latter is particularly 
relevant for certain PAHs, such as benzo(a)pyrene, which can be metabolized by 
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these cells (NEPI, 2000). Uptake of contaminants by the skin is merely a diffusion 
process with the thickness of the skin, the chemical properties of the contaminant and 
the concentration on top of the skin being the most important variables determining the 
bioavailability of contaminants following dermal exposure. The human health risks 
associated with dermal exposure to soil-bound contaminants are the result from the 
direct toxic effects of the contaminant on the skin or by absorption of the compound 
through the skin and subsequent systemic toxicity. The dermal bioavailability of soil 
contaminants can be compared to oral bioavailability (see part 2.5) since it also 
consists of two parts: chemical availability (bioaccessibility) and absorption. 
Bioaccessibility describes the fraction of the chemical that desorbs from the soil matrix 
and is available for absorption by the skin, whereas absorption describes the transport 
of the chemicals across the skin biological membranes to the blood stream (NEPI, 
2000).  
Ingestion 
Because the gastrointestinal (GI) tract is the principal site of nutrient uptake, it is a 
prime location for uptake of contaminants as well, not only soil-bound contaminants but 
also hazardous compounds in nutrition, drinking water or ingestion of contaminants 
from children’s toys. Although the transport of contaminants across biological 
membranes is fairly similar for the different exposure pathways, the digestive 
processes inside the GI tract result in more complicated transport phenomena than 
with inhalation or dermal contact. For example, a colloid- or particle-bound 
contaminant can reside in the GI tract for hours to days which will affect the particle-
contaminant associations in the intestinal lumen to a large extent. Additionally, the 
absorption processes are more complicated: besides diffusion processes of simple 
organic compounds, specific ions can also be transported as well as non-charged 
elements that are associated to for instance amino acids (NEPI, 2000). This complexity 
of oral exposure to environmental contaminants will be discussed below.  
2. Oral exposure to contaminated soil  
2.1 Ingestion  
Oral exposure to soil-bound contaminants mainly occurs by ingestion of soil and 
dust particulates and consumption of badly cleaned vegetables. In HHRA, typical 
human soil ingestion rates are estimated between 1 and 500 mg d-1 (Brunekreef et al., 
1987; Vanwijnen et al., 1990; Calabrese et al., 1997a, 1997b; Stanek et al., 1997). 
Site-specific risk assessment studies incorporate soil ingestion with a maximal daily 
intake of 50 and 150 mg soil d-1 for adults and children, respectively (EPA, 1997). Soil 
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ingestion may seem rather unlikely for adults, yet the pathway is more indirect. 
Depending on the profession or the weather situation, soil particles may end up in the 
gastrointestinal tract. For example, construction workers may get exposed to soil and 
dust particulates via the inhalatory route, especially under windy and dry weather 
conditions. As discussed earlier, particulates that are too large to reach the alveolar 
region of the inhalatory tract, may migrate up to the pharynx again through mucociliary 
movements. These soil particles may then be ingested and eventually reach the 
intestinal lumen. It is estimated that construction workers are exposed to 300 mg soil  
d-1 on average (EPA, 2001). Likewise, the soil surface from urban areas is more prone 
to atmospheric depositions from diesel exhaust particles, PAHs from car tires and 
several combustion processes. Especially in densely populated or industrial areas, this 
indirect ingestion route of soil particulates may reach significant values. In addition, 
ingestion of soil particles also occurs by vegetables or fruits that are grown in the 
garden. It is estimated that the soil loads for vegetables with leafy tissues is 20 mg soil 
kg-1 DW (dry weight) after normal washing and for fruits 2 mg soil kg-1 DW. However, 
higher soil ingestion rates are also encountered, primarily then by small children that 
ingest larger amounts of soil due to their hand-to-mouth behavior. Estimated soil intake 
rates by small children are between 100 and 500 mg d-1. Direct soil ingestion may even 
impose a larger health risk to pica-afflicted children, who, due to their unusual hand-to-
mouth behavior, occasionally ingest several grams of soil with reported intakes 
between 5 and 60 g d-1 (Calabrese et al., 1999).  
These examples of incidental soil ingestion are important pathways of contaminant 
exposure in HHRA. In its basic form, the intake equation for incidental ingestion of soils 
is (NRC, 2003): 
⎟⎠
⎞⎜⎝
⎛ ×⎟⎠
⎞⎜⎝
⎛ ××=
AT
EDEF
BW
RAFIRCIntake s  
where: 
 Cs = chemical concentration in the soil at the point of contact 
 IR = incidental ingestion rate of soil 
 RAF = relative absorption factor 
 BW = Body Weight 
EF = Exposure frequency 
ED = Exposure duration 
AT = attenuation time (period over which exposure will be averaged) 
 
To exemplify, the intake of lead from a contaminated soil (500 mg lead kg-1 soil) by 
children can be calculated using scenario-specific values and default values as 
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proposed by the EPA (EPA, 2001). Default values for soil ingestion by children are a 
soil ingestion of 200 mg d-1, body weight 15 kg, 350 d yr-1 exposure frequency, 3 yr 
exposure duration and an attenuation time of 6 yr. The relative absorption factor 
considers the fact that not 100% of the lead will be intestinally absorbed because a 
fraction is still bound to the soil matrix. If an RAF of 60% is chosen, then the incidental 
lead ingestion by children is calculated as: 
dkgBW
µgPbIntake
*
9.1
6
3350
15
6.02.0500 =⎟⎠
⎞⎜⎝
⎛ ×⎟⎠
⎞⎜⎝
⎛ ××=  
In general, human health risk assessment models assume that 100% of an 
ingested contaminant is absorbed and taken up in the systemic circulation. However, 
the availability of contaminants ingested with soil is an important variable significantly 
affecting soil ingestion exposure factors (Palumbo and Klinck, 2002). Researchers 
have indicated that current risk assessment models are not reliable by demonstrating 
that the actual absorption of soil-bound contaminants is substantially lower than 100% 
(Williams et al., 1998; Pu et al., 2003). The oral bioavailability process with regards to 
soil ingestion will be discussed below (part 2.5). 
 
2.2 Human gastrointestinal tract 
The primary function of the GI tract is to degrade ingested food particles to this 
extent that smaller, individual molecules can be more easily absorbed and taken up in 
the blood circulation. In this way, complex sugars of different polymerization and 
substitution degree can be broken up in single sugar molecules, proteins are split into 
amino acids and fats are converted to triglycerides and fatty acids. Besides that, 
vitamines and trace elements make up a smaller, but crucial part of the nutritional 
composition. The GI tract roughly measures 8 meters from the mouth to the rectum 
and is basically the ‘inner outside’ of the human body (Figure 1.3). Ingested 
components are only taken up by the body if they are digested into molecules small 
enough to be intestinally absorbed. Food compounds are first mechanically broken up 
by chewing from the mouth. This entails that the cell walls from ingested plant tissues 
are destroyed, exposing the cell content more easily to the digestive juices such as 
saliva, gastric juice, intestinal juice, bile and pancreatic juice. Absorption of available 
nutritional compounds primarily takes place in the small intestine, whereas the 
residual, non absorbed compounds are transferred to the large intestine, further 
digested by the present microorganisms and eventually excreted with the feces.  
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Mouth. The mouth is the first place of enzymatic digestion of food compounds. The 
secreted saliva contains enzymes that convert polysaccharides to maltose and the 
latter to glucose molecules. Good chewing is therefore very important in the digestion 
of starch which makes up an important amount of our daily food intake. A good mixture 
of the food with saliva also ensures an easier swallowing and transport to the 
esophagus, which is the least important part of the GIT, connecting the mouth with the 
stomach.   
 
Figure 1.3 Overview of the gastrointestinal tract and relevant organs 
 
Stomach. The stomach is a widened part of the GIT, consisting of 4 parts: the 
cardia, the corpus, the fundus, and the pyloric antrum, the latter giving access by the 
pyloric sphincter to the duodenum. An empty stomach is characterized by an open 
pyloric sphincter and relatively little gastric juice, mainly consisting out of water and 
mucin which is secreted by glands in the stomach wall. The ingested food that enters 
the stomach via the cardia, is grinded in the corpus, while the fundus serves more as a 
storage. The ingestion of food also results in a higher secretion of gastric juice which 
changes in composition by the higher concentration of hydrochloric acid and digestive 
enzymes. The hydrochloric acid solubilizes food components and has an important 
bactericidal effect towards microorganisms that are taken up with the nutrition. A 
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mucus layer covers the stomach wall to protect the epithelium from the acidic 
environment inside (pH 1 to 2). The acidic environment is also crucial in the activation 
of the digestive enzyme pepsin, which has proteolytic activity in an optimum pH range 
of 1 to 3 (Ganong, 1997). Hormones are also involved in the stomach digestive 
processes. Gastrin stimulates the hydrochloric acid production in the stomach, 
whereas secretin also promotes the pancreas to secrete digestive enzymes. After a 
certain residence time, the chyme from the stomach is gradually released to the 
duodenum by intermittent opening of the pyloric sphincter and the peristaltic movement 
from the small intestine. 
Small intestine. The small intestine is the most important part of the GI tract. The 
human food digestion which is initiated for starch in the mouth and for proteins in the 
stomach, comes to completion in the small intestine, which is about 5 meters long and 
can be separated in the duodenum, the jejunum and ileum (Charman et al., 1997; 
Hidalgo, 2001). The proximal part, the duodenum, starts from the pyloric sphincter and 
is about 30 cm long. It receives the secretions of the pancreas and the liver, i.e. the 
bile via the gal bladder. The pancreatic juice and bile play a crucial role in the further 
digestion of the semi-digested food from the stomach. The strong acidic chyme from 
the stomach contains mainly maltose and glucose from starch, other more complex 
sugars, polypeptides and smaller protein fragments and lipids, which are not yet 
digested in the stomach. The alkalic pancreatic juice neutralizes the acidic stomach 
content to a pH of 7.5 and several pancreatic enzymes such as amylases, proteases 
and lipases are responsible for the further food digestion process. The enzymatic 
conversions in the small intestine entail the conversion of sugars to single sugar 
molecules, the breakdown of peptides to their individual amino acids and the 
conversion of lipids to fatty acids. The latter process, which is carried out by pancreatic 
lipases, is stimulated by the secretion of bile, produced in the liver and stored in the gal 
bladder. 
The secreted bile does not contain enzymes but consists out of bile salts which act 
as an emulgator to distribute large fat globules to small fat droplets. This process of 
emulsification makes the lipids more accessible to the pancreatic lipases so that the 
digestion efficiency of lipids is increased. The chyme is transported from the 
duodenum to the jejunum and ileum through peristaltic movements. Although the 
jejunum and ileum are the main site of absorption of nutrients and electrolytes, they 
also have a digestive function as the epithelial wall secretes digestive juices, which 
contain enzymes that finish the digestion process: small peptides are converted to their 
amino acid building blocks and remaining disaccharides are converted to the 
monosaccharides glucose, galactose and fructose. These basic food components are 
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the compounds which are then available for intestinal absorption. Non-absorbed food 
compounds are further transported through the GI tract and reach the large intestine.  
Large intestine. The large intestine receives the chyme that is poor in components 
with direct nutritional value, since the latter are absorbed in the small intestine. From 
the food digestion perspective, the primary function of the large intestine is to absorb 
most of the water from the chyme and the remaining electrolytes. The colon absorbs 
sodium by an active carrier and chloride in exchange for bicarbonate (Cummings et al., 
2004). Potassium is the dominant cation excreted in fecal fluid. The absorption of 
electrolytes creates a difference in osmotic pressure over the colon epithelium 
resulting in the absorption of 90% of the water in the chyme (Sandle, 1998). In contrast 
to the small intestine, which contains limited amounts of bacteria, the large intestine is 
heavily colonized with microorganisms: more than 400 different microbial species are 
present in concentrations of 12 log CFU/g. This is roughly about ten times as much as 
the amount of human cells in the body. It is now recognized that the metabolic 
potential of the human colon microbiota is extremely large, rivaling that of the liver in 
the number of biochemical reactions and transformations in which it participates 
(Macfarlane and Macfarlane, 1997). Given the absence of oxygen in the large 
intestinal lumen, the microbial community typically performs fermentation processes. 
The main microbial transformation processes are carbohydrate and protein 
fermentation, transformation of bile salts and steroids and the metabolism of xenobiotic 
compounds (Gibson and Williams, 1999). Besides that, the microbial community also 
plays a critical role in the immune system and may (in)activate potential mutagenic 
metabolites. The average residence time in the large intestine is much longer (36 to 48 
hours) than in the small intestine (6 to 8 hours). Besides the normal absorption of 
water and elektrolytes, the colon epithelial wall may also absorb microbial fermentation 
products and other metabolites.  
 
 
2.3 Intestinal transport 
2.3.1 Morphology 
The digestion process in the GI tract would be useless if the basic nutritional 
compounds could not be absorbed and transported across the intestinal wall. The 
absorption of compounds is however controlled by the mucosa which lines the luminal 
wall of the GI tract, hence functioning as a selective permeability barrier (Hidalgo, 
2001) permitting the absorption of nutrients such as sugars, amino acids, peptides, 
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lipids and vitamins (Strum, 1981; Said et al., 1987) and limiting the absorption of 
xenobiotics, digestive enzymes, and bacteria. The predominant site of absorption is 
the jejunum and ileum where the mucosa can be divided into three distinct layers: the 
muscularis mucosa (the deepest layer), the lamina propria (bounded by the epithelium 
above and the muscularis mucosa below) and the uppermost single-layered epithelium 
(Doherty and Charman, 2002). The lamina propria is a structural support for the 
epithelium, containing lymph vessels, nerves, lymphocytes, macrophages that attack 
foreign compounds that enter this layer from the GIT and blood vessels for 
nourishment of the epithelium.  
The epithelium is in direct contact with the chyme (intestinal suspension). Intestinal 
absorption is facilitated by several modifications that increase the absorptive surface 
area of the small intestine to 150-200 m2 (De Sesso and Jacobson, 2001). The large 
surface of the intestinal wall is established by the formation of circular folds (Kerckring 
folds or plicae circulares) and by folding of the intestinal epithelium itself, called villi, 
fingerlike formations of 1 mm long in the intestinal lumen (Figure 1.4A). Each villus 
contains blood and lymphatic capillaries by which absorbed compounds are 
transported to the liver (portal vein) or the rest of the body. The surface of each villus 
consists of different cell types such as goblet cells, which secrete mucin, endocrine 
cells and enterocytes, which are absorptive cells. The enterocyte is the most 
predominant cell type in the villi and is characterized by the presence of small 
microstructures, microvilli that are 1 µm long and 0.1 µm wide (Figure 1.4B). The 
presence of these microvilli significantly contributes to the large extension of the 
available surface area for intestinal absorption. 
 
2.3.2 Types of transport  
Ingested and digested food components, drugs or environmental contaminants can 
become available for transport across the intestinal epithelium. Depending on the type 
of compound, different types of absorption can be distinguished (Figure 1.5).  
Firstly, paracellular transport is the aqueous extracellular absorption of compounds 
through the tight junctions that separate the enterocytes. This type of transport is 
reserved for small, hydrophilic molecules that can easily migrate between two 
enterocytes by the process of diffusion (Hidalgo, 2001). The other types of intestinal 
transport all occur through the enterocyte and can be grouped as transcellular 
transport, which entails transport across the cell membrane itself. The surface area of 
the transcellular route is much larger than that of the paracellular route (99.9% versus 
0.01%). Hence, compounds that are only transported through the paracellular pathway 
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have a low absorption, whereas compounds that are readily transported across the cell 
membrane have a high absorption (Pade et al., 1997). 
 
 
B 
Figure 1.4 Scheme of the ileum luminal structure with the circular folds and villi (A) and 
magnification of the villi to show the enterocytes and microvolli structures (B)  
 
The simplest mechanism of transcellular transport is passive diffusion by which 
molecules migrate through the enterocyte down a concentration gradient. Products of 
fat digestion, hydrophobic vitamins and other hydrophobic compounds such as organic 
contaminants or certain drugs may be incorporated in mixed micelles with bile salts, 
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which diffuse to the brush border where they are absorbed by the lipid membrane of 
the enterocytes (Koldovsky et al., 1995; Hack and Selenka, 1996; Oomen et al., 2000). 
 
 
Figure 1.5 Schematic representation of the different intestinal transport routes across the 
epithelium. 1: paracellular transport, 2: passive diffusion, 3: transcytosis, 4: 
carrier mediated transport 
 
However, specialised transport systems that make use of carrier proteins, may also 
affect the absorption rate of specific compounds by either facilitated diffusion (no 
energy required), active transport (energy-consuming) or even specific efflux transport 
(Tsuji and Tamai, 1996). In this way, certain compounds may exhibit absorption values 
that are different from the expected values that are based on their intrinsic membrane 
permeability properties. The small intestine expresses several types of carrier proteins 
which are responsible for the transport of nutrients such as hydrophilic dipeptides or 
vitamins. Additionally, some of these carrier proteins are also believed to be involved in 
the transport of drugs or specific xenobiotic compounds.  
In contrast to this carrier-mediated transport, there is also carrier-limited transport 
which mediate the transport of compounds from the enterocyte cytoplasm to the 
intestinal lumen. This process is known as apical efflux. The best-studied efflux carrier 
protein is the P-glycoprotein which is known to limit the intestinal absorption of a large 
number of drugs (Sparreboom et al., 1997; Dautrey et al., 1999; Stephens et al., 
2001). Currently, two genes have been described that code for this apical efflux 
activity: mdr1 and mdr2 (MDR: multiple drug resistance) (Chin et al., 1993). MDR1 
gene products would be responsible for the drug resistance that have been described 
in several cancer cells (Juliano and Ling, 1976) and other tissue including the liver, 
kidney, pancreas and intestinal epithelium (Thiebaut et al., 1987), whereas MDR2 
gene products would primarily occur in the liver.  
 15
Chapter 1 
The final transport mechanism by the enterocytes is the vesicular transport which 
may enhance the absorption of xenobiotic compounds. This type of transport basically 
consists of the formation of invaginations of the enterocyte plasmamembrane which 
pinch off and form intracellular vesicles that surround the absorbed compound.  
Absorbed compounds from the small intestine that escape biotransformation by the 
enterocyte, are usually transported to the liver where they can be subjected to liver 
biotransformation processes, after which they may reach the target organs or be 
excreted from the body by the urinary and biliary tract. 
 
2.3.3 Permeability of colonocytes versus enterocytes.  
Although the morphology of the large intestine, or colon, is substantially different 
from that of the small intestine, the colon is lined with epithelial cells, colonocyctes, 
which allow the absorption of components across the intestinal wall too. Non-digested 
food components, digestion products, secreted human metabolites and microbial 
fermentation products may (partly) become available for absorption. Hence, the small 
intestine is not the only site of absorption. This is of importance for colon specific drug 
release. The colon microorganisms produce a large number of degrading enzymes 
that enable to degrade polymers that are used to encapsulate drugs. This microbially 
controlled delivery of drugs to the colon is independent of pH variations along the GI 
tract or enzymatic processes, since the drug, peptide, or protein is only released upon 
arrival of the dosage form at the colon (Zhang et al., 2002).  
The colon also harbours a vast microbial community with an enormous metabolic 
potency. Ingested contaminants or xenobiotic compounds in general may thus be 
biotransformed by the indigenous microbial population, leading to metabolites that may 
become available for absorption. Hence, risk assessment studies that monitor the 
bioavailability of ingested contaminants, also need to consider the fraction absorbed 
from the colon and their metabolites. Although the available surface area for colonic 
absorption is much smaller than that of the small intestine, it may be of significant 
importance given the possibility that hazardous microbial metabolites may be produced 
that pose a risk to the colon epithelium. 
In general, the permeability to hydrophylic compounds decreases once the small 
intestine is passed. This can be attributed to the smaller surface area of the colon 
membrane and the increased tightness of the epithelium (Ungell et al., 1998). 
However, this decreased permeability is not always observed with hydrophobic 
compounds. Depending on the type of compound and the species of origin, membrane 
transport studies show higher permeability to hydrophobic compounds in the colon 
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than in the small intestine, and vice versa. A sound explanation for these differences is 
not yet available but one of the reasons may be that epithelial enzymes that are 
involved in metabolic conversion processes, are responsible. A second reason may be 
the presence of efflux carrier proteins (p-glycoprotein) in the colon epithelium, thus 
interfering with the absorption process. It may be interesting to report that comparative 
in vitro permeability studies with small intestine and colon epithelia revealed that the 
colon epithelium is more permeable to the natural estrogen 17β-estradiol than the 
small intestine epithelium (van der Bijl and van Eyck, 2003). In conclusion, identifying 
the different transport mechanisms for specific compounds of interest, such as 
ingested contaminants, is extremely important for assessing the internal dose of these 
compounds in risk assessment studies.  
 
 
2.4 Biotransformation of xenobiotics 
Many organic contaminants in the environment are xenobiotic or in other words, 
foreign to the human body or the natural environment in general: drugs, carcinogens, 
pesticides, food contaminants, toxins… Many xenobiotic compounds are highly 
hydrophobic and tend to accumulate in the body where they may potentially exert toxic 
effects. The human body has therefore developed a defense mechanism, called 
biotransformation, which has as main purpose to convert these xenobiotic compounds 
to more hydrophilic compounds so that they can be more easily removed from the 
body. Biotransformation of ingested components in the gut wall and gut lumen is of 
significant importance to the biological availability of those xenobiotics and hence to 
their potency to become biologically active in the body. Metabolism in the gut wall 
during intestinal absorption or in the liver may lead to the elimination of the xenobiotic 
compound before it reaches the systemic circulation. Metabolism in the gut lumen is 
also possible and is carried out by intestinal microorganisms. Here, the amount of the 
ingested compound which is available for intestinal absorption may be modulated by 
detoxification processes, but also toxification processes. In summary, the 
biotransformation of ingested xenobiotics can thus be divided into human and 
microbial metabolism. 
 
 
 17
Chapter 1 
2.4.1 Human biotransformation activity 
Most ingested xenobiotic compounds that undergo intestinal absorption are 
subjected to enzymatic activity from the human body. Although the liver is the prime 
site of biotransformation activity, every organ or tissue in the body is capable of 
performing biotransformation reactions: skin, lungs, heart, kidneys, bone marrow, 
brains… (Connely and Bridges, 1988). The process of inactivating ingested 
contaminants after oral absorption and before entering the systemic circulation is 
referred to as first-pass effect (Klaassen, 1986). Especially the enterocytes, the cells 
from the intestinal epithelium, play a significant role in the biotransformation of 
ingested and subsequently absorbed components, provided that suitable enzymes are 
present in the enterocyte. This entails that biotransformation in the enterocytes can 
only occur during transcellular transport (Doherty and Charman, 2002). The extent of 
such first-pass metabolism depends partly on enzyme concentration (Klippert et al., 
1982) and also on the rate of drug transfer through the mucosal cells (Borm et al., 
1985). The highest concentration of biotransformation enzymes in the intestinal 
epithelium can be found in the tips of the villi whereas their content decreases towards 
the crypts (Guengerich, 1997). The metabolic activity is usually higher in the 
duodenum and jejunum compared to the ileum and colon. Yet, this can not be 
generalized, as evidenced by data that showed that 2-aminofluorene acetylase activity 
in the colon and duodenum epithelial wall are not different (Ilett et al., 1990). Research 
on the gene expression of cytochromes P450 in different parts of the human 
gastrointestinal tract revealed that specific cytochromes P450 are indeed more present 
in the small intestinal enterocytes, but that other cytochromes P450, such as CYP 1B1, 
is better represented in the colonocytes, particularly from the ascending colon (Table 
1.1) (Finnström, 1998).  
 
Table 1.1 Occurence of Cytochrome P450 (CYP) biotransformation complexes as a 
function of their human intestinal localisation  
CYP Duodenum / 
jejunum 
Ascending colon Transverse 
colon 
Descending 
colon 
1B1 + ++++ + + 
2E1 ++ ++ + ++ 
3A4 ++++ ++ + ++ 
3A5 +++++ ++++ +++ ++ 
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Non-biotransformed xenobiotic compounds that have been absorbed from the 
intestinal lumen, may then be transported via the portal vein to the hepatocytes of the 
liver. Here, they may be biotransformed which may result in the excretion of the 
compound via the bile in the duodenum. Biotransformation reactions were previously 
thought to induce detoxification of the ingested contaminants, yet it has become clear 
that biotransformation enzymes may also ‘bioactivate’ compounds, resulting in stable 
or unstable metabolites that are more toxic than the parent compound. Unstable 
intermediates generally exert their toxicity in the tissue(s) where they are produced, 
whereas stable ones may be formed in one tissue only (usually the liver), released into 
the bloodstream and then affect other tissues (Connelly and Bridges, 1988). In several 
instances there are competing metabolic pathways between activation and 
detoxification of a foreign chemical. Whether a toxic reaction will be initiated in such 
situations will depend on the relative balance between these pathways (Dybing et al., 
2002). 
 
Basically, the human biotransformation process can be split up in two major steps: 
phase I, the functionalization reactions including oxidation, reduction and hydrolysis) 
and phase II, the conjugative reactions (Nebbia, 2001).  
Phase I reactions usually result in the introduction of functional groups (-OH, -NH2, 
-SH, -COOH) on the xenobiotic molecule, which makes it more easy to conjugate the 
compounds with endogenous substrates (Gibson and Skett, 1994). Several enzymes 
are involved in phase I reactions: alcohol and aldehyde dehydrogenases, xanthine and 
amine oxidases, aromatases, and hydrolysis initiating enzymes. Enzymes from the 
cytochrome P450 (CYP) superfamily are represented the most. CYP enzymes that are 
involved in the metabolism of organic chemicals are predominantly from the CYP1, 
CYP2 and CYP3 subfamilies, which can be further divided in isoenzymes with affinity 
for specific compounds. Isoenzymes that have been detected in the enterocytes from 
the small intestine are CYP1A1, CYP2C, CYP2D6 and CYP3A4, the latter accounting 
for 60% of the phase I enzymes in the enterocytes and responsible for metabolization 
and inactivation of a large number of compounds (Hebert et al., 1992; Doherty and 
Charman, 2002). Additionally, the apical efflux activity from P-glycoproteins seems to 
be coregulated with the CYP3A4 enzyme (Wacher et al., 1995). This way, the P-
glycoprotein efflux pump contributes more efficiently to the inactivation of xenobiotics. 
In general, CYP mediated oxidation reactions can be regarded as the most important 
pathway by which bioactivation of compounds occurs. Benzo(a)pyrene, one of the 
most dangerous PAH species, is for example biotransformed by CYP1A enzymes to 
7,8 epoxide derivatives which are potent pro-carcinogens (Stroomberg, 2002).  
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Although phase I biotransformation reactions may sometimes lead to the 
bioactivation of xenobiotic compounds, they are an important prerequisite to phase II 
reactions, since the phase I metabolites are good substrates for conjugation enzymes, 
which effectively detoxify the initial metabolite. Yet, phase II biotransformation 
reactions may also occur with xenobiotics that have not gone through a phase I step. 
The resulting conjugates are much more hydrophilic than their precursors and may 
hence be easily removed from the body via biliary or urinary excretion. Chemicals 
which are less hydrophobic and show intermediate polarity may only be subjected to 
phase II enzymes and not phase I.  
The human intestinal epithelium has been described to contain relatively high 
levels of phase II enzymes, mostly glucuronyltransferase, N-acetyltransferase, 
sulfotransferase and glutathion-S-transferase (Table 1.2). Xenobiotics excreted into 
the bile as glucuronide conjugates, may re-enter the circulation after being hydrolysed 
by glucuronidase activity from gut microbiota. This process is called enterohepatic 
circulation (Dybing et al., 2002). 
 
Table 1.2 Typical phase I and phase II biotransformation enzymatic families or enzymes 
(Source: WHO, 2002 IPCS training) 
Enzyme substrate 
Cytochrome P450 1A1 Polycyclic aromatic hydrocarbons  
Cytochrome P450 1A2 Aryl and heterocyclic amines 
Cytochrome P450 2A6 Coumarin 
Cytochrome P450 2C19 Drugs (diazepam, omeprazol…) 
Cytochrome P450 2D6 Drugs 
Cytochrome P450 2E1 Ethanol, organic solvents, nitrosamines, paracetamol 
Cytochrome P450 3A5 Chlorinated compounds 
N-acetyltransferase Aryl amines 
Sulfotransferase  Aryl and heterocyclic amines 
Glutathion S-transferase Polycyclic aromatic hydrcarbons, oxides and diol-epoxides 
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2.4.2 PAH: example compound for human biotransformation 
In view of the research that will be described in this dissertation, it is recommended 
to give a short description of the human biotransformation processes for polycyclic 
aromatic hydrocarbons (PAH). PAHs form a group of chemicals of concern that are 
generated during the combustion of fossil fuels and other organic fuels. It is assumed 
that anthropogenic combustion activities are responsible for more than 90% of the 
polycyclic aromatic hydrocarbons (PAH) that are released in the environment. 
Together with the persistent organic pollutants (POP) such as heterocyclic amines, 
polychlorinated biphenyls, dioxine-like chemicals and certain pesticides, PAHs are 
considered to be one of the most hazardous xenobiotic compounds in the environment 
to which the human can be exposed. The toxic effects include cancer, immunologic 
compromise, birth defects, endocrine disruption, genotoxicity… The fundamental 
problem with these compounds is their persistence in the environment and their 
resistance to photocatalytic breakdown, chemical and biological degradation in the 
atmosphere, soil and water phase (Schafer and Kegley, 2002). These recalcitrant 
properties explain their long residence time and stability in the environment and also 
their bioaccumulation in biological tissues and biomagnification throughout the entire 
foodchain.  
A common characteristic of PAHs, similar to polychlorinated biphenyls (PCB), 
polychlorinated dibenzo-furanons (PCDF) or -dioxins (TCDD), is their binding affinity 
for the human aryl hydrocarbon receptor (AhR), once they are taken up in the human 
body. This triggers several biotransformation processes which result in the 
detoxification and excretion of the compounds from the body, or their possible 
bioactivation and bioaccumulation which give rise to several toxic effects.  
 
2.4.2.1 Role of the aryl hydrocarbon receptor  
The intracellular mechanism by which PAHs are biotransformed in the body and 
subsequently exert their toxic effects, has been thorougly investigated (Birnbaum, 
1995; Whitlock et al., 1996; Seidel et al., 2000). When reaching the enterocytes or 
hepatocytes or other cells with biotransformation capacity, these compounds may act 
as ligands to the aryl hydrocarbon (or dioxin) receptor (AhR) protein in the cytoplasm 
(Figure 1.6), which has been described to play a central role in the toxic response of 
specific aromatic hydrocarbons by the regulation of typical human biotransformation 
enzymes.  
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Figure 1.6  Binding of benzo(a)pyrene as model PAH compound to the AhR, migration to 
the cell nucleus, binding to the DNA responsive element (DRE) in the promotor 
region, transcription and CYP 1A1 protein synthesis. 
 
Together with the aryl hydrocarbon receptor nuclear translocator (Arnt), the AhR is 
part of a heterodimeric transcription factor called the aryl hydrocarbon receptor 
complex (Hankinson, 1995; Schmidt and Bradfield, 1996). When activated by a ligand 
– the PAH molecule – the AhR is subjected to a conformational change which exposes 
a nuclar localization sequence. The AhR-ligand complex is then transferred to the cell 
nucleus (Denison et al., 2002) where it dissociates from the protein complex and binds 
to the Arnt (Figure 1.6). The Arnt-AhR heterodimer formation results in the 
transformation of the AhR-ligand complex to its DNA-binding form (Hankinson, 1995). 
This subsequently binds to DNA responsive elements (DRE) in the promotorregion of 
genes which are responsible for the production of cytochrome P450 1A1 enzymes 
(Poland and Knutson, 1982) in the case of environmental contaminants such as 
TCDDs and PAHs. It is generally assumed that AhR binding appears to be essential 
for toxicity, although non-AhR binding mechanisms have not been ruled out  
(Birnbaum, 1995). The regulation of other genes and geneproducts by ligand activation 
of the AhR is similar and has been reported for CYP 1A2, CYP 1B1, NADPH quinon 
reductase and glutathion-S-transferase. 
 
2.4.2.2 Health effects from PAHs 
Acute toxicity. There are only limited reports on the acute oral toxicity of PAHs. In 
general, PAHs are highly lipophilic and are therefore easily accumulated in the 
phospholipid bilayer of cell membranes. This harms the cell membrane integrity and 
may lead to nonpolar narcosis. However, such significant acute toxic effects from 
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PAHs are only caused at high, rather unrealistic concentrations. Naphthalene turns out 
to be the most acute toxic PAH compound with LD50 values ranging from 354 to 1200 
body weight (BW) for mice and guinea-pigs respectively whereas the LD50 values for 
fluoranthene and anthracene were estimated around 2000 and 18000 mg kg-1 BW 
respectively in rat and mice experiments (Smyth et al., 1962; Shopp et al., 1984; Sax 
and Lewis, 1984; Montizaan et al., 1989).  
Carcinogenesis. The real health hazard from PAHs comes from the potency of 
these compounds to bind the AhR and thus promote the production of 
biotransformation enzymes which may bioactivate the PAH compounds, leading to 
more toxic intermediates than the parent compounds. The activation of the AhR is 
considered the most important parameter for the carcinogenic potency of not only 
PAH, but also PCB, TCDD, PCDF… (Cheung et al., 1993). PAHs thus have a 
promotor function since they interfere with gene expression systems and are therefore 
epigenetic carcinogens. The purported effects from epigenetic carcinogens are usually 
resulting from long or very high exposures. However, PAHs may also react as 
genotoxic carcinogens. One single exposure to a genotoxic substance may already be 
sufficient to induce tumour formation.  
Biotransformation of PAHs usually leads to the addition of hydroxyl groups on the 
PAH molecule. The phase II conjugation of the hydroxy-PAH with a glucuronide- or a 
sulphate-group facilitates the excretion with bile or urine (Figure 1.7). In contrast to 
this, the hydroxylation of the PAH molecule may also lead to the formation of epoxides 
(James and Boyle, 1998; Penning, 1993). Epoxides are highly reactive because the 
internuclear bond angles are smaller compared to normal sp3 bond angles. The 
epoxides may be hydrolysed by the enzyme epoxide hydrolase to form dihydrodiols. 
Reaction with dihydrodiol dehydrogenase then leads to a stable diol that can be 
conjugated and excreted (Penning, 1993). However, some dihydrodiols go through a 
second epoxidation to yield a diol-epoxide. This diol-epoxide can react with 
macromolecules, such as proteins or DNA (Figure 1.7), to covalently bind to cellular 
DNA and form adducts with guanin or adenin (Jeffrey et al., 1976). While protein 
adducts cause little or no effects, DNA-adducts can give rise to mutations and 
subsequent carcinogenesis. This usually occurs by removal of the adducted DNA-base 
or misreplication of it.   
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Figure 1.7 Biotransformation of benzo(a)pyrene as model PAH compound by cytochrome 
P450 enzymes (Source: Penning, 1993, Source: Stroomberg, 2002). 
 
Endocrine disruption. The increasing concern of PAHs and many other persistent 
organic pollutants in the environment not only arises from their acute toxic or 
carcinogenic effects, but also from the increasing number of reports that they possess 
estrogenic characteristics, even at low concentrations. There is growing evidence that 
PAHs may also act as endocrine disruptors since several PAH metabolites, especially 
from the 4- and 5- ring PAHs, show affinity for the estrogen receptor (ER) α and β in a 
variety of test systems (Chaloupka et al., 1992; Tran et al., 1996; Clemons et al., 1998; 
Arcaro et al., 1999; Fertuck et al., 2001a). The explanation for this ER affinity lies in the 
structural similarity between hydroxy-PAHs and the natural hormone estradiol (Figure 
1.8). Some hydroxy-PAHs may act similarly as estradiol by acting as a ligand to the 
human ER (pseudo-estrogens). They may also block the receptor causing failure of 
natural hormones to bind the receptor (anti-estrogens). This binding or blocking of PAH 
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metabolites is not only limited to the ER, but also takes place at the androgen receptor 
in which case androgenic effects are the result. This way, PAH metabolites may 
potentially interfere with estrogen signaling in important developmental and 
reproductive processes and lead to unnecessary promotion or inhibition of receptor 
depending gene transcription (Cooper and Kavlock, 1997). There is growing concern 
about human exposure to environmental pseudo-estrogens because they may result in 
reproductive malfunctions, teratogenic effects, decrease of sperm quality and even 
estrogen-related cancers.  
Figure 1.8 Molecular structure of b(a)p as model PAH compound and the natural estrogen 
17β-estradiol 
 
2.4.3 Microbial biotransformation activity 
2.4.3.1 Types of microbial metabolism 
The human large intestine harbours an incredibly diverse microbial ecosystem 
comprising 400-500 species at concentrations of 1011 microorganisms per gram gut 
content. For many years it was believed that the main purpose of the large intestine 
was the resorption of water and salt by the body and the facilitated disposal of waste 
materials. However, it has now become clear that the colon bacteria play a key role in 
many processes that are in direct relationship with our body. Numerous studies show 
the role of intestinal microorganisms in the synthesis of short chain fatty acids that 
provide energy to the colon epithelium (Cummings and Englyst, 1987), the stimulation 
of the gut immune system (Salminen et al., 1998), the synthesis of vitamins K and B 
(Conly and Stein, 1993) and the colonisation resistance against exogenous pathogens 
(Hopkins and Macfarlane, 2003).  
Fermentation processes. Human colonic contents are a diverse mixture of 
bacteria, yeast, and other microorganisms, undigested or unabsorbed food, 
desquamated epithelial cells, bile, mucus, bacterial fermentation products, salts and 
water. The vast majority of the colon microbial population performs saccharolytic 
fermentation processes. Most simple sugars in the nutrition are already digested and 
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absorbed in the small intestine, but sugar molecules as raffinose, stachyose and 
lactulose and sugar alcohols such as sorbitol and xylitol reach the colon and become 
available to the resident microbiota. The main carbon and energy sources for the 
microbial population in the colon are resistant starches, plant cell wall polysaccharides 
and host mucopolysaccharides together with various oligosaccharides, proteins and 
peptides. The colon microbiota are able to ferment these substances to short chain 
fatty acids (SCFA), hydroxy- and dicarboxylic organic acids, H2, CO2, CH4 and other 
end products (Macfarlane and Macfarlane, 1997). More in particular, SCFA production 
is important since these compounds are the main energy source for the colonocytes 
and influence colonic function by stimulating water and sodium absorption and 
modulating motility (Cherbut et al., 1997). It is estimated that from the 20-60 g d-1 of 
carbohydrates that are available in the colon (Cummings and Macfarlane, 1991), 300-
500 mmol SCFA are daily produced with 95% being absorbed by the colon epithelium. 
Theoretical calculations show that up to 540 kcal d-1 might be obtained from 
carbohydrate fermentation, contributing up to 10% of the hosts daily energy 
requirements (Cummings, 1995). Additionally, butyrate also induces differentiation, 
stimulates apoptosis of cancerous cells in vitro and may thus inhibit cancer 
development (Scheppach et al., 1995; Reddy, 1999). Recently, Jan et al. (2002) 
demonstrated that also propionate induced colorectal carcinoma apoptosis. Moreover, 
propionate produced by the intestinal microbiota may contribute to plasma cholesterol 
lowering through inhibition of hepatic cholesterol synthesis (Chen et al., 1984; Wright 
et al., 1990; Demigné et al., 1995). Carbohydrate fermentation is by far the major force 
driving the activities of the colon microbiota. It is proportionally more important in the 
proximal part of the colon, this in contrast to the distal colon where amino acid 
fermentation is gaining importance, due to carbohydrate depletion.  
The entire colon is an intensely proteolytic environment containing a complex 
mixture of bacterial and pancreatic peptidases. Proteolysis is an important ecological 
and physiological process in the colon because it provides nitrogen for growth by the 
different microbial groups in the colon. However, unlike carbohydrate metabolism, 
where the end-products are benign and may even be considered as beneficial to the 
host, many products of protein fermentation or putrefaction are toxic to the host. These 
include ammonia, indols, phenols and amines. A higher degree of proteolytic activity 
can therefore be associated to higher risks of colon cancer (Rowland, 1992). Ammonia 
concentrations may reach up to 40 mM in the colonic content which is well above 
concentrations of 10 mM which have already been described to alter the morphology 
and intermediary metabolism of intestinal cells, increase DNA synthesis and promote 
tumerogenesis (Ichikawa and Sakata, 1998). A higher proteolytic activity and lower 
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saccharolytic activity, especially in the distal part of the colon, would thus be more 
detrimental to human health.  
Xenobiotic metabolism. Most resident colon microbiota typically perform 
fermentation processes, but several groups are also capable of transforming 
xenobiotic compounds (Macdonald et al., 1983; Ilett et al., 1990; Aura et al., 2002). 
The metabolic potential of  the intestinal microbiota is considered to be enormous, 
rivalling that of the liver in the number of biochemical ractions and transformations in 
which it participates (Macfarlane and Macfarlane, 1997). Intestinal microbiota thus play 
an important role in the first-pass metabolism of compounds which are poorly or 
incompletely absorbed by the gut mucosa. A wide range of metabolic reactions can be 
catalyzed by a large diversity of microbial enzymes (Table 1.3). In contrast to the 
oxidative and conjugative reactions from the phase I and II enzymes in the enterocytes 
and hepatocytes, the bacterial metabolism is more reductive, hydrolytic and even of 
degradative nature with a great potential for both bioactivation as detoxification of 
xenobiotics (Ilett et al., 1990). Additionally, intestinal microbiota also interfere with the 
human biotransformation process through the enterohepatic circulation of xenobiotic 
compounds. Compounds that have been absorbed in the intestine and subsequently 
detoxified are usually conjugated with polar groups (glucuronic acid, glycine, sulfate, 
glutathion and taurine) in the liver prior to secretion with the bile (Ilett et al., 1990). 
Once released in the intestinal lumen, these conjugates may be hydrolyzed again by 
bacterial enzymes such as β-glucuronidase, sulfatase and other glycosidases. This 
would negate the detoxification cycle and delay the excretion of many exogenous 
compounds since the original compounds or phase I metabolites are more prone to 
intestinal absorption than their phase II conjugates. For example, guinae pig 
experiments showed that the hydrolysis of benzo(a)pyrene conjugates by intestinal 
microbiota resulted in de novo production of toxic benzo(a)pyrene intermediates which 
caused the formation of DNA adducts in the colon (Bowes and Renwick, 1986). 
In summary, the colon epithelium may be exposed to potential toxicants from the 
non-digested nutrition and soil matrix, from the secretion of human phase II 
metabolites in the intestinal lumen, from the enzymatic activation of procarcinogens by 
the colon microbiota or from the direct production of toxic microbial compounds 
(McBain and Macfarlane, 1998).  
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Table 1.3  Metabolic potency of human gastrointestinal microbiota (after: Ilett et al., 1990). 
Reactions Enzyme  Bacterial species / origin of sample 
Hydrolysis   
Glucuronides β-glucuronidase E. coli 
Glycosides β-glucosidase Enterococcus faecalis, Eubacterium rectale, 
Clostridium sphenoides 
Amides Amide hydrolase E. coli, B. subtilis 
Esters Deacetylase Enterococcus faecalis 
Sulfamates Arylsulfotransferase Clostridia, enterobacteria, enterococci 
Reduction   
Azo-compounds Azoreductase Clostridia, lactobacillli 
Unsaturated lacton    Unsat. glycoside 
hydrogenase 
Eubacterium lentum 
Aliphatic double 
bounds  
Unsat. fatty acid 
hydrogenase 
Enterococcus faecalis 
Nitro-compounds Nitroreductase E. coli, bacteroides 
N-oxides N-oxide reductase Human colon 
S-oxides Sulfoxide reductase E. coli 
Ketones Hydrogenase Rat caecum 
Hydroxylamines Nitroreductase Rat GIT 
Dehydroxylation   
Demethylaton Demethylase Enterococci, lactobacilli, clostridia 
Deamination Deaminase Bacteroides, clostridia 
Decarboxylation Decarboxylase Enterococcus faecalis 
Dehydrogenation Dehydrogenase Clostridium welchii 
Dehalogenation Dehalogenase E. coli, Aerobacter aerogenes 
Synthetic reactions   
Esterification Acetyltransferase E. coli 
N-nitrosation  Enterococcus faecalis, E. coli 
Other reactions   
Oxidation Oxidase  E. coli, Enterococcus faecalis 
Isomerization Isomerase Eubacterium rectale, clostridium sphenoides 
Fission aliphatic Tryptophase E. coli, Bacillus alvei 
Fission ring C-S lyase Pig GIT, Eubacerium aerofaciens 
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2.4.3.2 Factors affecting microbial metabolism 
The metabolic potency of the colon microbiota largely depends on the community 
composition. Basically, different microbial groups can be distinguished, each one 
capable of performing certain metabolic reactions such as carbohydrate breakdown, 
protein fermentation, endotoxin production and other metabolic processes. These 
microbial groups thus differ in their metabolic capabilities, which may often be the 
basis of classifying microbial groups according to their health-promoting or detrimental 
effects. This distinction was already conceptualized by Metchnikoff (1907) who 
argumented that some gut bacteria are beneficial to health, while others may be 
harmful. Gibson and Roberfroid (1995) reasoned that a classification as depicted in 
Figure 1.9 was conceivable. Yet, this can not be generalized since the beneficial 
and/or harmful effects of certain microbial groups largely depend on the conditions 
prevailing in the colon lumen or on the host himself. 
Age. The age of a person is of major importance for the presence and absence of 
specific microbial groups throughout the gastrointestinal tract. Hence, as the microbial 
population changes, also the potency of performing metabolic reactions changes. The 
GI tract of the foetus in the mothers womb is sterile, but at birth, an infant’s GI tract 
rapidly becomes colonized with organisms acquired from the mother and the local 
environment. In the first few days of life, enterobacteriaceae and enterococci are the 
predominant organisms in neonatal stool samples. These organisms create anaerobic 
conditions by oxygen depletion which allows the growth of bifidobacteria which 
become predominant after two weeks (Rotimi and Duerden, 1981) and which are 
stimulated by fresh human milk for breast-fed infants (Bullen et al., 1977). Formula-fed 
babies also have high bifidobacteria concentrations, but Enterobacteriaceae, 
Bacteroides spp. and clostridia remain at high levels. The difference in microbial 
composition between breast-fed and formula-fed infants may lead to early differences 
between individuals when investigating the metabolic potency of the intestinal 
microbiota. In some instances, the lack of xenobiotic metabolizing ability observed in 
infants is not due to absence of certain microbiota, but rather to the immaturity of the 
bacterial enzyme systems in the gut lumen. For example, the development of bacterial 
enzymes such as β-glucosidase and reductase can be reflected in the dependency 
with age of the metabolism of digoxin (Linday et al., 1987), cholesterol and methane 
production (Ilett et al., 1990). 
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Figure 1.9 Dichotomy of the microbiota based on potentially toxic or beneficial 
properties (after: Gibson and Roberfroid, 1995; source: De Boever, 
2000) 
 
Diet. The host’s diet may significantly influence the composition of the intestinal 
microbial community and thus also its metabolic capabilities. It is known that the 
different diets consumed by various ethnic groups results in distinct microbial patterns 
in the intestine. An increased microbial colonization of the lower gut has been 
observed when dietary fibre content was decreased and refined carbohydrates and fat 
content were increased (Goldin, 1986) while a high-beef diet resulted in increased 
bacteroides populations in the human gut. Also the metabolic activity is influenced by 
dietary changes. A high cellulose and fibre content in the diet will decrease the 
intestinal transit time, increase the cecal size and the activity of cecal azoreductase, 
arylnitroreductase, β-glucosidase and β-glucuronidase in the rat (Rowland et al., 
1983).  
Antibiotics and xenobiotics. (Ilett et al., 1990). Antibiotics largely influence the 
deconjugation enzymes that are responsible for the enterohepatic circulation of 
conjugated xenobiotic compounds in the body. In this way, the failure of oral 
contraceptives such as ethynylestradiol could be related to a concurrent antibiotic 
administration, lowering the enterohepatic recycling of the conjugated synthetic 
estrogen excreted in the bile. The too frequent use of antibiotic compounds since the 
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second world war as a treatment for bacteria-associated diseases has rapidly resulted 
in the emergence of antibiotic resistant strains. This involves not only changes in the 
cell membrane material, but also the metabolic potency of the resistant strain allowing 
them to inactivate antibiotic compounds.  
 
In short, further research is needed to discover the metabolic capabilities of 
intestinal microbiota towards xenobiotic compounds and excreted phase II metabolites 
in the small intestine. Identifying those parameters that influence this capability and 
estimating the extent of the microbial metabolism may allow to achieve a more reliable 
assessment to what extent intestinal microorganisms contribute to the total risk that is 
posed by ingestion of environmental contaminants.  
 
2.5 Oral bioavailability  
2.5.1 Introduction 
When native Indian communities in pre-Columbian South America were extracting 
curare from Strychnos toxifera plants, they understood quite well that this agent was 
harmless when ingested, but that it had a paralyzing effect when directly injected into 
their preys. Little did they know about the charged quaternary nitrogen atom in the 
alkaloid curare molecule which prevented transport of ingested curare across the 
intestinal epithelium thus avoiding the paralyzing effect in the organism. Similarly, the 
Egyptian Ebers Papyrus of 1550 BC reports on the ingestion of charcoal to take away 
the effects of poisons. Quite obviously, this ancient precursor of active carbon acted as 
an adsorbent towards toxic components, thus preventing uptake in the gastrointestinal 
tract and subsequent toxicity. These two examples illustrate that ancient civilizations 
had touched, without knowing, onto the concept of biological availability or 
‘bioavailability’.  
In essence, this term refers to observations that the concentration of a chemical in 
soil is not the actual concentration that the human body will experience. A complex 
mixture of physical, chemical and biological processes causes only a fraction of the 
measured chemical being available to impact the health of humans. These findings are 
part of other, more general reports which showed that hydrocarbons and other organic 
chemicals present in soil become less available due to interactions between the 
chemical and the soil and that this drop in availability lowers the risk of these 
chemicals to human (and ecological) receptors. With respect to oral exposure, 
differences in binding degrees of chemicals to the soil matrix result in different release 
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rates and thus intestinal absorption rates. The internal exposure of an ingested 
compound will therefore depend on the compound, the type of soil matrix or other 
factors such as fed or fasted state of the exposed subject (Linz and Nakles, 1997; 
NRC, 2003). 
Measuring the bioavailable fraction of a compound has several consequences. Not 
only is it important to correctly assess the probable effects of contaminants towards 
human or ecological receptors. It may also influence the decisions that need to be 
made with regards to the determination of cleanup levels at contaminated sites (NRC, 
2003). An adequate understanding and measurement of the bioavailability is therefore 
one of the key processes to make the outcome of risk assessment study more 
accurate and reliable.  
 
2.5.2 Bioavailability definitions 
General. Despite its critical importance to the risk assessment process, there is no 
clear consensus on how to define the term bioavailability. It has several definitions, 
depending on the scientific field in which it is used: biodegradation, plant uptake, 
human toxicology, ecotoxicology… (Table 1.4). It may represent the fraction of a 
chemical accessible to an organism for absorption, the rate at which a substance is 
absorbed into a living system or a measure of the potential to cause a toxic effect 
(NRC, 2003). Environmenal scientists usually consider bioavailability as being the 
accessibility of a solid-bound chemical to assimilation and possible toxicity (NRC, 
2003), whereas pharmacologists and toxicologists consider it to be the fraction 
absorbed and able to reach the systemic circulation (Klaassen, 1986). Others consider 
a chemical as being bioavailable when it has crossed a biological membrane and 
becomes available at the site of biological activity.  
Oral bioavailability. When handling issues of oral exposure to environmental 
contaminants, the term ‘oral bioavailability’ is used. In this respect, it was suggested 
that the oral bioavailable fraction is the amount of compound that is removed from soil 
through desorption processes in the intestinal lumen, subsequently followed by 
transport to the circulatory system. In this light, toxicologists also refer to the 
importance of the peak plasma concentration and the time to peak plasma 
concentration as important parameters in characterizing availability in the body. 
Measurements of these parameters may not always be useful in risk assessment since 
several compounds are also subjected to human metabolism and other physiological 
factors of importance, which influence the concentration of the parent compound in the 
plasma as such. Although all these definitions are very much related to each other, 
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they create confusion for environmental scientists and a significant level of uncertainty 
when measuring the bioavailable fraction of chemicals. Given the legal and regulatory 
implications of the bioavailability concept as part of the risk assessment framework, the 
term must be clearly understood. 
 
Table 1.4 Definitions of bioavailability 
Definition Source 
Generally used to describe the extent and rate of absorption for a xenobiotic 
which enters the systemic circulation in the unaltered (parent) form from the 
applied (exposure) site. 
 
A concept that describes the ability of a chemical to interact with living 
organisms. 
 
The extent to which a substance can be absorbed by a living organism and 
can cause an adverse physiological or toxicological response 
 
A term used to indicate the fractional extent to which a dose reaches its site 
of action or a biological fluid from which the drug has access to its site of 
action. 
Hrudy et al., 
1996 
 
 
NEPI, 2000 
 
 
Battelle and 
Exponent, 2000 
 
Wilkinson, 
2001 
 
The NRC bioavailability report (2003) aimed to bring some clarity by identifying 
different parameters that are all important prerequisites to the oral bioavailability of a 
compound. The bioavailability process, as depicted in Figure 1.10, incorporates 
exposure by release of soil-bound contaminant and subsequent transport, direct 
contact of a bound contaminant, uptake by passage through the intestinal membrane 
and incorporation into an organism.  
 
 
Figure 1.10 Bioavailability processes from soil contaminants by oral uptake (Source, NRC, 
2003) 
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Following ingestion of a soil- or nutrition-bound contaminant, process A represents 
the contaminant release from its matrix and binding by other media in the intestinal 
suspension. It refers to the physicochemical and biological processes that influence 
the solubilization of a compound in the surrounding medium. Examples of parameters 
of influence are the octanol/water partition coefficients (Kow) of the ingested 
contaminant as such, pH and redox values in the intestinal lumen, critical micelle 
concentration (CMC) for the mixed bile salt micelles, digestive enzymes or microbial 
metabolism. Process B involves the migration of a released contaminant to the 
membrane of an organism. Depending on the pKa value of the compound, this can be 
in an ionized or uncharged form or a released chemical can be integrated in mixed bile 
salt micelles which migrate to the intestinal epithelium. Process C involves the 
movement of contaminants that are still bound to the solid phase and that may interact 
from that state with the intestinal wall. Processes A, B and C all occur within the 
intestinal lumen. It is only from process D, that the movement of compounds from the 
intestinal lumen across a membrane into a living organism is envisaged. The exposure 
to both dissolved and solid-bound contaminants can therefore lead to chemical 
interaction with the membrane of an organism and subsequent uptake. Process E in 
Figure 1.10 refers to the subsequent paths of a chemical following absorption. It may 
be biotransformed, bioactivated, transported and exert a toxic effect at the site of 
biological response. The various definitions of the term “oral bioavailability” often 
disagree whether or not process E should be incorporated or not. The reasoning 
behind this is that chemicals which are detoxified during the biotransformation process, 
may be excreted again from the body via the bile or urine. Oomen et al. (2002) for 
example consider the biotransformation processes in the liver to be part of the oral 
bioavailability process.  A formula incorporating different parameters in the equation 
thus allows to calculate the bioavailable fraction: 
F = FBAcc * FAbs *  FMet   
with FBAcc being the bioaccessible fraction (the fraction which is released in the 
intestinal lumen and at maximum available for uptake), FAbs being the fraction 
transported across the intestinal membrane and FM being the fraction which passes 
the liver without being metabolized. For instance, the bioavailability of soil-bound lead 
upon soil ingestion would be 20% if the released fraction from the soil (FBAcc) is 40%, 
the fraction absorbed (FAbs) 50% and the fraction passing the liver 100%.  
This equation includes process E from Figure 1.10, in correspondence with the 
definition by Hrudy et al. (1996) who focused on the parent compound itself. This is in 
agreement with medical and toxicological literature, where the parameters FA and FH 
are taken together under the term ‘absorption’. It pertains to absorption into the 
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systemic blood stream, i.e.: absorption includes both intestinal absorption and the 
process of first-pass metabolism. 
According to Semple et al. (2004), this interpretation may however present a 
problem to risk assessers since it does not include that absorbed contaminants may be 
biotransformed to bioactive compounds which may reside in the body. This way, an 
underestimation of the actual biological availability of a contaminant is obtained, since 
the metabolites in the body are not considered. In this light, it is better to have a more 
conservative oral bioavailability definition, which does not depend on the degree of 
biotransformation activity. Semple et al. (2004) therefore avoid this approach and 
define bioavailability as “that which is freely available to cross an organism’s cellular 
membrane from the medium the organism inhabits at a given time.” Processes which 
do not involve the transfer of a contaminant between its matrix and the organism – 
storage, assimilation, transformation or degradation – are therefore not part of the term 
bioavailability. Translated to human contaminant exposure by oral uptake, this means 
that biotransformation processes are not considered and that from Figure 1.10, only 
processes A through D are taken up in the assessment. Despite these conflicting 
interpretations of the term ‘bioavailability’, it is generally agreed that the entire process 
of a compound to become bioavailable encompasses several processes, including the 
release from the soil matrix, uptake across the intestinal epithelium, first-pass effect 
and distribution to specific organs or cells (NRC, 2003). 
 
 
Calculations. Developing a transparant procedure for performing risk assessment 
studies therefore requires some consensus in how to define oral bioavailability and to 
clearly envisage what fraction of an ingested compound will be measured. To aid in the 
elucidation of the bioavailability process and to allow a pragmatic application of the 
term bioavailability in risk assessment studies, two measures of oral bioavailability can 
be distinguished, especially for HHRA. Absolute bioavailability is the fraction of a 
compound which is ingested, actually absorbed and reaches the systemic circulation 
(Hrudy et al., 1996). Absolute bioavailability (BA) can be defined as the ratio of an 
internal dose (Dint) to an external dose (Dext): 
100int ×=
extD
DBA  
In other words, the absolute bioavailability indicates the relationship between the 
external dose and internal dose of a contaminant to which an organism is exposed 
(Figure 1.11).  
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External Dose 
Increasing Absolute Bioavailability 
Internal 
Dose 
 
Internal Dose Internal 
Dose  20% bioavailable 100% bioavailable 
40% bioavailable
 
Figure 1.11 Influence of bioavailability onto the internal dose of a chemical 
 
For studies of absolute bioavailability, the absorbed dose is often determined by 
measuring the concentration of the compound in blood over time or by measuring the 
mass of the compound in such excreta as urine, feces, or exhaled air (Batelle and 
Exponent, 2000). However, most human toxicity data used in risk assessments are 
based on laboratory animal studies in which the chemical is delivered to the test 
animal in a pure form or as part of a solid or liquid diet. Since the bioavailability of an 
ingested chemical in these toxicity studies is different than in soil, there is a need to 
develop correction factors. The absolute bioavailability is therefore not often used in 
HHRA. Additional tests for estimating contaminant bioavailability, especially for 
hydrophobic contaminants such as PCB, TCDD or pesticides, include measuring the 
contaminant concentration in the fat tissue of an organism. 
Relative bioavailability (RBA) is a measure of the extent of absorption among two 
or more forms of the same chemical (e.g., lead carbonate vs. lead acetate), different 
vehicles (e.g., food, soil, and/or water), or different doses (Batelle and Exponent, 
2000). Matrix effects substantially influence the bioavailability of a soil-bound or 
nutrition-bound contaminant, compared to the medium that was used to test the toxicity 
of that same contaminant. Relative bioavailability can be calculated as:  
sm
s
F
FRBA =  
where Fs is the fraction of the chemical absorbed from soil under circumstances of 
environmental exposure and Fsm is the fraction of the chemical absorbed from the 
study matrix which is used in toxicity studies. Basically this means that the aspect of 
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oral bioavailability is incorporated in this equation, since it takes into account that 
ingested chemicals may differ in absorption, depending on the matrix in which they 
were ingested. If the absorption from soil is found or assumed to be the same as 
absorption in the toxicity study, then the RBA is 1.0 (or 100%). This does not 
necessarily mean that the absorption as such is complete, since the absorption of a 
compound in the toxicity study may also be uncomplete (thus in theory the RBA can 
even be higher than 100%), depending on the test chemical itself or on the 
physiological conditions of the test organism. The relative bioavailability factor thus 
accounts for the difference in oral bioavailability caused by the matrix of ingestion 
(NRC, 2003). If there is no difference between the chemical form or test matrix that 
was used in the toxicity study and that which is of interest in the risk assessment of a 
contaminated soil, there is no need to determine the RBA.  
 
2.5.3 Use of bioavailability in risk assessment 
The previous discussion on what bioavailability means and what types of measures 
can be distinguished, is of significant importance to the risk assessment process for 
oral exposure to soil bound contaminants. It suggests that greater attention to this 
biological availability or ‘bioavailability’ of chemicals is needed to realistically evaluate 
their potential risk. Hence, current risk assessment procedures not only compare 
contaminant concentrations from the soil with risk-based screening levels from toxicity 
studies, which represent a conservative estimate of risk. They also incorporate the 
input of site-specific parameters, including bioavailability, thus decreasing the 
uncertainty levels and making a more accurate site-specific risk assessment possible. 
Incorporation of bioavailability into risk assessment happens at all four levels of the 
risk assessment process: risk identification, dose-response assessment, exposure 
assessment and risk characterization. The risk identification step at a contaminated 
site allows to determine the different risk groups and the pathways of how soil 
contaminants may end up in the human gastrointestinal tract. For example, ingestion 
of fine inhaled soil particles by construction workers or ingestion of larger soil 
particulates will clearly affect the bioavailability of the soil contaminants and also the 
selection of a specific method to investigate the actual exposure. 
As discussed above, the dose-response assessment entails the generation of 
toxicity values that are based on several biological assays (in vivo or in vitro) in which 
the relationship between the dose of a chemical and its toxic effects are evaluated and 
which allow an extrapolation to the field situation. Although bioassays are valuable 
tools in the characterization of toxic action of chemicals and in the understanding of 
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associated toxicity, they do not consider all the processes in the body or other 
environmental factors that influence toxicity (Fent, 2003). Most toxicity values are 
therefore based on applied doses, rather than the doses to which the human body is 
really exposed. This implies that the toxicity value is still a function of the rate and 
extent of absorption that occurs in the study. In other words, it is dependent on 
bioavailability processes that are not inherently part of those processes that make up 
the actual toxicity of a compound (Figure 1.12). Hence, working with toxicity values 
and performing reliable risk assessment studies implies a proper understanding of 
those processes that influence bioavailability, such as the interaction of freely 
dissolved contaminants with dissolved or particulate organic matter in the intestinal 
lumen. 
During the exposure assessment, knowledge of the bioavailability of a contaminant 
in soil is necessary to accurately estimate the fraction of the exposure dose of the 
contaminant that has the potential to impact human health. The soil ingestion equation 
as defined in part 1.2 incorporates bioavailability data. It can either be used to modify 
the chemical concentration in the soil (Cs) by expressing it as the concentration of the 
bioavailable fraction of contaminant rather than the chemical concentration, or it can be 
used in the relative absorption factor. Since most risk assessment studies currently 
assume that the absorption of soil-bound contaminants is 100%, there may be a large 
overstimation of the actual risk posed by that contaminant. Further research 
investigating those processes that precede bioavailability is therefore warranted. 
 
 
Figure 1.12 Ecotoxicological effects are dependent on the bioavailable fraction of 
pollutants, and concentrations at the target sites induce molecular effects that 
propagate to a variety of toxic manifestations in organisms. Adapted from  
Escher et al. (1997). 
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The final step in the risk assessment process determines whether the risk from 
soil-bound contaminants when ingested, exceeds acceptable levels. From the dose-
response and exposure assessment, it can be concluded that the bioavailability 
process will impact the internal exposed dose and also the subsequent risk. The risk 
characterization step which relies on the PEC/PNEC ratio, therefore also relies on 
accurate bioavailability measurements. More specifically, bioavailability is inversely 
related to risk-based cleanup levels from soil (Figure 1.13). The regulatory 
consequences of the bioavailability concept are thus considerable.  
 
 
Figure 1.13 Relationship between bioavailability and risk assessment endpoints (Batelle 
and Exponent, 2000). 
 
 
2.5.4 Bioaccessibility – a novel concept in HHRA 
As discussed above, the measurement of bioavailable fractions of ingested 
contaminants is crucial for a successful HHRA. In vivo experiments allow a 
comprehensive study of the fraction of a chemical reaching the blood compartment 
and its toxicity. Yet, those processes that preclude intestinal absorption are a black box 
to these experiments. Several parameters play a crucial role and at this point, it is 
important to introduce the term bioaccessibility which is basically a compilation of 
processes A, B and C in Figure 1.10 describing a fraction of the ingested contaminant 
which comes into consideration for intestinal absorption. This differentiation of 
bioaccessibility from bioavailability corresponds to the definition from Hamel et al. 
(1998) who state that “The bioaccessibility is defined as the maximal amount of 
contaminant that is soluble in a synthetic gastrointestinal fluid and therefore potentially 
available for uptake across the intestinal lumen.” Other researchers have also 
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identified the fraction of the contaminant that is mobilized from soil into the digestive 
juice chyme as the bioaccessible fraction (Ruby et al., 1996; Ruby et al., 1999; Oomen 
et al., 2002). This fraction is considered to represent the maximum amount of 
contaminant available for intestinal absorption. Bioaccessible contaminants can 
subsequently be absorbed, that is, transported across the intestinal wall, 
biotransformed by the liver and transferred to the blood or lymph. Assessment of the 
bioaccessibility of an ingested soil-bound chemical can be very useful for a final 
estimate of the oral bioavailability. Bioaccessibility is thus an important parameter to 
integrate in the exposure assessment step. 
A series of compartments are involved in human uptake of ingested soil 
contaminants. The overall pathway leads the soil with contaminants from the 
mechanical grinding in the mouth through a series of chemical and microbiological 
processes to partial dissolution through the entire gastrointestinal tract (bioaccessibility 
processes). Most of the dissolution processes are completed before the material is 
leaving the small intestine, and it is generally accepted that most of the uptake takes 
place in the small intestine. The physicochemical conditions in the intestinal lumen 
may depend on the physiological state of the host (fasting or eating), the age, the 
contaminated matrix which is ingested… All these processes and parameters influence 
the bioaccessibility of ingested contaminants and therefore, also their bioavailability 
(Oomen et al., 2002). The most important functions and parameters of influence of the 
bioaccessibility process occur in the mouth, stomach and small intestine. The mouth 
primarily has a grinding function, decreasing the size of the ingested matrix, and the 
enzymatic cleavage of starch by amylase. The residence time varies from seconds to 
minutes and the degree of grinding is of large influence for the dissolution of a 
contaminant from its matrix.  
The specific effects of the stomach conditions towards soil-bound chemicals is 
mainly oriented towards dissolution and release of chemicals in the gastric suspension. 
This is established by pH values that may go as low as 1, but that may also be as high 
as 4 under fed conditions. Depending on the fed or fasted state, the residence time in 
the stomach may vary from 3 hours to only 10 minutes. The contaminant dissolution 
functions in the small intestine are more variable and complex. The pH in the small 
intestine varies from 4.5 to 7 whereas the residence time is usually between 3 and 10 
hours. A large number of dissolution and complexation processes in the small 
intestinal suspension may further release contaminants from soil, but on the other 
hand, several complexation reactions may also occur as for example with metals that 
are precipitated at higher pH values or with phosphate. Cationic metals and 
hydrophobic contaminants are more easily solubilized by the complexation with bile 
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salts which increases the bioaccessible fraction and thus their chance of being 
absorbed across the intestinal epithelium. Also, lipids and other soluble organic matter 
in the intestinal suspension can add to the carrier effect of the bile.  
Clearly, the complexity of processes occuring in the gastrointestinal tract are of 
large influence to the bioavailability of an ingested soil-bound contaminant. For the 
relative bioavailability process, bioaccessibility would thus represent a very important 
rate limiting step, next to intestinal absorption. The bioaccessibility process is very 
sensitive to the different luminal factors from the gastrointestinal tract, whereas 
intestinal absorption of bioaccessible compounds is less sensitive to luminal processes 
and biotransformation of absorbed contaminants would be insensitive. Assessment of 
the relative bioavailability of a chemical would thus rely on the measurement of the 
bioaccessibility and the intestinal absorption as the two rate limiting steps. If the 
bioaccessibility process is rate limiting (i.e. if dissolution is slower than absorption), 
then bioaccessibility will determine the relative bioavailability. If the absorption process 
is rate limiting (i.e. absorption of dissolved contaminants is to slow to be completed 
before transit), the intestinal absorption will dominate the relative bioavailability.  
 
2.5.5 Problems with bioaccessibility  
The term bioaccessibility for environmental contamination was introduced by Ruby 
et al. (1993) who investigated the relative solubility of ingested lead (Pb) from different 
mine wastes in the gastrointestinal tract. Since then, it has been used for other 
contaminants such as heavy metals, lindane, PCBs, PCDD/Fs, PAHs, radionuclides 
(Hack and Selenka, 1996; Davis et al., 1997; Hamel et al., 1999; Oomen et al., 2000; 
Ellickson et al., 2002; Van de Wiele et al., 2004a) and also for nutritional constituents 
such as isoflavones, folic acid, and carotene (Arkbåge et al., 2003, Vuong et al., 2003; 
Walsch et al., 2003). Bioaccessibility measurements for site-specific risk assessment 
studies are significantly gaining importance since they offer an efficient, cheap and 
high-throughput alternative to the time-consuming and expensive in vivo methods that 
are often used. 
However, there is one big flaw in the current use of the bioaccessibility concept: 
almost every research group that applies it, uses another method to measure the 
bioaccessible fraction in the intestinal lumen. The two causes are that 1) the in vitro 
models all differ in complexity and digestion parameters (different enzyme 
concentrations, pH values and residence times) and 2) different methods for 
separating bioaccessible from non-bioaccessible contaminants are used. There is 
currently no consensus at all what seperation process is best. Depending on the used 
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in vitro method or on the compound under study, researchers have used 0.45 µm 
filtration (Ruby et al., 1996), 3000×g centrifugation (Oomen et al., 2001; Ruby et al., 
2002), 7000×g centrifugation (Hack and Selenka, 1996), a combination of 1100×g 
centrifugation with 0.45 µm filtration (Holman et al. 2002), 10 kDa ultrafiltration 
(Minekus et al., 1995)… Obviously, using different methods to measure the 
bioaccessible fraction will lead to a different outcome when soils are tested.  
Although several in vitro methods have been validated against in vivo data 
(Minekus et al., 1995; Hack and Selenka, 1996; Rodriguez and Basta, 1999), this has 
only been done under well-defined circumstances and it can not always be extended to 
other site-specific situations. Obviously, if all methods claim to give an estimate of 
bioaccessibility and if all methods are substantially different, different correction factors 
that relate bioaccessibility to oral bioavailability need to be implemented, which 
unnecessarily adds to the uncertainty of the risk assessment. Additionally, if 
bioaccessibility values for one single contaminated soil change with the used in vitro 
method, the risk assessment process itself is totally unreliable. 
For this reason, the BioAccesibility Research Group of Europe (BARGE) was 
established in 2000 which assembles several scientific and governmental institutes 
from Europe (Figure 1.14). The actively involved partners are affiliated with the British 
Geology Survey (UK), University of Nottingham (UK), TNO Nutrition and Food 
Research (The Netherlands), The National Institute for Public Health and the 
Environment (RIVM, The Netherlands), DHI Water and Environment (Denmark), The 
Flemish Institute for Technological Research (VITO, Belgium) and Ghent University 
(Belgium). American and Canadian partners take part of the discussions and are 
affiliated with Ohio State University, Oak Ridge National Laboratories and Jacques 
Whitford Environment.  
 
 
Figure 1.14 Logo of the BioAccessibility Research Group Europe.  
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The goal of BARGE is to compare and evaluate the many models and systems that 
have been developed over the years to estimate bioaccessibility and contaminant 
exposure. The ultimate goal is to develop a methodology which indicates what the 
default digestion parameter values are for different risk groups and which parameters 
need to be changed to specifically use in vitro models for site specific risk assessment. 
From the BARGE viewpoint, it is assumed that more realistic and defensible 
bioaccessibility factors can be obtained which can then be used for risk assessment 
and policy making. In a first research initiative, Oomen et al. (2002) showed that 
indeed the variability among in vitro digestion models is extremely high and that this is 
also translated in the outcome of bioaccessibility measurements. Five different in vitro 
models of the human gastrointestinal tract were used to measure lead, arsenic and 
cadmium bioaccessibility from different contaminated soils. The in vitro digestion 
models produced a wide range of bioaccessibility values for three contaminated soils 
(Table 1.5). 
 
Table 1.5  Bioaccessibility values (%) for arsenic, cadmium and lead in Montana 2711 soil 
as obtained from 5 in vitro digestion models of the human GI tract.  
  Arsenic Cadmium Lead 
SBET (BGS) 59 99 90 
RIVM method 50 79 68 
DIN (Bochum University) 59 40 11 
SHIME (Ghent University) 10 6 3 
TIM (TNO-Nutrition) 50 58 17 
 
Clearly, these numbers reveal nothing more than that there is a large variability in the 
data set due to differences between the model digestion parameters. Comparison of 
specific parameters however revealed that key parameters in the bioaccessibility 
process were the low stomach pH and the presence of food particles, both positively 
influencing bioaccessibility of soil-bound heavy metals. The acidic environment in the 
stomach mobilizes more easily metals thus increasing the released fraction, while food 
particles provide complexation niches in the intestinal liquid matrix, thus driving the 
contaminant equilibrium between soil and chyme towards desorption from the soil 
matrix. It was  concluded that organic matter from food particles enhance mobilization 
and thus the bioaccessible fraction. Chapter 2 of this dissertation will study these in 
vitro methods in more detail. 
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3. Studying the human GI tract  
3.1 In vivo experiments 
The main advantage of in vivo models is that the complexity of physiological 
parameters is integrated in the experiments. Investigating desorption and complexation 
processes in the gut of resp. oligochaetes, other invertebrates, fish, rodents and other 
mammals has proven to be useful as relevant tests of oral bioavailability (Gomot-de 
Vaufleury and Pihan, 2002; Koganti et al., 1998; Loonen et al., 1997; Oste et al., 2001; 
Yan and Wang, 2002; Willett et al., 2001). Additionally, metabolic studies using 
conventional and germ-free or gnotobiotic animals may be used to investigate the 
metabolism by gastrointestinal microbiota (Hirayama et al., 2000). In general, drug 
absorption in animals is believed to be a good predictor of absorption in humans. 
Animals integrate all the biological factors that may affect drug absorption and 
metabolism. Unlike in vitro systems, in which a correlation to in vivo data must be 
established, this step is unnecessary when animals are used (Hidalgo, 2001). An 
additional advantage of using animals for oral bioavailability and microbial metabolism 
studies is that the used species in these studies can be same as those used in 
pharmacological and toxicological studies.  
Disadvantages to in vivo studies are the relatively large amount of material that is 
needed, the complexity of analytical methods for the analysis of blood and tissues and 
the time-consuming and labor-intensive nature of the experiments. Additionally, in vivo 
experiments provide little mechanistic information on the processes that are important 
prerequisites to oral bioavailability. It is impossible to separate the variables involved in 
the process of absorption, thus making identification of individual rate-limiting factors 
impossible. Hence, contaminant release and complexation processes that influence 
the bioaccessible fraction of a compound inside the GI tract are unknown mechanisms 
in such studies. Moreover, given the discrepancies between the physiology of humans 
and other organisms, as well as the low reproducibility and ethical constraints 
associated with such studies, a more efficient alternative is desirable (Ruby et al., 
1999). In vitro models from the human GI tract have therefore been developed. 
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3.2 In vitro experiments 
In vitro digestion experiments are specifically designed to aid in the exposure 
assessment step of the risk management process. Although the outcome of such 
studies may significantly contribute in the interpretation of bioavailability data, the value 
of in vitro digestion experiments may not be overestimated since it merely deals with a 
physicochemical approach. In contrast to in vivo tests, in vitro experiments should 
focus solely on bioaccessibility measurements because this step in oral bioavailability 
is assumed to represent the step that is most sensitive to the ingestion matrix. In 
addition, an in vitro model facilitates a systematic investigation of many variables 
(Oomen et al., 2003) thus focusing on all processes and parameters that influence the 
dissolution of a compound from its matrix and its availability for intestinal absorption. In 
vitro digestion models that mimic the human GI tract can elucidate these phenomena. 
These models, based on the physiology of humans, are generally more simple, less 
time-consuming and especially more reproducible than animal tests. Tests that 
simulate stomach and small intestinal conditions (Hack and Selenka, 1996; Ruby et al., 
1996; Jin et al., 1999; Oomen et al., 2000) and intestinal transport through Caco-2 
tissue cultures have been described before (Oomen et al. 2001) and could provide a 
rapid and inexpensive method for developing more accurate exposure estimates for 
use in human health risk assessments. Specifically for the risk assessment of 
contaminants ingested with soil, Oomen et al. (2003) define a couple of requirements 
that an appropriate in vitro method should fulfill:  
 Representation of human physiology, and more specifically, physiology of 
children, because soil ingestion is an important route of exposure for 
children due to frequent hand-to-mouth behavior (Duggan and Inskip 1985; 
Davis and Waller 1990; Calabrese et al. 1997a). 
 Representation of a worst-case situation, but this should be as realistic as 
possible. This situation is compound-dependent. 
Several in vitro methods are sequential extractions with two distinct extraction 
steps: a gastric-phase extraction that simulates the acidic biochemical stomach 
environment and a subsequent intestinal-phase extraction that simulates the 
biochemical environment of the small intestine (Schröder et al. 2003). The 
bioaccessible fraction of the soil contaminants that are subjected to these two steps, is 
then related to the relative bioavailable fraction by validation with animal models. This 
approach of mimicking the gastrointestinal conditions in a two-phase extraction test 
has been used to estimate the bioaccessibility of lead (Ruby et al., 1996; Oomen et al., 
2001, 2003), cadmium (Hamel et al., 1998), arsenic (Rodriguez and Basta., 1999) and 
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also some organic contaminants such as lindane (Oomen et al., 2000), PCB (Hack and 
Selenka, 1996) and PAHs (Van de Wiele et al., 2004a). 
 
In vitro models can be split up in static and dynamic models. Most models are 
static gastrointestinal models, which simulate transit through the human digestive tract 
by sequential exposure of the soil to simulated mouth, gastric, and small intestinal 
conditions. In the simplest approach, the in vitro stomach model, mobilization of the 
contaminants from soil under gastric pH conditions is simulated. The best known 
example of an in vitro stomach model is the SBET method or Simple Bioaccessibility 
Extraction Test which simulates the mobilization of contaminants in the acid conditions 
of the stomach. An intestinal compartment is not employed. This model is adapted 
from a model described by Ruby et al. (1993), which was initially developed for 
measuring lead bioaccessibility but which has also been used for other metals (Oomen 
et al., 2002). This model has been validated to the in vivo situation using swine studies 
(Ruby et al., 1999). Although the SBET method has proven its applicability in several 
studies, its major disadvantage is that it does not include a small intestinal step. 
Although correction factors are used to relate the SBET experimental data to relative 
bioavailability estimates, the uncertainty is fairly high and the actual release 
complexation process of contaminants are not elucidated. Several static models have 
therefore been developed to also include the small intestinal step to arrive to more 
realistic conditions for the gastrointestinal lumen. The PBET method stands for the 
Physiologically Based Extraction Step and is used by Ruby et al. (1999) and the BGS 
institute (UK) for the bioaccessibility assessment of lead and arsenic. The German 
method E DIN 19738 has its origin in the in vitro digestion models by Rotard et al. 
(1995) and Hack and Selenka (1996). It is a static in vitro gastrointestinal model using 
synthetic digestive juices. Because it is assumed that saliva has only a negligible effect 
on the level of mobilization of contaminants from soil, only synthetic gastric and 
synthetic intestinal juices are used. Whole milk powder (50 g/L) may be added to the 
test system to simulate the influence of food on the mobilization of contaminants. The 
National Institute of Public Health and the Environment (RIVM) in the Netherlands has 
also developed a static in vitro model which resembles that of Germany. However, a 
saliva step is also introduced into this model to simulate the biochemical conditions 
from the mouth.  
In contrast to these static models, dynamic gastrointestinal models mimic the 
gradual transit of ingested compounds through the digestive tract and may mimic more 
aspects of the human physiology. Major disadvantages are the complexity and cost of 
such models and also the fact that only a limited number of samples can be tested at 
 46
Literature review 
the same time. A first example of a dynamic model for the human gastrointestinal tract 
is the TIM model (TNO Intestinal Model) that simulates the transit through the 
gastrointestinal tract, the gastric and intestinal pH profiles, and the secretion of 
digestive juice over time (Minekus et al., 1995). This model has been validated by 
comparing the dissolution profile of drugs in vivo and in vitro, and with food 
components. The experiments with soil are performed while reproducing conditions 
that occur during digestion of a semiliquid meal.  
A second example of dynamic models is the SHIME (Simulator of the Human 
Intestinal Microbial Ecosystem) which effectively models the human intestinal tract 
(Molly et al., 1993; 1994). It is an automated and robust multi-stage reactor that is 
amenable to bioavailability estimates. This computer-controlled dynamic model 
consists of five compartments, each compartment vessel simulating a different part of 
the GI tract from the stomach and small intestine to the proximal and distal part of the 
colon. The SHIME reactor differentiates itself from other in vitro intestinal models, 
because it comprises the whole GI tract taking into account the enzymatic processes in 
stomach and duodenum and the different characteristics of the microbiota along the 
colon reactors. Models such as these allow to investigate the biochemical and physical 
processes, contributing to contaminant release from soil matrices inside the human 
gastrointestinal tract. 
 
In vitro models of the gastrointestinal tract are also specifically suitable when 
research has to be carried out on the intestinal microbiota. Since the proximal colon is 
unaccessible to routine investigations, microbiological research on the GI tract is 
usually carried out by isolating microorganisms from fecal matter and growing them in 
batch cultures or one-compartment chemostats. The most simple experimental setup 
for studying the metabolism of intestinal microbiota is an anaerobe batch reactor. In 
these fermentor vessels suspensions of fecal material are brought in a buffered growth 
medium and incubated under anaerobic conditions. This method is very userfriendly 
given its simplicity. Yet, it is only useful for limited periods of time since environmental 
parameters such as pH, redox potential, available nutrients and microbial population 
dynamics constantly change. In order to maintain the inoculated intestinal microbiota 
over a longer timeframe, semi-continuous fermentor vessels were developed where 
the intermittent supplementation of nutritional medium and the removal of microbial 
suspension could be simulated (Miller and Wolin, 1981; Manning et al., 1987). The 
latter systems typically make use of one single fermentor. The colon is however a very 
heterogeneous region with clear differences in substrate availability, fermentation 
activity, microbial composition and several environmental conditions. This makes it 
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impossible to simulate a representative culture of colon microbiota in one compartment 
(Macfarlane et al., 1998). Several multi-compartment reactors were developed to 
simulate the different conditions of the colon lumen (Veilleux and Rowland, 1981; 
Macfarlane et al., 1989; Miller and Wolin, 1981; Molly et al., 1993; Minekus et al., 
1999). In light of the research that was conducted for this PhD, the TIM2 model from 
TNO Nutrition and the SHIME developed by LabMET are the most important 
examples. 
 
In vitro digestion models are likely to become increasingly important in risk 
assessment of polluted soils, especially for determining the urgency of remediation 
(Oomen et al., 2002). At present there is no standard method to estimate 
bioaccessibility. Many digestion models exist with various experimental designs. The 
different models rarely result in similar bioaccessibility values and it needs further 
investigation to identify the key parameters that influence the bioaccessibility of a 
compound in these models. Future research should aim at narrowing the window of 
uncertainty and arrive to a standard procedure of how to use the different models to 
assess bioaccessibility. 
 
4. Objectives 
Ingestion is one of the most important exposure routes by which contaminants may 
enter the human body. Assessing the risks that are associated with this exposure 
necessitates an adequate understanding of the different steps that are involved from 
the ingestion of a contaminant to its bioavailability and eventual toxicity. In this PhD 
research two aspects were studied in more detail: bioaccessibility and microbial 
biotransformation. The reason for this is that literature study indicated that these 
parameters are not fully understood or investigated when estimating health risks from 
ingested soil contaminants.  
Firstly, the use of in vivo experiments using rats, mice, guinae-pigs or primates as 
the most relevant approach to assess contaminant bioavailability does not allow a 
complete elucidation of those processes that are important processes determining the 
bioavailable fraction. Luminal processes towards ingested contaminants remain a 
‘black box’ to these types of in vivo experiments. Secondly, specific toxicokinetic and 
pharmacological studies allow to investigate the processes to which chemicals are 
subjected once transported across the intestinal wall. Yet, the non-absorbed chemicals 
may still become available to colon microorganisms that are capable of metabolizing 
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chemical compounds, not only nutritional but also xenobiotic. Except for some 
pharmaceutical compounds, not much information is available about this microbial 
metabolic potency. These two issues will be addressed in this PhD research in the 
following outline. 
 
Chapter 2 will first describe different in vitro methods of the human gastrointestinal 
tract that have been used to assess the bioaccessible fraction of soil-borne lead. The 
outcome of the different methods will be compared and possible differences will be 
explained by parameters that distinguish one model from the other. Additionally, a brief 
comparison will be made with in vivo data from a study in which the bioavailability of 
lead from that same soil matrix was measured with human volunteers. In contrast to 
this chapter that deals with lead, the other research chapter all investigated 
bioaccessibility or microbial biotransformation of PAHs. The reason for this is that the 
comparison study from Chapter 2 was conducted within the BARGE consortium. Due 
to the high complexity of the different bioavailability and bioaccessibility processes, the 
BARGE consortium has decided to initially investigate the behavior of soil-borne heavy 
metals in the gut. Studying organic contaminants such as PAHs currently causes 
several practical problems making the research more complex for several institutes to 
carry it out in parallel. 
Chapter 3 will specifically focus on the release and complexation processes of 
PAHs in the intestinal lumen, which is important for a proper assessment of the 
bioaccessible fraction of ingested soil-bound PAHs. This part of the research will deal 
with several parameters that are playing a keyrole in the bioaccessibility process and 
will describe a mathematical model which can be specifically used for the PAH 
contaminated soil which was investigated. The subsequent chapters will deal with the 
microbial processes that may be related to PAH toxicity in the intestinal lumen. Based 
on preliminary bioassay data, there were good indications that colon microbiota were 
capable of transforming PAHs into more bioactive compounds, more in particular with 
estrogenic activity.  
Chapter 4 describes the development and optimization of an analytical method 
using liquid chromatography coupled to mass spectrometry (LC-MS) to screen for 
microbial PAH metabolites that may have estrogenic properties, more specifically 
hydroxy-PAHs. 
Chapter 5 focuses on the estrogenic activity of the PAH metabolites. Using two 
bioassays, the aryl hydrocarbon receptor yeast assay and the estrogen receptor yeast 
assay, the affinity of PAH parent compounds and hydroxy-PAH metabolites for human 
receptors will be measured. This will be brought in direct relationship with the PAH 
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bioactivation potency of intestinal microbiota, an aspect that has not been investigated 
thus far in HHRA.  
Chapter 6 reports that supplementation of inulin, a much studied prebiotic 
compound, not only has prebiotic effects, but also a chemopreventive action. More in 
particular, it will be shown that the PAH bioactivation potency of the colon microbiota is 
largely inhibited by the indirect effects that inulin supplementation purports in the colon 
lumen.  
Chapter 7 will give a general discussion of the different research chapters and 
deliver some take home messages that have come out of the research. Additionally, 
important links can be made with future scientific research which will study the 
contribution of luminal processes in the intestine, including microbial metabolism, to 
the total risk of ingested contaminants, not only from soil, but also from nutrition. An 
important link with the relationship between the intestinal microbiota and the intestinal 
epithelial wall can be brought forward and open perspectives for new research 
initiatives.  
 
All experiments in this PhD research were carried out with the aid of a SHIME reactor 
(Figure 1.15). Batch experiments with SHIME specific parameters were used to 
perform the large number of digestion experiments. A full-scale SHIME run was 
applied to monitor shifts in the microbial community in Chapter 6. 
 
 
Figure 1.15 Laboratory setup of the Simulator of the Human Intestinal Microbial Ecosystem 
at LabMET. 
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Comparison of five in vitro models of the human 
gastrointestinal tract to assess lead bioaccessibility 
 
Abstract 
This paper presents a multi-laboratory comparison study of in vitro models 
assessing bioaccessibility of soil-bound lead in the human gastrointestinal tract under 
simulated fasted and fed conditions. Bioaccessibility is an important prerequisite to oral 
bioavailability. Yet, the relation between these two parameters is not wel understood. 
Therefore, the bioaccessibility results of this round-robin were compared with 
bioavailability data from a previous human in vivo study in which the same soil was 
investigated. In general, the bioaccessible lead fraction was significantly (p<0.05) 
different for each in vitro method and ranged for the fasted models from 2 % to 33 % 
and for the fed models from 7 % to 29 %. The in vivo data from literature were 26.2 % 
for fasted conditions, compared to 2.5 % for fed conditions. Three in vitro methods 
gave higher lead bioaccessibility values under fed conditions whereas two other 
methods showed the reverse trend, the latter in analogy with the in vivo study. The 
separation step for estimating bioaccessible lead (centrifugation speed, filtration, 
dialysis) was of major influence for the interpretation of the results. The use of 
ultrafiltration membranes mimics the in vivo data more closely, both under fasted as 
fed conditions. We conclude that the relationship between bioaccessibility and 
bioavailability depends on both the used in vitro model as the separation tool to assess 
bioaccessibility. It appears that the use of hollow-fibre membranes may decrease the 
correction factors needed to link in vitro to in vivo results. 
 
 
 
 
 
Redrafted after: Van de Wiele TR, Oomen AG, Wragg J, Cave M, Minekus M, Hack A, 
Cornelis C, Rompelberg CJM, De Zwart LL, Klinck B, Van Wijnen J, Verstraete W, Sips AJAM. 
Comparison of five in vitro digestion models with in vivo data: lead bioaccessibility in the human 
gastrointestinal tract. Submitted. 
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Introduction 
Lead is a wide spread heavy metal in the environment and toxic to the human body 
by both chronic or acute exposure. The nervous system is the most sensitive target of 
lead exposure (Rosen, 1995), but basically, lead can affect every organ system, 
leading to anemia, renal problems and hypertension (ATSDR 1999). Lead can also 
decrease sperm count and increase abnormal sperm densities (Alexander et al., 1996; 
Telisman et al., 2000). Exposure to lead primarily occurs through inhalation and 
ingestion of contaminated matrices. Unfortunately, the soil and dust of urban areas 
with their associated high traffic and industrial density have higher lead concentrations 
than remote areas (ATSDR, 1999). 
Oral exposure not only to lead, but other environmental contaminants via soil ingestion 
is an important public health issue. Site-specific risk assessment studies incorporate 
soil ingestion with a maximal daily intake of 50 and 150 mg soil d-1 for adults and 
children, respectively (EPA, 1997). Reported human soil intake rates generally range 
from 1 to 50 mg d-1 for adults and from 100 to 500 mg d-1 for children (Brunekreef et 
al., 1987; Vanwijnen et al., 1990; Calabrese et al., 1997a). However, pica afflicted 
children may show an unusual hand-to-mouth behavior and can ingest several grams 
up to 20 g soil d-1 (Calabrese et al., 1997a). Estimating the health risk associated with 
ingestion of contaminated soils requires an understanding of how contaminants are 
solubilized in the intestinal suspension and which fraction is considered for intestinal 
absorption.  
The concepts of bioaccessibility and oral bioavailability are fundamentally important for 
investigating oral exposure to environmental contaminants. Bioaccessibility refers to 
the fraction of a contaminant that is released from soil into solution by digestive juices. 
It gives the maximum amount of contaminant that is available for intestinal absorption. 
In general, only a fraction of these bioaccessible contaminants can be absorbed by the 
intestinal epithelium and subsequently transported to the liver for biotransformation 
processes. The fraction of parent compound that reaches the systemic circulation is 
referred to as the bioavailable fraction (Figure 2.1). The two principal factors limiting 
the bioavailable fraction of a contaminant, are dissolution in the gastrointestinal tract 
and the actual intestinal absorption. In current risk assessment practice for 
environmental contaminants, oral doses from various exposure routes are compared 
with toxicological reference values based on intakes from water or food matrices. Soil 
bound contaminants, however, have different desorption and complexation processes 
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in the gastrointestinal tract than those found in food or water. These processes are 
suspected to influence their bioaccessibility (Oomen et al., 2002). 
 
Figure 2.1  Overview of how ingested matrix-bound contaminants may become 
bioavailable in the gastrointestinal tract 
Human bioavailability data from actual human feeding tests are scarce (Maddaloni et 
al., 1998) and in vivo experiments in general are costly, time consuming and related to 
ethical constraints. An alternative is the application of in vitro models that simulate the 
human gastrointestinal tract. These screening methods are fast, reproducible and 
reliable and can be used to measure the bioaccessible contaminant fraction, as 
bioaccessibility is an important parameter prior to bioavailability. Several in vitro 
methods of the human gut have been developed (Molly et al., 1993; Minekus et al., 
1995; Ruby et al., 1996; Hack and Selenka, 1996; Jin et al., 1999; Oomen et al., 2002) 
and validated. Some of these methods have already been applied to measure 
bioaccessibility of both heavy metals and organic compounds (Hack and Selenka, 
1996; Ruby et al., 1996; Oomen et al., 2000; Ruby et al., 2002). In a previous paper, 
we compared five in vitro digestion models that were applied on standard reference 
soils contaminated with arsenic, cadmium and lead (Oomen et al., 2002). However, no 
clear association exists between the bioaccessible fraction assessed in these tests and 
human bioavailability data. The purpose of this research was to compare in vitro 
bioaccessibility estimates with in vivo data.  To accomplish this we used five different 
in vitro digestion models to estimate lead bioaccessibility from the Bunker Hill soil and 
compared these results to those of Maddaloni et al. (1998) who measured oral lead 
External exposure 
Mouth
Stomach, Small intestine 
Small intestine, Portal vein 
Liver
Systemic circulation 
Exposure to matrix bound contaminant 
Ingestion of matrix and contaminant
FBAcc=Fraction released from the matrix (Bioaccessibility)
FAbs=Fraction of FBAcc absorbed by small intestine 
FMet=Fraction of FAbs passing liver without metabolism 
F=Fraction of external dose reaching systemic circulation
F = FBAcc * FAbs * FMetInternal exposure 
 53
Chapter 2 
bioavailability in adults for the same Bunker Hill soil. Similar to the in vivo study, we 
investigated fasted and fed conditions in the gastrointestinal tract. Our intention was 
not only to evaluate the different in vitro methods but also to highlight areas in which 
the models should converge to best mimic in vivo results. This comparison study could 
improve our understanding of how to relate bioaccessibility to oral bioavailability of 
ingested soil contaminants.  
  
Materials and Methods 
Soil. The standard reference Bunker Hill soil was kindly provided by Mark 
Maddaloni. It contains mostly clay and 3% organic matter and has a pH-H2O of 5.5. 
The bioavailability of Pb in Bunker Hill soil to humans has been determined in an in 
vivo study by Maddaloni et al. (Maddaloni et al., 1998). Bunker Hill soil in the present 
study has not been subjected to γ irradiation for sterilization.  
  
Experimental design. The bioaccessibility of Pb in the Bunker Hill soil was 
assessed with five in vitro digestion models. Four of the models are so called ‘static 
models’: the modified PBET method (Physiologically Based Extraction Test) operated 
by the BGS (United Kingdom); the German E DIN 19738, applied by the Ruhr-
Universität Bochum (Germany); the RIVM (the Netherlands) in-vitro digestion model 
and the SHIME procedure used by LabMET (Ghent University, Belgium). The only 
dynamic gastro-intestinal model used is the TIM method (TNO, the Netherlands). The 
models are described in more detail below. Maddaloni et al. (1998) investigated two 
scenarios in their bioavailability study of a lead contaminated soil: fasted conditions in 
which soil was ingested with water upon overnight fasting and fed conditions where 
soil was ingested with a standard breakfast meal. In this study, fasted and fed 
conditions were applied for every in vitro model too. However, the composition of the 
nutrition was in most cases not the same as that used in the in vivo study, since the 
intrinsic intentions and concepts of the methods (for example simulation of the child’s 
gut) were left unchanged.  
 
Pb analysis. Pb analysis of the digestive juices, the pellets and the Bunker Hill soil 
was performed by the Flemish Institute for Technological Research (VITO, Belgium). 
This way, possible differences in bioaccessibility values that would originate from the 
different analytical methodology to measure the lead content in the samples were 
eliminated.  The Bunker Hill soil was analyzed in triplicate for lead content using a 
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closed microwave oven destruction with HCl/HNO3 (3+1) and ICP-AES quantification.  
The pellets from the in vitro bioaccessibility tests were dried until constant weight; lead 
determination was performed the same way as for the soil analyses.  Liquid samples 
were digested by semi-open microwave oven destruction with HCl/HNO3 (3+1) and 
ICP-MS or ICP-AES determination depending on the lead concentration in solution.  
Blank digestion solutions were analyzed as a control. 
 
Description of in vitro digestion models. 
PBET (Physiologically Based Extraction Test), BGS, United Kingdom. (Ruby et al., 
1996). 1.0 g of soil was weighed into wide mouthed HDPE (high density polyethylene) 
bottles.  100 mL of simulated gastric solution (1.25 g pepsin, 0.50 g sodium malate, 
0.50 g sodium citrate, 420 µl lactate and 500 µl acetate per liter de-ionised water, 
adjusted to pH 2.5 with concentrated hydrochloric acid) was added to each bottle.  The 
bottles were placed in a water rotator set at 37°C. For the fed and fasted experiments, 
1 g of Bunker Hill soil was extracted in triplicate for each method. After one hour at 
37°C, a 5.0 mL aliquot was removed and filtered through a 0.45 µm cellulose filter disk 
for analysis. This extraction sample is known as the stomach phase. Five mL of the 
original gastric solution was then back-flushed through the filter into the HDPE bottle to 
retain the original L/S ratio (liquid (mL) to soil (g) ratio). The conditions in the vessel 
were then altered from stomach to small intestinal conditions by titration to pH 7.0 with 
saturated sodium bicarbonate and the addition of 175 mg bile salts and 50 mg 
pancreatin. The samples were then incubated in the water bath for four hours. These 
samples represented the small intestine. The experiments to simulate fed state 
included the addition of 1.0 g of baby whole milk powder (Cow & Gate, UK) to the 
digestive suspension. The composition of this whole milk powder was (47% 
carbohydrates from which 3% fibre, 45% lipids and 8% proteins).  
 
Method E DIN 19738, Ruhr-Universität Bochum, Germany.  
The German method E DIN 19738 has its origin in the in vitro digestion models of 
Rotard et al. (Rotard et al., 1995) and of Hack and Selenka (Hack and Selenka, 1996). 
It is a static gastrointestinal model that uses synthetic digestive juices. Since it is 
assumed that saliva has a negligible effect on the level of mobilization of contaminants 
from soil, only synthetic gastric juice and synthetic intestinal juice was used in the 
present round robin. Whole milk powder (50 g L-1) was added to the gastric juice to 
simulate the influence of food on the mobilization of contaminants. The composition 
was 40% carbohydrates, 26% lipids and 26% proteins. Two g of contaminated dry soil 
were suspended in 100 mL gastric juice for two hours at pH 2.0. This was followed by 
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the addition of 100 mL of intestinal juice, the pH was set to 7.5, and digestion 
proceeded for six hours. The temperature was controlled by means of a water bath (37 
°C). Mixing occurred with an agitator at 200 rpm. The digestion mixture was 
centrifuged for ten minutes at 7000 g, after which the supernatant was decanted. The 
residual pellet was stirred in 30 mL of distilled water for 0.2 h, centrifuged, and the 
supernatant decanted. The decanted intestinal solutions were combined for analysis.  
 
In vitro digestion model, National Institute of Public Health and the Environment 
(RIVM), The Netherlands.  
The fasting model and the composition of its digestive juices have been described 
in detail by Oomen et al. (Oomen et al., 2003). Briefly, the digestion was started by 
addition of 9.0 mL saliva of pH 6.5 to 0.6 g dry matter soil. This mixture was rotated 
end-over-end at 55 rpm at 37 ºC. Then, 13.5 mL gastric juice of pH 1.07 was added, 
and rotated at 37 ºC. After two hours, 27 mL duodenal juice (pH 7.8) and 9 mL bile 
juice (pH 8.0) were added. This mixture was rotated at 37 ºC for 2 hours and 
subsequently centrifuged at 3000g for 5 minutes. The supernatant (total volume 58.5 
mL) represented the chyme. For the fed model, 6 mL of simulated saliva (pH 6.8), 4.5 
g of infant formula (macaroni based), and 12 mL of stimulated gastric juice (pH 1.30) 
were added to 0.4 g dry matter soil. The mixture was rotated end-over-end at about 55 
rpm at 37 ºC for 2 h. Subsequently, 12 mL of stimulated duodenal juice (pH 8.1), 6 mL 
of stimulated bile juice (pH 8.2) and 2 mL NaHCO3 (85 g L-1) were added. The latter 
was to adjust the pH of chyme to 6.5-7.0. After 2 h incubation, the chyme was 
separated from the pellet by centrifugation at 3000 g. For both models, the pH was 
determined at the end of the stomach and of the intestinal phase. The composition of 
the non-stimulated digestive juices is based on human physiology and is described in 
more detail (Oomen et al., 2003). Stimulated saliva contains more bicarbonate, α-
amylase and less mucine than non-stimulated saliva. Stimulated gastric juice contains 
more pepsine, whereas stimulated duodenal and bile juice contains more pancreatine 
and lipase and five times more bile than non-stimulated duodenal juice. 
 
SHIME (Simulator of Human Intestinal Microbial Ecology), LabMET (Ghent 
University, Belgium).  
The SHIME procedure as employed in the present set-up represented a static 
gastrointestinal system simulating the gut of young children. The different digestive 
juices were added to the same reactor. The system can be extended to more reactors 
in which case a dynamic system with larger volumes and pH gradients can be 
obtained. The gastrointestinal model can also be extended with a compartment 
 56
Bioaccessibility measurements from five in vitro methods 
representing the colon by introduction of colon microbiota into the system. This 
possibility was not applied in this study. 
Five grams of soil were introduced into 50 mL of SHIME nutritional medium, which had 
a starting pH of 5.2 and this was supplemented with pepsin. The gastric pH was 
brought to 2.0 for fasted conditions and to 4.0 for fed conditions. SHIME nutritional 
medium contains per liter sterile distilled water 15 g Nutrilon plus, 16 g pectin, 8 g 
mucin, 5 g starch, 1 g cellobiose, 1 g glucose and 2 g proteose peptone. Nutrilon is 
nutrition for children between 4 and 18 months, and is obtained from Nutricia (Bornem, 
Belgium). Main constituents are lactose (56 %), fat (12 %), and casein (10 %). After 3 
hours of incubation at 37 °C, 25 mL of a solution of pancreatic enzymes and bile salts 
was supplemented in order to obtain small intestinal fluid. This solution consists of 12 g 
NaHCO3, 4 g bovine bile and 0.9 g pancreatine per liter of distilled water. This small 
intestinal suspension had pH 6.5, and was stirred at 150 rpm at 37 °C for 5 hours. 
Subsequently, the samples were centrifuged for 10 minutes at 7000 g, after which 
pellets and supernatants were analyzed. When fed conditions were simulated, 200 mL 
of gastric juice were supplemented to 5 g of soil. For the small intestinal digestion, 100 
mL of the enzymatic and bile solution were dosed to the gastric suspension. 
 
TIM (TNO gastro-Intestinal Model), TNO, The Netherlands.  
The TNO model is a dynamic model that simulates the pH profile as well as 
continuous addition of enzymes, bile, and other components during gradual transit of 
soil through the different compartments of the gastro-intestinal tract (Minekus et al., 
1995).  The amount of soil and the meal was based on the study presented by 
Maddaloni et al. (Maddaloni et al., 1998). One hundred milligrams of soil were 
introduced in the model with 240 mL of water or the standard breakfast from the in vivo 
study to study the fasted and fed situation, respectively. Briefly, the main constituents 
of the standard breakfast were 25 g of wheat cereal, 130 g of whole milk, 1 large hard-
boiled egg (approximately 48 g), 50 g of firm whole wheat bread, 6 g of butter, 5 g of 
jam/preservatives, and 6 g of white sugar. The nutritional composition was 50% 
carbohydrates, from which 15% fibre, 20% lipids and 30% proteins. The halftime of 
gastric emptying was 30 min for the fasted and 80 min for the fed situation. The initial 
gastric pH during fed situation was 5 and gradually decreased to 3.5, 2.5 and 2 after 
30, 60 and 90 minutes, respectively. During the fasted situation, the gastric pH started 
at pH 4.5 whereafter it decreased to 3.2, 2.8 and 1.8 in 10, 20 and 40 minutes, 
respectively. Subsequently, the soil was gradually transferred to the intestinal 
compartments, representing the duodenum (pH 6.5), the jejunum (pH 6.8) and the 
ileum (pH 7.2). The gastric and duodenal secretion was set to 0.5 and 1 mL min-1, 
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respectively. The total digestion time is 360 minutes. The chyme is mixed and 
transported by peristaltic movements. Dialysis membranes (Hospal, MWcutoff 5000-
10000) are used to remove bioaccessible contaminants, digestive metabolites and 
water from the chyme. 
 
Round robin. 
Experimental design. The bioaccessibility of Pb in the Bunker Hill soil was 
assessed with the in vitro digestion models described above. There were 4 static 
models: PBET, DIN, RIVM method and SHIME and 1 dynamic model: TIM. The soil 
was distributed by the RIVM institute, which ensured that the input material in the 
different digestion models was the same. Each of the institutes applied their in vitro 
model on the soil, both with fasted conditions as with fed conditions. The PBET and 
RIVM models measured lead bioaccessibility in both the stomach compartment alone 
as the stomach/intestine compartments combined. The RIVM method also performed 
digestion experiments at two different L/S ratios, 100 and 1000. Bioaccessibility was 
calculated as: 
100*
)(
)(
(%)
µgdigestionbeforesoilinpresentlead
µgdigestionduringsoilfrommobilizedlead
bilityBioaccessi =  
Contaminant concentrations in the chyme and pellet were determined. This allowed a 
mass balance for each of the methods to be calculated.  
  
Statistical information. 
Standard practice for comparing different tests is to use analysis of variance 
(ANOVA). However, since there are relatively few data points for the methods used in 
this study, there are different numbers of replicate measurements for each test and 
there is no guarantee of the data being normally distributed, a simpler approach to a 
statistical comparison of these tests was to use a permutation test (Resampling Test 
software, 2001). In this instance the null hypothesis is that there is no significant 
difference in the bioaccessibility of lead as measured by the different methods. In order 
to test this, the individual mean values for each method are calculated along with the 
overall mean of all the tests being considered. The absolute differences between each 
test mean value and the overall mean are then calculated and summed. This provides 
the benchmark statistic. The data for all the tests are then randomly shuffled (retaining 
the same number of data points for each method) and the test statistic is recalculated. 
This process of random shuffling and calculation of the test statistic is repeated 10000 
times recording the test statistic each time. The number of times the test statistic 
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exceeds the benchmark statistic is recorded. If there is no significant difference 
between the methods then test statistic is likely to exceed benchmark statistic in a 
large proportion of the reshuffling trials. If, however, there is a significant difference 
between the methods then it is unlikely that a randomly shuffled trial will exceed the 
benchmark statistic. The probability cut-off chosen in this study is that of 5 % (i.e. 
p=0.05). Therefore if 5 % or more of the trials are greater than the benchmark statistic 
then the null hypothesis is confirmed and there is no significant difference between the 
methods. If there are less than 5 % of the reshuffled trials greater than the test statistic 
then the results of the different methods are significantly different. The advantage of 
using this approach is that it is simple to carry out (calculations were carried out in 
Excel using Resampling Stats software, 2001) and no assumptions about the 
distributions of the data need to be made. 
 
RESULTS 
Bioaccessibility data from the different in vitro methods and bioavailability data, 
obtained from Maddaloni et al. (1998), were largely dependent on the absence or 
presence of food components. Figure 2.2 shows a comparison of the differences 
between the average bioaccessibility/bioavailability for the fasted and fed conditions. 
The resampling test showed that, apart from the RIVM stomach extraction for both 
1/100 and 1/1000 liquid to solid ratios, these differences are significant. In analogy with 
the human bioavailability data, the TIM model showed much lower bioaccessibility 
results when fed conditions were simulated. The same trend was observed for PBET 
stomach, RIVM intestine 1/100 and RIVM intestine 1/1000, but to a lesser extent. 
Higher bioaccessibility data for fed conditions were obtained  with the PBET intestine 
method, the SHIME and DIN method. The presence of food components in the digest 
suspensions thus plays a major role for the outcome of the bioaccessibility results.  
Our quality assurance and quality control steps found that the lead concentration in the 
Bunker Hill soil was 3060 ± 55 mg Pb kg-1 soil similar to the value of 2924 ± 36 mg Pb 
kg-1 soil (dry weight) from the in vivo study (Maddaloni et al., 1998). In addition, lead 
recoveries from the fasted digestion types ranged from at least 92 % up to 98 %. The 
fed digestion types delivered lower recovery data ranging from 73 % to 93 % (Table 
2.1). It should be noted that the lead analysis was performed by one analytical 
laboratory with all participants sending their samples to this institute for analysis. 
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Figure 2.2 Difference in bioaccessibility (bioavailability for the in vivo study (Maddaloni et 
al., 1998)) between fasted and fed condtions (p values < 0.05 indicate a 
significant difference between fed and fasted). Grey bars are significant, white 
bars are not significant. A positive value means that bioaccessibility was higher 
under fasting conditions than under fed conditions. 
Table 2.1  Lead recovery percentage, liquid to soil ratio and bioaccessibility results (± 
standard deviation) for the different in vitro gastrointestinal digestions of Bunker 
Hill Soil (2924 ± 36 mg Pb kg-1 soil DW) 
 n % recovery L/S % Bioaccess. 
PBET     
Fasted 3 98 100 13.0 ± 0.8 
Fed 2 93 100 21.8 ± 0.4 
DIN     
Fasted 3 96 100 13.6 ± 0.6 
Fed 3 88 100 28.6 ± 1.6 
RIVM     
Fasted 3 90 ± 2 98 31.8 ± 2.5 
Fed 3 78 ± 8 101 23.9 ± 2.4 
SHIME     
Fasted 2 92 15 2.0 ± 0.1 
Fed 3 83 62 24.1 ± 0.1 
TIM     
Fasted 2 89 51 32.5 ± 4.5 
Fed 2 73 51 7.0 ± 1.5 
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Fasted conditions. The in vitro methods differed significantly from each other and 
the in vivo data (p=0.003) (Figure 2.3). The SHIME method showed the lowest 
bioaccessibility value (2.0 %), followed by PBET intestine (13.0 %) and DIN (13.6 %), 
whereas the RIVM intestine method (31.8 %) and TIM (32.5 %) displayed higher 
bioaccessibility values (Table 2.1), quite comparable with the oral bioavailabitiliy value 
of 26.2 %. Lead bioaccessibility values from the PBET (25.0 %)  and RIVM (70.9 %) 
stomach digests were higher than the respective small intestine and stomach digests 
combined. RIVM also performed digestions at two different liquid to soil (L/S) ratios, 
being approximately 1000:1 and 100:1 (Table 2.2). L/S ratios of 1000 caused higher 
bioaccessibilities, 85.9 % and 47.4 % for stomach and small intestine respectively, 
compared to digests at a L/S ratio of 100, 70.9 % and 31.8 % for stomach and small 
intestine, respectively. It should be emphasized that bioaccessibility was assessed 
differently in each model and that this bioaccessibility value is not physiologically 
directly linked to the blood values (=bioavailability) obtained in the in vivo study 
(Maddaloni et al., 1998). 
 
 
Figure 2.3  Comparison between methods of the bioaccessibility data upon simulated 
fasted conditions and the bioavailability data from the in vivo study (Maddaloni 
et al., 1998). Bars show the range of results that were obtained with different 
replicates within one method. 
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Table 2.2 Bioaccessibility results (± standard deviation) from the PBET and RIVM models 
upon stomach digestion. The RIVM method also obtained bioaccessibility data 
with L/S ratios of 1000 
 L/S % Bioaccess. Stomach % Bioaccess. Intestine 
RIVM method    
Fasted 975 85.9 ± 11.4 47.4 ± 3.2 
 98 70.9 ± 0.9 31.8 ± 2.5 
Fed 1013 84.4 ± 4.5 38.8 ± 1.9 
 101 62.5 ± 7.4 23.9 ± 2.4 
PBET    
Fasted 100 25.0 ± 0.7 13.0 ± 0.8 
Fed 100 16.2 ± 0.2 21.8 ± 0.4 
 
Fed conditions. Significant differences (p=0.0008) between all methods, including 
the in vivo study by Maddaloni et al. (1998), were obtained. The bioaccessibility values 
from all small intestinal digestions, except for TIM, were higher than the in vivo 
bioavailability results (Figure 2.4). The DIN method had the highest bioaccessibility 
value (28.6 %), whereas the digestion models SHIME, RIVM and PBET produced 
slightly lower values of 24.1%, 23.9% and 21.8 %, respectively. These bioaccessibility 
results were significantly different from the bioavailability data. The TIM method on the 
contrary returned the lowest fed bioaccessibility value, 7.0 %, quite comparable with 
the in vivo bioavailability of 2.5 %. The stomach bioaccessibility results for the RIVM 
method at L/S ratios of 100 (62.5 %) and 1000 (84.4 %) were higher than the small 
intestine bioaccessibilities (23.9 % and 38.8% respectively). The PBET method 
simulating fed conditions returned a lower bioaccessibility value in the stomach (16.2 
%) than in the small intestinal digest (21.8 %), this in contrast to the fasted conditions 
of the PBET method in which the opposite was observed.  
 
Static versus dynamic models. The bioaccessibility results obtained with the 
dynamic TIM model were not significantly different from the in vivo bioavailability data, 
both under fasted and fed conditions. Concerning the variability of the bioaccessibility 
results, we observed low RSD values for all in vitro methods compared to high RSD 
values of 31 and 66 % for the in vivo data obtained from fasted and fed conditions, 
respectively. Generally, the static models PBET, DIN, SHIME and RIVM returned RSD 
values below 10 % whereas the dynamic TIM model showed slightly higher RSD 
values of 14 and 21 % for fasted and fed conditions, respectively. These variabilities 
show that the bioaccessibility measurements with all methods are quite reproducible.  
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Figure 2.4  Comparison between methods of the bioaccessibility data upon simulated fed 
conditions and the bioavailability data from the in vivo study (Maddaloni et al., 
1998). Bars show the range of results that were obtained with different 
replicates within one method. 
 
Discussion 
In vitro – in vivo comparison. Since the bioaccessibility process is an important 
precursor to bioavailability, in vitro methods should always return bioaccessibility 
values that are higher than the bioavailability values from in vivo experiments on the 
same soil. The in vitro methods appeared to be a conservative estimator of lead 
bioavailability under fed conditions, because higher or similar bioaccessiblity values 
were obtained in comparison with bioavailability values (Figure 2.4).  Under fasting 
conditions, methods such as the PBET intestine, DIN and SHIME methods under-
estimated bioavailability whereas the PBET stomach, RIVM and TIM models gave 
higher bioaccessibility than in vivo bioavailability results (Figure 2.3). Upon simulated 
fed conditions, only the RIVM and TIM methods showed a decrease in bioaccessibility 
compared to fasted conditions, similar to that seen with the in vivo bioavailability data 
(Figure 2.2). To partly explain some of the discrepancies, we should keep in mind that 
the PBET, DIN, RIVM and SHIME methods specifically simulate the gastrointestinal 
tract of small children, whereas Maddaloni et al. (1998) arrived to bioavailability data 
from adults. The differences between the in vivo and in vitro results also arise because 
the in vitro approaches measure bioacccessibility and the in vivo, bioavailability of lead 
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from the ingested soil. Clearly, those two parameters are different and we should have 
a clear view on how bioaccessibility is brought into relationship with bioavailability.  
As introduced earlier, the bioaccessible contaminant fraction is this fraction which is 
released from the soil, solubilized in the gastrointestinal tract and is available for 
intestinal absorption (Figure 2.1) (Ruby et al., 1996; Oomen et al., 2000; Hamel et al., 
1998). Bioaccessible contaminants are partly absorbed through the small intestinal 
wall and subsequently reach the blood stream after which they can be biotransformed 
in the liver. For lead, hepatic biotransformation is however not an issue. The lead 
fraction that actually reaches the blood stream is considered as bioavailable. 
Bioaccessibility is thus an important prerequisite to bioavailability, hence a higher 
bioaccessible contaminant fraction should be obtained in vitro than the bioavailable 
fraction. In general, an in vitro approach will only be reliable if liberation from soil in the 
gastrointestinal tract is the limiting step in the oral bioavailability process (Ruby et al., 
2002). For the simulated fed conditions, all in vitro methods are applicable for risk 
assessment since they return higher bioaccessibility values than in vivo bioavailability 
data. The relationship with the bioavailable fraction can be made, provided a correction 
factor should link bioaccessibility with bioavailability. We should keep in mind that this 
correction factor will be different for every single method, since different tools are used 
to measure bioaccessibility.  
 
Presence of food components. The presence of food components was of 
significant influence on the outcome of the bioaccessibility results (Figure 2.2). The 
DIN, PBET and SHIME gastrointestinal models gave higher bioaccessibility values 
during fed conditions than during fasted conditions, whereas the RIVM and TIM-model 
showed the reverse trend. Maddaloni et al. (1998) observed that lead bioavailability 
decreased upon soil ingestion together with a standardized breakfast meal. A 
decrease in intestinal lead absorption was already described when lead was 
complexed to rhamnogalacturonan-II dimers, a pectide polysaccharide of the cell wall 
of fruits and vegetables (Tahiri et al., 2000). The presence of nutrition in the 
gastrointestinal juice means that more dissolved organic matter is present, providing 
more complexation niches for lead in solution. However, this also means that lead is in 
a complexed state with solubilized organic material, rather than in a free absorbable 
state. This will be reflected in a lower fraction of released lead that can actually be 
considered for small intestinal absorption. Obviously, intestinal absorption is not 
considered by any of the in vitro methods, but preceeding steps to intestinal absorption 
are considered when the bioaccessible lead fraction is determined. The PBET, DIN 
and SHIME methods use whole milk powder or milk based nutrition that are rich in fat 
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content. Fat globules can take up desorbed lead from the soil matrix and thus increase 
the lead fraction in the intestinal suspension. However, the 0.45 µm filtration or 7000×g 
centrifugation may not be stringent enough to separate these lead-dissolved organic 
matter complex. The nutrition used in the RIVM and TIM models was also fat rich – 
TIM even used the same breakfast meal as the in vivo study – but was also higher in 
carbohydrate content, especially the breakfast meal that was rich in food fibres due to 
the presence of whole grain bread and cereals. Fibre/lead complexes are larger than 
lead complexes with whole milk fat globules and can therefore be more easily 
separated. This may be reflected in the RIVM data where lower lead bioaccessibility 
with fed conditions was obtained after a 3000×g centrifugation. Yet, RIVM arrived to a 
bioaccessibility as high as that obtained with the other methods (Table 2.1). The TIM 
method on the contrary, gave quite similar bioaccessibility data as the bioavailability 
data. Models that use ultrafiltration membranes as a separation step will remove more 
lead-dissolved organic matter complexes from bioaccessibility samples and will 
probably approach bioavailability more closely. Therefore, our data suggest that 
ultrafiltration membranes may be a technology that could be implemented for all 
digestion models to better mimic the effects of food on contaminant bioavailability. 
 
Other parameters of influence. The static in vitro methods of the GI tract 
simulated conditions of the infant’s gut, whereas the data from the dynamic TIM model 
and the in vivo bioavailability data from Maddaloni et al. (1998) were derived from 
adults. An important difference in digestion parameters can be noted. Firstly, the 
stomach pH of infants under fasted conditions (pH 3) is not as low as that of adults 
(1.5). This has important consequences on the release of metals such as lead from a 
soil matrix. Secondly, the amount of secreted digestive juices for an infant’s gut is 
lower than that of an adult, which will lead to lower L/S (liquid to soil) ratios. This will 
influence the equilibrium between complexed and released contaminants in the chyme. 
Given the large discrepancies between the different models, it would be more useful 
for future experiments to mimick the gut of adults, rather than using the current 
digestion parameters which were developed to simulate the infant’s gut. This would 
make an adequate comparison with in vivo data more possible. 
The L/S ratio had an influence on the bioaccessible lead fraction, as shown by the 
results from RIVM (Table 2.2). Higher bioaccessibility values were obtained from soil 
digests using L/S ratios of 1000, compared to soil digests where L/S ratios of 100 was 
applied. These data do not correspond to the statement that bioaccessibility of metals 
mobilized from soils in in vitro synthetic gastric juice are only slightly influenced by 
changes in gastric fluid L/S ratios for the range 100 to 5000 (mL g-1) (Hamel et al., 
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1998). However, this influence may also be site-specific and thus dependent on the 
soil characteristics. Digests with a very low L/S ratio of 15 were investigated using 
LabMET’s SHIME method, which was applied as a model for children assuming a 
hypothetical ingestion of 1 g soil kg-1 BW. The low bioaccessibility compared to the in 
vivo bioavailability may be attributed to this parameter, since most other parameters 
such as method of separation, stomach pH and time of digestion were quite 
comparable to for instance the DIN method, which arrived at higher bioaccessibility 
values. A second parameter of influence is the pH of the gastric juice which has an 
important effect on lead desorption or complexation. Data from the PBET and RIVM 
method showed that higher lead bioaccessibilities were obtained in the stomach 
compared to the intestine. The respective pH of 1.5 and 1.1 support solubilization of 
lead ions into the aqueous solution. The SHIME method applied the highest pH (4.0) of 
all models under fed conditions. Quite remarkably, a much higher bioaccessibility was 
observed. The much higher L/S ratio of 60 of the SHIME method compared to that of 
the fasted model, L/S 15, may explain this shift in equilibrium towards the 
bioaccessible fraction, together with the presence of food components in the fed 
model. The residence time of the gastric and intestinal digestions differ amongst the 
different in vitro methods. Too few data were however obtained in which the effect of 
digestion time could be investigated in this study. The underestimation of the 
bioavailable fraction by the PBET method upon fasted conditions may be due to the 
short gastric digestion time of 1 hour in comparison with longer gastric digestion times 
of 2 to 3 hours with the other models.  
Differences in bioaccessibility between models may also be explained by the 
different purposes for which the models were initially developed. Firstly, the PBET, 
DIN, RIVM and SHIME model are designed to simulate the gastrointestinal tract of 
small children, because children are regarded to be at higher risk of ingestion of 
contaminated soils, due to their hand-to-mouth behavior, than adults are. Secondly, 
most in vitro models are static, which means that the gastrointestinal transit of soil 
particles is simulated by sequential exposure to synthetic saliva, gastric and intestinal 
juices. The TIM method on the contrary, is a dynamic model. Dynamic models can 
simulate more aspects of the human physiology, for instance the pH profile as well as 
continuous addition of enzymes, bile, and other components during gradual transit of 
soil through the different compartments of the gastrointestinal tract. The SHIME is 
often applied in this manner but not in this study. These dynamic models are fairly 
sophisticated whereas static models are easy to use and allow simultaneous 
determination of a large number of samples. The TIM method is a more advanced in 
vitro model, simulating gradual transfer of matrix and contaminant to subsequent 
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gastrointestinal compartments, whereas the other models have applied the 
gastrointestinal digestion in a more general way. This model complexity is reflected in 
a slightly higher variability of the TIM results compared to that seen with the other in 
vitro methods. Although all in vitro methods from this study gave bioaccessibility values 
that were quite reproducible, the advantage of the static in vitro models is that they 
may be used as high through-put screening methods with which site-specific risk 
analysis can generate many results in a limited time frame.   
 
Relationship between bioaccessibility and bioavailability. There are 2 principal 
limiting factors when the bioavailable fraction of an ingested contaminant is to be 
estimated, namely dissolution in the gastrointestinal tract and intestinal absorption. In 
vitro methods of the human gut do not simulate intestinal absorption and are therefore 
only reliable as risk assessment tool when contaminant release from the soil matrix is 
the rate limiting step in the oral bioavailability process (Ruby et al., 2002). The tool for 
measuring the bioaccessible fraction is however dependent on the used separation 
method. The PBET method applied a 0.45 µm filtration in analogy to Holman et al. 
(Holman et al., 2002), whereas the RIVM method separated the bioaccessible lead 
fraction during a 10 minutes centrifugation step at 3000×g, as suggested by Ruby et al. 
(1996). Both the DIN and SHIME methods used a 7000×g centrifugation step, whereas 
the TIM model used hollow fibre membranes with a molecular cut-off of 5 to 10 kDa. 
These differences are of critical importance when bioaccessibility data are to be 
interpreted. Some of the desorbed lead may however be present in complexes this 
large that intestinal absorption will not occur. From that instance, the rate limiting step 
for a compound to become bioavailable is not the soil desorption, but the complexation 
processes within the intestinal lumen. For this, each in vitro model uses correction 
factors to relate lead bioaccessibility to bioavailability. It is important and crucial for risk 
assessment to recognize that this correction factor will be different depending on the 
separation method that is used to measure bioaccessibility. Hence, interpretation of 
bioaccessibility data for risk assessment should not only consider what type of in vitro 
method is used to account for the different parameters and characteristics of the 
model, but should also make corrections, depending on which separation step is used. 
This separation step is directly related to investigating lead speciation in 
gastrointestinal fluids (Oomen et al., 2003). This will provide a more detailed 
understanding of complexation processes in the intestine and of the lead fraction that 
may be available for transport across the intestinal epithelium.  
The results from this study indicate that most of the five methods gave fairly similar 
bioaccessibility results. The methods over-estimated bioavailability under fed 
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conditions and gave mixed results under fasting conditions. The use of hollow-fibre 
membranes such as those used in the TIM probably mimics the results from an in vivo 
study more closely. We hypothesize that this may be the ability of hollow-fibre 
membranes to reject large lead-organic matter complexes that form in the 
gastrointestinal tract. In conclusion, our results suggest that in vitro models are an 
effective way to mimic the human digestive process and that the addition of 
ultrafiltration as separation step may increase the accurateness of bioaccessibility 
measurements. 
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Polycyclic aromatic hydrocarbon release from a soil matrix in 
the in vitro gastrointestinal tract 
 
Abstract 
Soil ingestion is an important exposure route by which immobile soil contaminants 
enter the human body. We assessed polycyclic aromatic hydrocarbon (PAH) release 
from a contaminated soil, containing 49 mg PAH kg-1, using a SHIME (Simulator of the 
Human Intestinal Microbial Ecosystem) reactor comprising the stomach, duodenal, and 
colon compartments. Polycyclic aromatic hydrocarbon release was defined as that 
fraction remaining in the digest supernatant after centrifugation for 5 min at 1500×g. 
The PAH release in the stomach digest was only 0.44% of the total PAH present in 
soil, resulting in PAH concentrations of 23 µg PAH L-1 chyme. The lower PAH releases 
in duodenum (0.13%) and colon (0.30%) digests, compared with the stomach digest, 
were thought to be attributed to combined complexation and precipitation with bile 
salts, dissolved organic matter, or colon microbiota. We studied these complexation 
processes in an intestinal suspension more in depth by preparing mixtures of 9-
anthracenepropionic acid, a Bacillus subtilis culture, and cholin as model compounds 
for PAHs, organic matter, and bile salts, respectively. Bile salts or organic matter in the 
aqueous phase initially enhance PAH desorption from soil. However, desorbed PAHs 
may form large aggregates with bile and organic matter, lowering the freely dissolved 
PAH fraction in the supernatant. Using the model compounds, mathematical equations 
were developed and validated to predict PAH complexation processes in the 
gastrointestinal tract. Contaminant release and subsequent complexation in the gut is 
an important prerequisite to intestinal absorption and thus bioavailability of that 
contaminant. The data from this research may help in understanding the processes to 
which PAHs are subjected in the gastrointestinal tract, before intestinal absorption. 
 
 
Redrafted after: Van de Wiele T, Verstraete W, Siciliano S. 2004. Polycyclic Aromatic 
Hydrocarbon Release from a Soil Matrix in the In Vitro Gastrointestinal Tract. Journal of 
Environmental Quality 33: 1343-1353 
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Introduction 
Soil ingestion is an important human and animal exposure route for environmental 
contaminants with typical human soil intake between 1 and 500 mg d-1 (Brunekreef et 
al., 1987; Vanwijnen et al., 1990; Calabrese et al., 1997a, 1997b; Stanek et al., 1997). 
Site-specific risk assessment studies incorporate soil ingestion with a maximal daily 
intake of 50 and 150 mg soil d-1 for adults and children, respectively (USEPA, 1997). 
However, high soil ingestion rates might impose a larger health risk for pica-afflicted 
children, who, due to their unusual hand-to-mouth behavior, occasionally ingest 
several grams of soil with reported intakes of 5 to 60 g d-1 (Calabrese et al., 1999). 
Concerning the toxicology of contaminants as such, the intestinal absorption and 
hepatic biotransformation of bioavailable xenobiotics have been intensively studied. 
However, the desorption and complexation processes before intestinal uptake are not 
well understood. Yet, these phenomena in the gut lumen require further study as they 
largely influence the extent of oral bioavailability of soil-bound contaminants. The 
released fraction of contaminants that is available for absorption is defined as the 
bioaccessible fraction. 
Polycyclic aromatic hydrocarbons (PAH) are common hydrophobic soil 
contaminants with natural and anthropogenic sources (Freeman and Cattell, 1990; Van 
Metre et al., 2000). Depending on their physicochemical characteristics, such as 
aromaticity, these compounds exhibit toxic, mutagenic, and carcinogenic effects or 
(anti)-estrogenic activities (Mastrangelo et al., 1996; Szeliga and Dipple, 1998; Hirose 
et al., 2001; Mersch-Sundermann et al., 2001). During intestinal transit, the presence 
of food components (Hack and Selenka, 1996) or bile (Oomen et al., 2000) in the 
gastrointestinal (GI) tract modulates the release of hydrophobic contaminants. Hack 
and Selenka (1996) ascribe the higher release of organic pollutants to the more 
hydrophobic character that food components give to the aqueous solution. In a similar 
manner, soluble soil organic matter forms microscale hydrophobic environments in the 
aqueous phase and acts as a mobile sorbent for hydrophobic compounds like 
polychlorinated biphenyls (PCBs) and PAHs (Chiou et al., 1986; Jota and Hassett, 
1991; Kögel-Knabner et al., 2000). Applying different bile salt and protein 
concentrations, Oomen et al. (2000) calculated specific release ratios for PCB in an in 
vitro digestive solution and found that PCB mobilization from a surrogate soil—
consisting of 10% peat, 20% kaolin clay, and 70% sand and prepared according to 
Organisation for Economic CoOperation and Development (OECD) Guideline 207—
was largely influenced by the presence of bile salt micelles. They characterized PCB 
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aggregates with bile salt micelles or proteins as determined in a supernatant after 5 
min at 3000×g, as bioaccessible. 
Investigating desorption processes in the gut of oligochaetes, other invertebrates, 
fish, rodents, and other mammals is useful for relevant tests of oral bioavailability 
(Loonen et al., 1997; Koganti et al., 1998; Oste et al., 2001; Willett et al., 2001; Gomot-
de Vaufleury and Pihan, 2002; Yan and Wang, 2002). However, contaminant release 
and complexation processes inside the GI tract are unknown mechanisms in these in 
vivo studies. Moreover, given the discrepancies between the physiology of humans 
and other organisms, as well as the cost and time constraints associated with such 
studies, a more efficient alternative is desirable (Ruby et al., 1999). In vitro digestion 
models that mimic the human GI tract can elucidate these phenomena. These models, 
based on the physiology of humans, are generally more simple, less time-consuming, 
and especially more reproducible than animal tests. Such tests simulating stomach, 
small intestinal digestions (Hack and Selenka, 1996; Ruby et al., 1996; Jin et al., 1999; 
Oomen et al., 2000), and intestinal transport through Caco-2 tissue cultures have been 
described before (Oomen et al., 2001) and could provide a rapid and inexpensive 
method for developing more accurate exposure estimates for use in human health risk 
assessments. The Simulator of the Human Intestinal Microbial Ecosystem (SHIME) 
effectively models the human intestinal tract (Molly et al., 1993, 1994) and is an 
automated and robust multistage reactor that is amenable to bioavailability estimates. 
(Figure 3.1).  
 
 
Figure 3.1 Picture of the Simulator of the Human Intestinal Microbial Ecosystem (SHIME). 
Vessels 1 to 5 respectively simulate conditions from the stomach, small 
intestine, colon ascendens, colon transversum and colon descendens. 
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This computer-controlled dynamic model consists of five compartments, with each 
compartment vessel simulating a different part of the GI tract from the stomach and 
small intestine to the proximal and distal part of the colon 
(http://www.avecom.be/shime_i.html). The SHIME reactor differentiates itself from 
other in vitro intestinal models, because it comprises the entire GI tract taking into 
account the enzymatic processes in the stomach and duodenum and the different 
characteristics of the microbiota along the colon reactors. Models such as these allow 
one to investigate the biochemical and physical processes contributing to PAH release 
inside the human GI tract. 
In this research, we investigated intestinal desorption processes of PAHs in the 
case of high soil ingestion rates. We subjected a PAH-contaminated soil from a 
recreational area to batch experiments from the SHIME model and monitored the 
released PAH amount as observed in the stomach, the first part of the small intestine 
(duodenum), and the large intestine (colon). Additionally, a mathematical model was 
developed from a model compound to help us understand how much PAHs and which 
PAH complexes were formed during digestion. This model was evaluated against 
observed data from the different digestion steps of a contaminated soil. Our intent was 
to combine digestion and mathematical models to elucidate release and complexation 
mechanisms of soil-bound contaminants inside the child GI tract and thereby give an 
indication of what fraction of soil-bound contaminants will be bioaccessible. 
 
Materials and Methods 
Soil Sampling and Characterization 
The top 0 to 6 cm of a soil was sampled from a recreation park in Zelzate, Belgium, 
which was contaminated with PAHs after 20 yr of atmospheric deposition from nearby 
industry. The soil samples were dried for 24 h at room temperature, homogenized, and 
stored until analysis at 4°C in the absence of light. Small rocks and plant material were 
removed by sieving (2 mm) before analysis. Soil organic matter content was 3.3% and 
determined by loss of mass on ignition in a muffle oven at 360°C for 2 h (Storer, 1984). 
The soil pH (H2O) was measured according to Black et al. (1965) using a 1:10 soil to 
water suspension and was 6.5. The soil contained 94% sand, 4% silt, and 2% clay and 
was classified as moderate wet sandy soil (Geo-Vlaanderen, Flemish Land Company; 
51°12’26” N, 3°48’20” E). 
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Digestions 
Three different digestion processes of the human GI tract were simulated and 
compared with one another. The amount of soil subjected to the different digests was 
20 g.  
Stomach model. In a first model, simulating the stomach, the effects of pH and 
liquid to soil ratios (L/S, volume/mass) were studied, as well as the influence of food 
components on PAH release. A salt solution (200 mL) containing 0.1 M KHCO3 and 
0.1 M NaCl was applied to 20 g of soil. This solution at L/S 10 was acidified with 1.3 
mL 5 M hydrochloric acid to a final measured pH of 1.5 after which porcine pepsin 
(Sigma-Aldrich, St. Louis, MO) was added to a final concentration of 10 mg pepsin L-1 
soil suspension. The soil suspension was stirred at 150 rpm for 2 h at 37°C. Acidity 
effects were evaluated by using only water as a diluent in the stomach. This treatment 
is comparable with the German standard method DIN 38 414 S4 for leachability of 
soils with water. Influence of L/S using the normal salt, acid, and pepsin concentrations 
was assessed using L/S of 2, 10, and 40. The amount of soil tested, 20 g, stayed the 
same. Large enough digest bottles were taken to provide the same stirring efficiency in 
all digests as a difference in mixing intensity could have influenced the release of 
PAHs from the soil matrix. The L/S of 10 and 40 correspond to a daily soil ingestion of 
20 and 5 g, respectively, during fasting conditions. The L/S of 2 was not derived from 
physiological data, but served as an additional data point to study the influence of L/S 
on PAH release at low L/S. The influence of food was assessed by adding liquid 
nutrition at a L/S of 40. The nutrition consists of a carbohydrate-based medium 
containing, per liter: 5 g Nutrilon and 3 g potato starch (Nutricia, Bornem, Belgium), 1 g 
arabinogalactan, 2 g pectin, 1 g xylan, 0.4 g glucose, 4 g mucin and 0.5 g cystein from 
Sigma-Aldrich, 3 g yeast extract, and 3 g pepton from BD (Franklin Lakes, NJ). 
Nutrilon is nutrition for small children, which consists of lactose (56%), fat (12%), and 
casein (10%). 
Duodenum model. Although intestinal bacteria are present in the last part of the in 
vivo small intestine (ileum), the duodenum digestion model focuses on enzymatic 
activities, bile salts, and dissolved organic matter (DOM) complexation processes. 
Twenty grams of soil, which had already gone through a L/S 10 stomach digestion 
without any centrifugation step, were supplemented with 100 mL pancreatic juice 
containing 12.5 g L-1 NaHCO3 (resulting in a measured pH of 6.3), 6 g L-1 Oxgall (BD), 
and 0.9 g L-1 porcine pancreatin powder (Sigma-Aldrich). The different pancreatic juice 
components were added separately or in combination to differentiate between PAH 
release due to the presence of bile salts, proteins, or complexes with DOM or 
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particulate organic matter. These small intestinal soil suspensions were stirred at 150 
rpm for 5 h at 37°C. The resulting L/S was 15. 
Colon model. Mobilization mechanisms influenced by gut microbiota were 
investigated in the colon digestion model. The small intestine digest suspension 
containing 20 g of soil with an L/S of 15 was supplemented with 100 mL of SHIME 
suspension which contains microbiota in a representative concentration and 
composition for the human colon (Molly et al., 1993). Total anaerobe and aerobe 
concentrations were 8.4 and 7.8 log colony forming units (CFU) mL-1 and included 
microbiota such as Lactobacilli, Bifidobacteria, Enterococci, Fungi, Staphylococci, and 
Clostridia. This colon digest was incubated at 37°C and stirred at 150 rpm for 18 h. 
The resulting L/S was 25. 
 
Sample treatment and PAH analysis 
During the different digestions, PAHs can be mobilized and subsequently 
complexed with several compounds such as bile salts, DOM, or particulate organic 
matter. We used a 1500×g centrifugation speed during 5 min to spin down aggregates 
larger than 5 µm. This was calculated with the Stokes equation using the centrifugation 
parameters. Upon centrifugation, supernatants and pellets were analyzed for PAH 
content. In the colon model, bacteria were present, also. To account for PAH 
adsorption to bacterial biomass, the colon samples were subsequently centrifuged at 
3000×g for 5 min, which roughly spun down small complexes with a 1.5 µm diameter 
as calculated with the Stokes equation (Stokes, 1851). Sample treatment for and 
determination of PAHs were performed by the Environmental Research Center 
(Erembodegem, Belgium). Briefly, PAHs from pellets were extracted by a 1:1 acetone 
and hexane mixture using an accelerated solvent extractor (Model 200; Dionex, 
Sunnyvale, CA). The PAHs from supernatants were extracted with dichloromethane. 
Analysis of the PAH content in the extracts was performed according to a standardized 
method (USEPA Method 8270) by gas chromatography coupled with mass 
spectrometry (GC–MS). The MS detector used was a quadropole mass spectrometer 
(Trace-MS; Thermo Finnigan, San Jose, CA). The detection limit for the different PAH 
components was 0.2 µg L-1. The quantification limit was 0.4 µg L-1. The extraction 
efficiency of the sample preparation step before PAH analysis was between 80 and 
110%, as determined with the reference soil CRM535. Organic matter content in the 
supernatants was assessed according to standardized method NBN 357.02 
(Greenberg et al., 1992). Briefly, this method consists of determining the loss of mass 
in the samples after they were heated at 600°C during 4 h. 
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Study of PAH complexation mechanisms 
The diversity of components in the intestinal suspension makes the study of 
mobilization and complexation processes in the GI tract difficult. We considered the 
presence of bile salts, DOM, and particulate organic matter as key factors in the 
release and complexation of PAHs during digestion and selected a single model 
compound for each of these factors. We prepared 320 samples in which the three 
model compounds were mixed in different concentrations. The first model compound, 
indicated with the letter A, was a fluorescent PAH derivative, 9-anthracene propionic 
acid (CAS no. 41034-83-7; Molecular Probes, Leiden, the Netherlands). This molecule 
could be used for epifluorescence analysis as it absorbs light at 366 nm and emits at 
414 nm. Due to the presence of the propionate group, the pKa value of this compound 
was 4.6 as calculated by Solaris Version 4.67 software (Advanced Chemistry 
Development, 2001). At a pH of 6, the log organic carbon partitioning coefficient (KOC) 
value was estimated to be 2.4, which was found hydrophobic enough to serve as 
model compound for low molecular weight PAHs that adsorb to organic matter. The 
solubility was estimated to be 0.497 mg L-1 (EPI Suite; EPA, 2004), which is higher 
than 0.0434 mg L-1 for anthracene. The 9-anthracene propionic acid was used at 
concentrations of 0.01, 0.5, 10, and 100 mg L-1. To study interaction with organic 
matter, a culture of Bacillus subtilis was prepared as previously described (Daughney 
and Fein, 1998) and supplemented in concentrations of 0, 0.06, 0.12, 0.31, 0.61, 1.22, 
1.83, and 3.05 g organic C L-1. This organism has been used as a standard to study 
contaminant interactions with particulate organic matter (Daughney and Fein, 1998). 
Apart from particulate organic matter, this culture also contained DOM under the form 
of nutritional compounds or metabolites. The concentrations for DOM were 0, 0.1, 0.4, 
0.8, and 1.6 g organic C L-1. The organic matter concentration is indicated with the 
letter O in the model. Organic matter content was determined according to the Belgian 
standardization method NBN 357.02. The last standard compound was cholin (Sigma-
Aldrich) to mimic the effect of bile salts. This compound was added at concentrations 
of 0, 0.05, 0.1, 0.25, 0.5, 1, 1.5, and 2.5 g L-1. The bile salt analogue is indicated with 
the letter B in the model. 
The different mixtures were kept at pH 6 with bicarbonate and stirred at 150 rpm 
for 1 h, after which they were centrifuged. One hundred microliters of the 1500×g and 
3000×g supernatants were brought in a 96 multiwell plate and fluorescence was 
measured with a SpectraMAX Gemini XS spectrophotometer (Molecular Devices, 
Sunnyvale, CA). The fluorescence was an indication for the amount of PAH analogue 
present in the supernatant. The fluorescence of the different mixtures gave an idea 
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how PAHs were complexed by a model bile salt and organic matter and to what extent 
they remained in the supernatants. Corrections were made for background 
fluorescence by subtracting the fluorescence intensity from blank sample sets – 
samples combining the bile salt and organic matter analogues without the fluorescent 
molecule – from the respective sample sets containing the fluorescent molecule. No 
significant quenching was observed from the bile salt analogue, nor the organic matter 
analogue towards the fluorescent molecule. The fluorescence data were used to 
calculate distribution coefficients, Kd, which give an idea how the PAH analogue is 
distributed over the different possible complexes that could be present in the mixture. 
This is explained in more detail in Eq. [3–5] in the Results section. 
 
Evaluation of the mathematical model 
We evaluated the utility of the obtained K values to predict PAH release in the 
batch digestion experiments that were performed on the PAH-contaminated soil 
samples. The input variables for the model in Eq. [4] were the bile salt (B) and organic 
matter (O) concentration that were used in the digestions, as well as the free PAH (A) 
concentrations that were measured. Since observed field data as well as model output 
had uncertainties, a bivariate scattergram was used to calculate unbiased values for 
the slope and intercept of the principal axis of the relationship between field data and 
model predictions (Daughney et al., 2002). An accurate model would yield a unit slope 
and an intercept of zero, if the predicted PAH release data were plotted against the 
observed PAH release data from the digests. The coefficient of determination (R2) was 
calculated by multiplying the correlation coefficient (R) with the ratio of the variances of 
the predicted and the observed data. 
 
Statistical analysis 
All statistical tests were performed using SPSS 11.0 software (SPSS, 2002). Tests 
for normality and homogeneity of variances were performed using the Shapiro–Wilkes 
and Levenes test. Non-normally distributed data were transformed using the natural 
logarithm for pellet and supernatant PAH amounts and the arcsine transformation on 
PAH release fractions. Comparison of means was tested with a one-way analysis of 
variance (ANOVA) using the F test. In case the assumption of equal variances did not 
hold, the Welch test was used. For supernatant analysis, transformed data were not 
normally distributed. The nonparametric Kruskal–Wallis test was used on the 
nontransformed data to compare means. Correlation of release fractions between 
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digest types were performed using the nonparametric Spearman's rho test. A general 
significance level of 0.05 for all tests was chosen. 
 
Results 
Digestion model 
The total PAH concentration in the soil was 49 ± 1.5 mg PAH kg-1 soil (Table 3.1) 
with individual PAH concentrations, except phenanthrene and benzo(a)pyrene, below 
the Flemish soil cleanup levels for recreational areas. The PAH mass balance recovery 
for the 12 different digestions (Figure 3.2) ranged from 89 to 108% with an average of 
96 ± 6.6%. The PAH input in the different digestion types varied between 752 and 918 
µg for 20 g of soil with no PAHs detected in the pancreatic solution or bacterial SHIME 
suspension. Polycyclic aromatic hydrocarbon release, determined as the PAH fraction 
present in a 1500×g supernatant, was limited, ranging from 0.4 to 11 µg for the 
different digest types (Table 3.2), with no significant differences in PAH content 
between pellets. 
 
Table 3.1  Concentrations for 10 polycyclic aromatic hydrocarbons (PAHs) in the soil 
samples, as analyzed by gas chromatography–mass spectrometry (GC–MS) 
compared with the Flemish Soil Remediation Directive. 1 
 CAS 
nr. 
Park soil  
(mg PAH kg-1 DW) 
Directive 
(mg PAH kg-1 DW) 
Naphthalene 91203 0.27 ± 0.16 160 
Phenanthrene 85018 4.88 † ± 0.06 3.5 
Fluoranthene 206440 9.53 ± 0.19 40 
Benzo(a)anthracene 56553 5.09 ± 0.06 50 
Chrysene 218019 6.18 ± 0.43 400 
Benzo(b)fluoranthene 205992 6.08 ± 0.30 55 
Benzo(k)fluoranthene 207089 3.02 ± 0.09 55 
Benzo(a)pyrene 50328 5.88 2 ± 0.01 1 
Indeno(1,2,3-cd)pyrene 193395 4.22 ± 0.87 50 
Benzo(ghi)perylene 191242 3.96 ± 0.37 50 
1 Values are means ± standard deviations of four replicates that were taken within 1 m from 
each other. Sample point coordinates are 51°12’26” N, 3°48’20” E. 
2 Park soil PAH concentration is higher than the Flemish soil remediation directive 
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Figure  3.2 Mass recoveries (%) for polycyclic aromatic hydrocarbons (PAHs) in the 
different soil sample digests. Error bars show standard deviation values of three 
replicates. 
 
The PAH release was greater (P < 0.003) for the water (0.5%) and stomach 
digestion (0.44%) compared with the release in the duodenum (0.13%) and colon 
(0.3%) (Table 3.2). Surprisingly, increasing the pH from 2 to 7 had no effect on PAH 
release whereas increasing the L/S enhanced PAH release. Release of PAHs in 
digestions with an L/S of 40 was twice as high (0.83%) (Mann–Whitney U test; P = 
0.037) as that of digests with an L/S of 10 (0.44%) and 16 times as high as that of 
digests with an L/S of 2 (0.05%). There was a logarithmic correlation between PAH 
release and L/S (Eq. [1]): 
%release = 0.1454 + 0.2622 ln(L/S)    R2 = 1.00  [1] 
 
We postulated that the effect of L/S on PAH release was due to variations in dissolved 
organic matter. This was confirmed by the fact that addition of food compounds almost 
doubled PAH release of a stomach L/S 40 digest from 0.83 to 1.4% (Figure 3.3). There 
was a strong relationship (Eq. [2]) between PAH and dissolved organic matter 
concentration for all stomach digestions: 
PAH (µg L-1) = 15.35 × organic C (g L-1) 0.0486  R2 = 0.97  [2] 
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No relationship was found between dissolved organic matter and PAH release for the 
colon and the duodenum digests. If the bile digest sample was not centrifuged, but 
sedimented for 30 min, the PAH content reached the value of 0.43%, which is more 
than two times greater than that observed during centrifugation (Figure 3.3). Similarly, 
the PAH content in the colon extract, spun down at 3000×g, was the lowest observed 
among all digests with a value of 0.10%. Yet, the organic matter content in these 
duodenum and colon digests was higher than that in the water and stomach digestions 
(Table 3.2). This suggested that complexes were formed that can spin down at 1500 or 
3000 × g if the complexes are large enough.  
 
Table 3.2  Release of PAHs during different stages of digestion.  Water, duodenal and 
colon digests were all performed at a Liquid/Solid ratio of 10, 15 and 25 
respectively. Values are averages of n replicates.1 
 
Water pH 7 
L/S 10  
n = 3 
Water pH 2 
L/S 10   
n = 3 
Stomach 
L/S 2   
n = 3 
Stomach 
L/S 10   
n = 3 
Stomach 
L/S 40   
n = 2 
Stomach 
L/S 40   
n = 2 
Nutrition 
Centrifugation 
speed (g) 
1500 1500 1500 1500 1500 1500 
Amount pellet 
(µg) 
917.7 902.7 829.1 844.3 769.9 786.9 
Amount 
supernatant 
(µg) 
4.7 4.3 0.4 3.8 6.3 11.0 
Organic matter 
(g L-1) 
0.46 - 2 1.08 2.16 0.99 1.6 
Concentration 
(µg PAH L-1) 
23.4 21.7 9.0 18.1 7.7 13.4 
Release ± s.e. 
(%) 
0.50 ± 0.026 0.48 ± 0.017 0.05 ± 
0.003 
0.44 ± 0.11 0.83 ± 0.028 1.38 ± 0.372
 Duodenum 
Bile L/S 10   
n = 2 
Duodenum 
Bile L/S 10   
n = 2 
Duodenum 
pancreatin 
L/S 10   
n = 1 
Duodenum
L/S 15 
 n = 3 
Colon 
L/S 25 
n = 4 
Colon 
L/S 25 
n = 2 
Centrifugation 
speed (g) 
1500 1 
(sedimented)
1500 1500 1500 3000 
Amount pellet 
(µg) 752.9 807.2 723.9 834.1 837.2 805.1 
Amount 
supernatant 
(µg) 
1.4 3.5 1.4 1.0 2.5 0.8 
Organic matter 
(g L-1) 0.94 2.35 1.4 1.49 3.05 2.1 
Concentration 
(µg PAH L-1) 4.5 11.3 13.5 3.2 6.1 1.9 
Release ± s.e. 
(%) 0.19 ± 0.067 0.43 ± 0.138 0.57 0.13 ± 0.052 0.30 ± 0.015 0.10 ± 0.019
 
1 Values are averages of n replicates. The term L/S is liquid to solid ratio. 
2 Artefacts in this sample caused an outlier value of 6.31 g L-1. 
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Figure 3.3  Overview of PAH release for the different results within the stomach, 
duodenum and colon digestions. Values represent averages of 3 or 4 
replicates. Error bars display standard error values. 
 
Study of PAH complexation mechanisms 
In our attempt to clarify the different complexation mechanisms in the in vitro GI 
tract, we used three model compounds and mixed them at different concentrations. 
The three compounds were analogues for low molecular weight PAHs (9-anthracene 
propionic acid), bile salts (cholin), and organic matter (Bacillus subtilis culture). The 
PAH analogue was fluorescent, which enabled us to rapidly screen for PAHs in the 
supernatant of the mixtures. We developed a model based on three operational 
definitions. Polycyclic aromatic hydrocarbons present in the 3000×g supernatant were 
free PAHs or PAHs in small complexes, PAHs present in the 1500×g supernatant were 
complexed PAHs in larger complexes, and PAH in the pellet were bound PAHs in large 
aggregates (Figure 3.4). All three compounds in the mixture could form complexes with 
each other according to Eq. [3]: 
boundboundcomplexcomplexfree AOABOAOABOAOABOBA +++++↔++  [3] 
 
where: A = PAH concentration 
B = bile salts concentration 
O = organic matter concentration 
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From this equation, the overall equilibrium distribution constant can be calculated 
as follows: 
536 **
*****
OBA
AOABOABOAOAOAB
K boundboundcomplexcomplexfreed =    (4) 
where: 
OAKAO
OBAKABO
OBAKABO
OAKAO
OAKAO
BAKAB
APboundbound
ABPboundbound
ABPcomplexcomplex
APcomplexcomplex
APfreefree
AB
**
***
***
**
**
**
=
=
=
=
=
=
 
 
   (5) AOboundABOboundABOcomplexAOcomplexAOfreeABd KKKKKKK *****=
 
The different K values are the equilibrium constants for the respective partial 
equations. These values were calculated for the mixtures in which two or three model 
compounds were combined at different concentrations (Table 3.3) The fluorescence 
analysis returned some variability resulting in K values with rather large variances but 
fairly constant values over the concentration range tested. The K values were unitless 
as they were calculated by dividing fluorescence intensity by fluorescence intensity. 
Multiplying these partial equilibrium constants from Table 3.3 gain yields the overall 
equilibrium distribution coefficient according to Equation (5). The log value of the 
overall distribution coefficient Kd as obtained with eq. 4 was -8.3 (sd=2.30), which 
approached the log Kd value obtained from eq. 5, -7.41 (sd=0.59). The highest partial 
distribution coefficient, 1.02, was found for the complex between PAH and bile (Table 
3.3). Organic matter complexation was also an important factor in PAH complexation 
with a K value of 0.068. However, tertiary reactions, i.e. the combination of bile salts 
and organic matter in one complex with PAHs, also contributed substantially with 
KABOcomplex values of 0.043 and KABObound of 0.084.  
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Figure 3.4  Possible complexes that are hypothesized to be formed in the gastrointestinal 
tract between polycyclic aromatic hydrocarbon (PAH) compounds (A), bile salts 
(B), and organic matter (O) 
 
 
Table 3.3  Distribution coefficients for the different partial complexation reactions. 1 
Distribution constant 2 Kd value 3 Standard error 
Kd AB 1.022 0.0911 
Kd AP free 0.011 0.0011 
Kd AP complex 0.068 0.0073 
Kd ABP complex 0.043 0.0037 
Kd ABP bound 0.084 0.0089 
Kd AP bound 0.014 0.0008 
1 Reported values are averages and standard errors from four replicates 
2 Subscripts indicate the different standard compounds, taken up in complexes with A = 
polycyclic aromatic hydrocarbon (PAH) analogue, B = bile salt analogue, and P = organic 
matter analogue 
3 Calculated by dividing complex fluorescence intensity by that of the compound in equilibrium 
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Evaluation of the Mathematical Model 
Comparison between Predicted and Observed Data from the Different 
Digestions. The obtained K values can be compared with each other and give us an 
idea to what extent complexes between model compounds could be formed. The 
equilibrium constants, derived from the fluorescence based lab experiments, were 
used to assess PAH release (predicted values) from the field soil in the different 
digestion types (observed values). The slope of the predicted versus observed plot 
was 1.08, while the intercept, -0.61 µg PAH L-1, indicated a slight underestimation of 
release (Figure 3.5).  The majority of the error was accounted for by the model 
(R2=0.7937), with only 20% of the variance in observed PAH release being 
unexplained. We were only able to validate the overall model, but if we assumed that 
the individual components of the model were also accurate, then the model predictions 
also gave an indication how PAHs could be allocated in the different complex types. It 
should be noted that the model only describes how desorbed PAHs are complexed 
and that it does not take into account PAHs still bound to the soil matrix itself. 
 
 
Figure 3.5  Predicted versus observed polycyclic aromatic hydrocarbon (PAH) 
concentration for the different digest types. The ellipse indicates how the slope 
and the intercept of the principle axis were calculated using the eigenvalues of 
the ellipse. The regression coefficient was calculated using the variances of the 
predicted and observed results as uncertainties were present in both data sets. 
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For example, in the presence of only pancreatin, 84% of the PAHs in the model 
remain in a supernatant after centrifugation at 1500×g and this would be divided 
between complexes (73%) and DOM (11%) (Table 3.4). Fifteen percent of the PAHs 
would stay behind as bound aggregates in the 1500 × g pellet. In case bile salts alone 
are added, only 60% of the PAHs would be present in the 1500 × g supernatant, 
partitioned over micelles (19%), DOM (3%), and complexes suspended in the 
supernatant (38%), whereas 40% of the PAHs would remain in the pellet. Accordingly, 
these findings correspond in a proportional way to the PAH amount in the 1500 × g 
supernatant of the pancreatin (0.57% PAH release) and bile salt (0.19% PAH release) 
digests (Table 3.2). As a second example, the model predicts that in the colon a much 
bigger proportion of desorbed PAHs would be present in larger complexes (51%) that 
spin down at 3000 × g but not at 1500 × g. Only 13% of the released PAHs would 
remain in the 3000 × g supernatant, divided between bile salts (7%) and DOM (6%). 
Proportionally, the colon digestion results gave rise to comparable observations to the 
model predictions, where 0.10% of the PAHs remained in the 3000 × g supernatant, 
whereas 0.30% of the PAHs were present in the 1500 × g supernatant (Table 3.2). 
 
Table 3.4 PAH distribution among the different complex types, expressed as percentages of 
the mobilized PAH fraction (typically less than 1%) from a field soil contaminated by 
20 years of atmospheric deposition. 
Digest type 
% in bile salt 
solution 
% associated 
with dissolved 
organic matter 
% adsorbed to 
particulates but 
remaining in 
supernatant 
% adsorbed to 
particulate that 
spins down at 
1500g 
Water pH 7 0  11 ± 1.6 73 ± 2.8 15 ± 2.3 
Water pH 2 0  11 ± 3.6 73 ± 6.3 15 ± 5.1 
Stomach L/S 2 0  11 ± 1.6 73 ± 2.8 15 ± 2.3 
Stomach L/S 10 0  11 ± 3.3 73 ± 5.6 15 ± 4.6 
Stomach L/S 40 0  11 ± 1.5 73 ± 2.7 15 ± 2.1 
Stomach nutrition 0  11 ± 2.4 73 ± 4.1 15 ± 3.4 
Bile salts  19 ± 1 3 ± 0.9 38 ± 1.4 40 ± 1.5 
Pancreatin 0 11 ± 2.1 73 ± 3.6 15 ± 4.0 
Duodenum 19 ± 0.7 3 ± 0.6 38 ± 1.0 40 ± 1.1 
Colon 7 ± 1.3 6 ± 1.3 51 ± 2.1 36 ± 1.8 
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Release of individual PAH compounds 
No significant differences in release were observed between different digestive 
compartments for individual PAHs (Figure 3.6), except for higher naphthalene release 
in water (p=0.025) and colon (p=0.039) digests. However, if the PAHs are grouped into 
high (>0.012 mg L-1) and low (<0.012 mg L-1) solubility groups, the low-solubility PAHs 
were mobilized to a greater extent than would be expected from their solubility. 
Logically, PAH release would decrease with decreasing solubility, which was indeed 
the case from naphthalene to benzo(a)anthracene. The individual PAH release, 
however, increased again with decreasing solubility from chrysene on to the most 
hydrophobic PAHs, like benzo(ghi)perylene. Other common molecular descriptors 
such as hydrogen to carbon ratios, molecular weight, molecular surface area, and log 
octanol–water partitioning coefficient (Kow) values of the individual PAHs were 
evaluated using Microsoft Excel (Microsoft, 2002) for their possible relationship to the 
release of individual PAH compounds in the water, stomach, duodenum, and colon 
digest. The most accurate parameter showing a correlation with the release rates of 
different individual PAH compounds was, however, the logarithm of the respective 
PAH solubility values (Eq. (6): S = solubility in mg L-1): 
% release = 0.368 + 0.206 log S + 0.0675 (log S)2 R2 = 0.92   (6) 
 
 
Figure 3.6  Release percentages of individual polycyclic aromatic hydrocarbons (PAHs) 
into the aqueous phase during water, stomach, duodenum, and colon digestion. 
Results plotted are averages. Error bars show standard error values from three 
replicates. 
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Discussion 
The combination of digestion experiments and the development of a predictive 
model in this research gave more insight on PAH mobilization from a soil matrix in the 
human digestive tract. Contaminant mobilization from a soil matrix and subsequently 
complex formation in the gastrointestinal tract are crucial first steps in the assessment 
of oral bioavailability, yet the understanding of these processes is incomplete. 
During intestinal digestion, PAHs desorb from the soil matrix and they can be 
divided into three groups. A first group comprises bound PAHs, mobilized from the soil, 
but adsorbed to large aggregates that spin down at 1500×g. A second group embodies 
complexed PAHs with bile salts and/or organic matter, which stay suspended after a 
1500×g centrifugation step, but spin down at 3000×g. Finally, the third group remains 
in solution after centrifugation at 3000×g and consists of free PAHs and PAHs taken 
up in small complexes with bile salts or dissolved organic matter. The choice of 
distinguishing these three groups merely relies on providing more insight on 
contaminant mobilization and complexation processes in the gut. They are not based 
on physiologically relevant values. However, the latter group, comprising the free 
PAHs and PAHs in small complexes, contains the bioaccessible fraction, which is the 
fraction available for intestinal absorption. This is an important fraction as it preceeds 
oral bioavailability. In their in vitro study, Oomen et al. (2001) used 3000×g to assess 
bioaccessible lindane and PCB concentrations. However, Holman et al. (2002) 
considered complexes smaller than 0.5 µm as bioaccessible, as these are the only 
ones able to pass between the microvilli. 
The complexation phenomena are not merely a prerequisite to uptake by blood or 
lymph, but are the dominant factors that influence the PAH fraction that can be taken 
up through the small intestinal wall. Understanding the distribution of PAHs in different 
complexes along the human GI tract may explain the differential toxicity observed for 
ingested PAHs. For example, five- or six-ring PAHs are better inducers of 
arylhydrocarbon (AhR) biotransformation enzymes in the duodenum, whereas three- or 
four-ring PAHs are more prone to induce AhR in the liver (Hrudey and Rousseaux, 
1996). Our model successfully predicted PAH release during passage through the 
SHIME but neither the SHIME nor any other gastric simulator is currently able to mimic 
the highly dynamic and active gut epithelial. 
 
 86
 PAH release from soil in the GI tract 
Digestions 
This study indicated that PAH ingestion from contaminated soil may be hazardous. 
Polycyclic aromatic hydrocarbon mobilization from a low-contamination soil yielded a 
PAH concentration in the chyme solution ranging from 2 to 23 µg L-1, which is 20 to 
200 times greater than the European drinking water directive of 0.1 µg L-1, although the 
latter is not always derived out of toxicological consideration. This occurred at L/S 
between 10 and 40, which are lower values compared with the ratios of 60 to 1000 
used in previous studies (Hack and Selenka, 1996; Holman et al., 2002; Oomen et al., 
2000), but comparable with the L/S experienced by children during fasting conditions. 
These L/S are derived from a hypothetical soil ingestion of 20 g, a chyme production of 
40 mL h-1, and a residence time of 8 h during the passage through stomach and small 
intestine. During fasting conditions, the chyme production drops to 40 mL h-1, whereas 
250 mL h-1 is produced while eating (Paterson et al., 2000). An acute exposure to 20 g 
soil d-1 would yield an L/S of 16 while fasting and 100 while eating. Our data are 
derived from very high ingestion rates and the high concentrations indicate that 
ingestion of soils, even at low contamination levels, may be hazardous for children as 
a risk group of high concern. The influence of L/S on contaminant release has thus far 
only been investigated in vitro to mimic ingestion of metal-contaminated soils by adults, 
covering an L/S range of 100 to 5000 (Hamel et al., 1998). Only a slight influence of 
L/S on metal release was observed. Although the L/S of 2 from this research was not 
derived from physiological data, we considered this data point together with the L/S 10 
and L/S 40 stomach digests to study the influence of L/S on PAH release at L/S ranges 
below 100. Concerning the level of soil contamination as such, this should not be 
underestimated as indicated by an atmospheric deposition of PCBs or PAHs up to 20 
µg m-2 d-1 in an urban area (Sanders et al., 1992, 1993). This contamination route was 
considered in the recent SOWA project (Halm and Grathwohl, 2003) and indicates that 
ingestion of soils, especially by children, is a relevant issue to investigate. 
The release percentage of the PAH compounds from the soil matrix was low, 0.1 to 
1.4%, and can be compared with the 0.5 to 2% GI solubility that Holman et al. (2002) 
obtained with an in vitro fasting digestion of crude-oil-contaminated soils. Kögel-
Knabner et al. (2000) assessed the aqueous mobilization of PAHs in aged soils and 
got similar release values of 1 to 3%. They found the mobilization process was highly 
dependent on organic matter content and ionic strength of the aqueous solution. These 
values are much lower than those observed by others (10–60%), investigating release 
of hydrophobic organic contaminants during in vitro digestion of freshly contaminated 
soils or Organisation for Economic CoOperation and Development soils (Hack and 
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Selenka, 1996; Oomen et al., 2000). Our results are derived from a historically 
contaminated soil, which may explain this descrepancy due to possible aging effects. 
Polycyclic aromatic hydrocarbon release, identified as the fraction present in the 
1500 × g supernatant of the digests, changed significantly as digestion proceeded from 
stomach to large intestine. The parameter that influenced this release the most was 
the organic matter content in the aqueous phase. Organic matter provides extra 
complexation sites for contaminant adsorption. This same mechanism was described 
in a study of Oomen et al. (2002) and had previously been proposed by Hack and 
Selenka (1996). However, this trend was not observed in the duodenum and colon 
digestions, where higher organic matter content did not lead to higher PAH release. 
This necessitated the development of a more complex model. 
 
Mathematical Model 
We developed a model with which the interactions of analogues for PAHs, bile 
salts, and organic matter were studied. The obtained equilibrium constants (K values) 
could be compared with one another and allowed us to gain more insight to what 
extent and in what complex types PAHs were present in a modeled intestinal 
suspension. These distribution constants thus have no direct physical significance that 
could be used for other contaminants or other soil types. 
In our experiments, we found that bile salts and dissolved organic matter interacted 
during the mobilization process of soil-bound PAHs. This is supported by Oomen et al. 
(2000), who found higher lindane and PCB mobilization rates in a 3000×g supernatant 
at higher bile salt and protein concentrations. They also used several mixtures of these 
compounds to calculate the distribution coefficients for the formation of PCB 
complexes. This method worked for the free PCB fraction present in the 3000×g 
supernatant. However, it did not incorporate the formation of larger complexes 
combining bile salts and dissolved or particulate organic matter, typically encountered 
in the large intestine. By including and calculating the formation of these intermediate 
complexes, the mathematical model accurately (8% overestimation) and closely (R2 = 
0.8) predicted observed PAH concentrations released from soil containing aged PAHs. 
By simplifying the complicated intestinal suspension, using three standard 
components, our model could not only predict PAH release from a field situation, but it 
also gave an idea about the types of complexes being formed. Normally, PAHs as free 
compounds or complexed in bile salt micelles can be taken up through the gut wall. 
Which fraction of PAH complexes is absorbed through the intestinal wall depends on 
the complex size. As the small intestine also contains some Peyer's Patch cells able to 
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take up particles of a few micrometers in size, PAHs in small complexes can be taken 
up in a small amount through the small intestinal wall. Thus, the amount released and 
also the type of complex formed are important for the toxicity of released PAHs. We 
were able to directly evaluate the accuracy of the model for PAH release but we lack 
direct spectroscopic data to confirm PAH complexation in the human gut. 
 
Differences in PAH compound 
Although empirically obtained, differences in release between PAHs were best 
described by a quadratic model (Eq. [6]). For the low molecular weight PAHs, a 
decrease in release was observed with decreasing solubility, whereas the release in 
high molecular weight PAHs increased with decreasing solubility. While this trend can 
be modeled using a quadratic response function, this trend might have been obtained 
due to measurement errors. However, what is clear is that PAH release does not 
continue to decrease in concert with aqueous solubility. The rationale for this was 
conceptualized by MacKay and Gschwend (2001), who described two competing 
factors influencing PAH contaminant release. They investigated the PAH 
concentrations in the ground water of a coal tar site and found that organic colloids 
enhanced PAH solubility by a factor of 16 for benzo(a)pyrene and up to 50 times for 
indeno(ghi)perylene. The enhancing solubilization effect by colloids increased with 
increasing hydrophobicity of the compound and may explain the increased release of 
high molecular weight PAHs we observed in the in vitro intestinal suspension. Such an 
increase in solubility for the high molecular weight PAHs is worrying for risk assessers 
as many of these compounds are known to possess carcinogenic or even estrogenic 
effects as they get bioactivated on intestinal absorption (Roos et al., 1996; Roos, 
2002). 
 
Conclusions 
In this study, we showed the importance of simulating the gastrointestinal tract of 
high risk groups that children form in risk assessment. As soil ingestion parameters like 
L/S differ substantially from other digestion models for other risk groups, the outcome 
of this study shows that contaminant concentrations in the intestinal tract are higher for 
higher L/S, and that the total amount of released contaminant will be substantial even 
when the soil is only slightly contaminated. Bile salts and organic matter in the digest 
aqueous phase have a dual effect on contaminant mobilization. On the one hand, they 
increase desorption as hydrophobic contaminants can more easily complex with these 
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compounds in the aqueous phase. On the other hand, complexes may be formed that 
decrease the chance of actually being absorbed through the small intestinal wall. This 
complicated complexation process was predicted by a mathematical model we 
developed, based on standard analogues for PAHs, bile salts, and organic matter. The 
model was useful in this specific case of a PAH-contaminated soil and could predict 
how many PAHs were released in the GI tract during in vitro digestion. Additionally, it 
allowed us to gain more insight into the complexation phenomena that are crucial 
processes in the gut lumen before bioaccessibility and oral bioavailability. An aspect of 
this research that requires further attention is the increased solubility for the high 
molecular weight PAHs, as these compounds are known for their possible 
carcinogenic or estrogenic properties. The combination of bioassays and analysis of 
PAH metabolites might deliver substantial information in the ongoing research. 
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Liquid chromatography–mass spectrometry analysis of 
hydroxylated polycyclic aromatic hydrocarbons, formed in a 
simulator of the human gastrointestinal tract 
 
Abstract 
Described is a liquid chromatography mass spectrometry (LC-MS) procedure for 
the determination of hydroxylated biotransformation products of poycyclic aromatic 
hydrocarbons (PAH) in the human gastrointestinal tract. The formation of hydroxylated 
PAHs was monitored upon incubation of PAHs with colon microbiota from the 
Simulator of the Human Intestinal Microbial Ecosystem (SHIME). The analytical 
method consisted of a biomass removal step followed by a solid phase extraction step 
using C18 packed columns to remove non-digested food compounds and microbial 
metabolites that interfere with the detection of the target compounds. For 
quantification, 9-hydroxy phenanthrene 13C6 was used as the internal standard.  The 
detection limits of the  hydroxylated PAHs were generally in the range 0.36 to 14.09 µg 
L-1, based on a signal/noise ratio of 3:1. The recovery of hydroxylated PAHs in 
intestinal suspension was variable ranging from 45% to 107%, with relative standard 
deviation between 5% and 17%. The analytical procedure was used to show the 
microbial production of 1-hydroxypyrene and 7-hydroxybenzo(a)pyrene, metabolites 
that may give colon incubated PAHs bioactive properties. 
 
 
 
 
Redrafted after: Van de Wiele T, Peru K, Verstraete W, Siciliano S,  Headley J. 2004. Liquid 
chromatography-mass spectrometry analysis of hydroxylated poycyclic aromatic hydrocarbons, 
formed in a simulator of the human gastrointestinal tract. Journal of Chromatography B 806: 
245-253 
 
The LC-MS research was performed at the National Water Research Institute (NWRI) from 
Environment Canada, Saskatoon, Saskatchewan, Canada, in collaboration with Dr. John 
Headley and Kerry Peru. 
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Introduction 
The levels of polycyclic aromatic hydrocarbons (PAH) in the environment has 
remained an area of extensive study in modern times, largely because of their 
prevalence in the environment and the mutagenic, carcinogenic and estrogenic effects 
of their metabolites (Mastrangelo et al., 1996; Szeliga and Dipple, 1998; Hirose et al., 
2001; Mersch-Sunderman et al., 2001). For urban areas in particular, nearby industry 
and dense traffic may lead to atmospheric deposition of PAHs at levels up to 20 µg m−2 
per day (Sanders et al., 1993). Inhalation of PAH containing particulates and ingestion 
of contaminated food are important exposure routes to the human body (Becher et al., 
1984; Buckley et al., 1992). PAH accumulation in the upper soil layers may also pose a 
serious risk to public health through for example, possible ingestion of contaminated 
soils or badly cleaned vegetables from these soils. There is growing interest in the 
study of hydroxylated PAH metabolites, as important intermediates of PAH 
biotransformation processes in the human body (Jongeneelen, 1996). Monitoring of 
urinary or biliary 1-hydroxypyrene and other PAH metabolites is often used as 
biomarkers for PAH exposure in aquatic and terrestrial ecosystems, but also for 
exposure to humans (Strickland et al., 1996; Adonis et al., 2003). Apart from their 
importance as transformation products, hydroxylated PAHs may possess estrogenic 
properties (Hirose et al., 1998; Fertuck et al., 2001a) and some are related to 
mutagenic and carcinogenic effects.  
Analysis of hydroxylated PAHs and PAH metabolites in general is usually 
performed using high-performance liquid chromatography with fluorescence detection 
(HPLC-F) (Escartin and Porte, 1999; Ruddock et al., 2003; Stroomberg et al., 2003). 
Earlier studies of PAH biotransformation have also applied gas chromatography (GC) 
coupled to mass spectrometry (MS) with chemical ionization to screen for PAH 
hydroxylates, while the PAH parent compounds were analyzed through classical HPLC 
with diode array detection (DAD) (Cajthaml et al., 2002). The liquid chromatography–
mass spectrometry (LC–MS) methods have utilized atmospheric pressure chemical 
ionization or electrospray ionization (ESI) in both positive and negative ionization mode 
to screen for hydroxylated PAH compounds (Galceran and Moyano, 1994; Galceran 
and Moyano, 1996). However reported detection limits of around 0.5 µg mL−1 are 
relatively high when taking into account that concentrations in the range 0.039–2.5 µg 
mL−1 have been previously used for detecting in vitro mutagenic effects and that 
urinary 1-hydroxypyrene levels of only 2.5 ng mL−1 may occur (Hauser et al., 1997; 
Adonis et al., 2003). Thus far, most research on PAH exposure and detection of 
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metabolites has been performed by analyzing biliary or urinary samples. Little is known 
however, about the biotransformation processes of environmental contaminants by 
intestinal microbiota from the gastrointestinal tract. This is due in part to a need for 
analytical methods that aresuitable for determining the transformation of xenobiotic 
compounds in the microbe and enzyme diverse environment of the colon (Ilett et al., 
1990). In this study, we present a LC–ESI–MS methodology for the quantification of 
hydroxylated PAH metabolites and some selected PAHs in water and the human 
gastrointestinal tract. The detection of these microbially formed hydroxylated PAHs in 
intestinal suspension has not been described previously. 
 
 
Materials and Methods 
Reagents 
The PAH hydroxylates (Figure 4.1) investigated were 1-hydroxynaphthalene 
(1OHN), 1-hydroxypyrene (1OHP), 9-hydroxyfluorene (9OHF) and 9-
hydroxyphenanthrene (9OHPh), obtained from Sigma-Aldrich (Bornem, Belgium) and 
7-hydroxybenzo(a)pyrene (7OHBaP), 7,8-dihydroxybenzo(a)pyrene (78OHBaP), and 
4,5-dihydroxybenzo(a)pyrene (45OHBaP) obtained from the NCI Chemical Carcinogen 
Reference Standard Repository (Midwest Research Institute, Kansas City, MO, USA). 
One additional compound, 2-phenylphenol (2PP) (Sigma-Aldrich, Bornem, Belgium), 
was also investigated as a putative PAH metabolite. PAH parent compounds were 
obtained from Sigma-Aldrich (Belgium), Janssen Chimica (Geel, Belgium) and Supelco 
(Oakville, Canada).  Stock solutions of the PAH hydroxylates were prepared in 
methanol and contained 100 µg mL−1 1OHN, 90 µg mL−1 1OHP, 93 µg mL−1 OHF, 98 
µg mL−1 9OHPh, 124 µg mL−1 2PP, 8 µg mL−1 7OHBaP, 16 µg mL−1 45OHBaP and 11 
µg mL−1 78OHBaP. A series of working standards was prepared by diluting the stock 
solution with 50% methanol to final concentrations of 1, 0.5, 0.25, 0.1, 0.05, 0.01 µg 
mL−1 for each individual PAH hydroxylate. In addition, similar standards were prepared 
with centrifuged colon suspension as diluent to compensate for possible matrix effects 
in the quantitative LC-ESI-MS analysis of colon suspension samples. 
Stock solutions of the corresponding PAH parent compounds were made in 
acetonitrile with concentrations of 218 µg mL−1 naphthalene, 220 µg mL−1 pyrene, 212 
µg mL−1 fluorene, 196 µg mL−1 phenanthrene and 164 µg mL−1 benzo(a)pyrene. To 
determine the removal of other PAH components during gastrointestinal digestion, an 
additional set of stock solutions containing 252 µg mL−1 acenaphthylene, 180 µg mL−1 
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anthracene, 180 µg mL−1 fluoranthene, 164 µg mL−1 benzo(a)anthracene and 168 µg 
mL−1 chrysene were used. No hydroxylated derivatives from these latter PAHs were 
analyzed. Mixed standard dilution series were prepared by diluting the stock solution 
with 50% methanol to final concentrations of 1, 0.5, 0.25, 0.1, 0.05, 0.01 µg mL−1 for 
each individual PAH compound. In addition, similar standards were prepared using 
blank colon suspension as the diluent. These solutions were used for LC-DAD 
analysis. 
 
Figure 4.1 Chemical structures of PAH hydroxylates 
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Incubations 
Samples were taken from the colon vessels of the Simulator of the Human 
Intestinal Microbial Ecosystem (SHIME). This dynamic model of the human 
gastrointestinal tract consists of 5 compartments representing the stomach, 
duodenum, colon ascendens, colon transversum and colon descendens, respectively 
(http://www.avecom.be/shime_i.html). The colon suspension contains an in vitro 
cultured microbiota that is isolated from human feces and is representative for the in 
vivo colon microbial ecology (Molly et al., 1993). The organic matter content of colon 
suspension typically varies around 2.2 g L−1 and originates from some food compounds 
but mainly microbiota at concentrations of 11 log CFU mL−1. 
A volume of 500 mL of colon suspension was sampled from the SHIME reactor 
and distributed in aliquots of 50 mL to ten penicillin flasks.  Each flask contained a 
different PAH compound. To avoid solubility problems, PAHs were first dissolved in 
ethanol and then introduced separately into the respective flasks at final 
concentrations for naphthalene, 2.56 µg mL−1, acenaphtylene, 3.04 µg mL−1, fluorene, 
3.32 µg mL−1, phenanthrene, 3.56 µg mL−1, anthracene, 3.88 µg mL−1, pyrene, 4.04 µg 
mL−1, fluoranthene, 4.05 µg mL−1, benzo(a)anthracene, 4.56 µg mL−1, chrysene, 4.56 
µg mL−1 or benzo(a)pyrene, 5.04 µg mL−1. These suspensions were then incubated for 
24 hours at 37°C. After this colon incubation, samples were centrifuged at 3000×g for 
a duration of 10 min. to remove biomass and subsequently stored at -20°C prior to 
analysis for PAH hydroxylates and parent compounds.  
In order to assess the extent of bacterial degradation, a number of control samples 
were included in the experimental setup. Firstly, in order to determine whether 
hydroxylated PAHs could be formed by extracellular enzymes, PAHs were incubated in 
colon suspension that had been centrifuged (3000×g, 10 min) to remove microbial 
biomass. Secondly, un-dosed colon samples were analysed to serve as a negative 
control as they presumably do not contain any of the PAHs. Thirdly, a stomach and 
small intestine digest of the PAHs prior to the colon incubation was performed as 
previously described in Chapter 3 and analyzed (Van de Wiele et al., 2004a). These 
digestion steps contained no bacteria, thus, no biotransformed PAHs should be 
measured from these samples.  
Samples were also incubated in the presence of β-glucuronidase and aryl 
sulfatase, both obtained from Sigma-Adrich (Belgium). After the PAH parent 
compounds had been incubated in SHIME suspension, a 1 mL aliquot of these 
samples were diluted in 1 mL 0.1 M acetate buffer and the pH was adjusted to 5 with 
sodium hydroxide. A volume of 400 µl β-glucuronidase (100 U mL−1) and 250 µl aryl 
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sulfatase (60 U mL−1) were added and the mixture was incubated for 6 hours at 37°C 
to hydrolyze the PAH conjugates. 
 
Sample preparation 
Due to the complexity of the colon suspension from the SHIME reactor, matrix 
interference was anticipated. To assess the extent of such interfences, calibration 
standards were prepared in both Milli-Q® (MQ) water and centrifuged colon matrix. 
Standard curves and recoveries in MQ water and colon matrix were compared to 
determine the influence of the colon matrix on the detection and quantification of the 
PAH hydroxylates and parent compounds. All samples were thawed and subsequently 
subjected to a solid phase extraction (SPE) using PrepSepTM C18 (250 mg) (Fisher 
Scientific, Edmonton, Canada). The C18 columns were placed on top of a SPE 
vacuum manifold (Chromatographic Specialty, Ontario, Canada) to aid solvent elution 
through the column. The C18 packing material was first conditioned with 10 mL of 
methanol and subsequently rinsed with 10 mL water. Sample volumes of 5mL were 
loaded on the columns; the aqueous solution was eluted as waste using a gentle 
vacuum together with 10 mL of MQ water to remove hydrophilic impurities that were 
present within the complex colon matrix. For the mixed standard solutions, the 
analytes (PAHs and hydroxylates) were eluted together with other hydrophobic 
compounds by loading four times 2.5 mL of methanol on the column. During the 
method development phase, each eluent was analyzed separately to determine in 
which  fraction a given analyte was recovered. As no significant amounts of analytes 
eluted in the fourth fraction, all other samples were eluted with 7.5 mL of methanol. 
Aliquots of 1.0 mL of the sample extracts were subsampled into amber glass vials and 
stored at 4°C prior to LC-ESI-MS analysis. 
 
Instrumental conditions 
HPLC analysis was performed using a Waters 2695 (Milford, MA, USA) separation 
module. The HPLC pump was primed with fresh eluent on a daily basis. The selected 
column was a 2.1 mm × 100 mm, 3.5 µm particle size, Waters XTerra MS C18 column 
(Milford, MA, USA) which was kept at a constant temperature of 26 °C. The binary 
eluent system consisted of methanol:water 90:10 v/v (eluent A) and methanol:water 
10:90 v/v (eluent B).  Gradient elution was performed using 50% eluent A for 5 min, 
then a linear gradient from 50% to 95% eluent A for 30 min at a flow-rate of 200 µl min-
1. At the end of each cycle, 95% eluent A conditions were held for 5 min to ensure all 
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sample components were eluted from the column. An injection volume of 10 µl was 
utilized employing a Waters 2695 autosampler for both samples and calibration 
standards. A diode array UV detector was plumbed inline prior to the mass 
spectrometer for detection of the parent PAHs at a wavelength of  280 nm. 
 
Mass spectrometry analysis was performed with a Quattro Ultima Mass 
spectrometer (Micromass Technologies, Manchester, UK) that was equiped with an 
electrospray interface operating in the negative ion mode. Instrumental control and 
data acquisition was performed with MassLynx software version 3.5. The ESI source 
was operated at 90°C, desolvation temperature 200°C, cone voltage 61 V, and a 
capillary voltage of 2.74 kV. Nitrogen gas served as the cone gas (flow rate of 159 L   
h-1), desolvation gas (490 L h-1) and nebulizer gas (set to maximum). The detector 
multiplier voltage was set to 650V. Selected ion monitoring was employed for 
quantitative analysis monitoring the (M-H)- of m/z 143.2 for 1OHN, 169.2 for 2PP, 
181.2 for 9OHF, 193.2 for 9OHPh, 199.2 for 9-hydroxyphenanthrene 13C6 (internal 
standard), 217.2 for 1OHP, 267.2 for 7OHBaP and 285.2 for 4,5OHBaP and 
7,8OHBaP. The dwell-times were set at 0.3 s and the inter-scan delay time was 0.1 s.  
As electrospray is a soft ionization technique, only the (M-H)- were formed. As it is 
preferred to monitor more than one ion per component of interest for quantification and 
confirmation purposes, cone induced and collision induced dissociation were 
evaluated. Under various experimental conditions the molecular ions did not form 
product ions therefore confirmation using a secondary SIM channel or reaction 
monitoring was not possible. In lieu of qualifier ions, the in-line diode array detector 
was used as a secondary confirmation of the identification of the hydroxylated PAHs.  
Detection of possible unknown metabolites of the PAH parent compounds was also 
performed with the mass spectrometer operated in full scan mode over a range of 100 
to 450 m/z.   
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Results and discussion 
Calibration and matrix effects 
Detection of hydroxylated PAHs in an intestinal suspension has not been described 
before. The difficulty of analysis of intestinal suspension pertains to the complexity of 
the matrix. The colon matrix is comprised of non-digested food components, several 
excretion products and hundreds of microbial metabolites. Following sample clean-up, 
several hydrophobic compounds may still co-elute with the target analytes and thus 
interfere with the identification and quantification of the PAH hydroxylates during LC-
ESI-MS analysis. In order to compensate for matrix effects on both chromatographic 
separation and electrospray ionization suppression/enhancement, a centrifuged blank 
colon suspension (3000×g, 10 min.) was used as the diluent when preparing the 
calibration standards. Calibration curves were therefore independently prepared, using 
either MilliQ® water or colon suspension that had been spiked with PAH standards 
and their hydroxylated derivatives at concentrations of 0.01, 0.05, 0.1, 0.25, 0.5 and 1 
mg L-1. For most of the compounds, linear correlations (R2>0.99) between peak areas 
and analyte concentrations were obtained. The calibration curve for 45OHBaP and 
78OHBaP showed a lower correlation (R2=0.947), whereas quadratic calibration 
curves were obtained for pyrene (R2=0.999) and fluoranthene (R2=0.998).  
Under the experimental conditions utilized for the gradient and column, the majority 
of the analytes were base-line resolved from interfering components. Representative 
ion chromatograms for the hydroxylated PAHs respectively for (a) concentrations of 1 
mg L-1, spiked in colon suspension; and (b) blank colon suspension with no spike 
addition of the target analytes are given in Figures 4.2 and 4.3. There was little to no 
background signals from the colon matrix that interfered with the detection of the 
selected PAH hydroxylates, nor with the detection of the target PAH parent 
compounds when spiked at 1 mg L-1 in colon suspension (Figure 4.4).  However, the 
separation of 45OHBaP and 78OHBaP was compromised compared to that obtained 
from MQ water (data not shown). This loss of chromatographic resolution was probably 
due to column overloading from the complex sample matrix. The two respective 
analytes were therefore quantified together as a pair in colon suspensions. Future 
method modifications should incorporate the improvement of HPLC separation in order 
to report individual levels of these two compounds in the complex colon suspension. 
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Figure 4.2  LC-MS ion chromatogram of the PAH hydroxylates fortified in colon suspension 
at a 1 mg L-1 concentration. Retention time is expressed in minutes. 
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Figure 4.3  Chromatogram for m/z ratios of PAH hydroxylates in a blank sample, which is 
typically colon suspension to which no PAHs or hydroxylated PAHs were 
supplemented. Time is expressed in min. Background signals from the colon 
suspension matrix eluted at retention times other than those from the standards 
of the PAH hydroxylates. Hence, little to no matrix interference was expected. 
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Figure 4.4 Retention times of the parent PAH compounds spiked at 1 mg L-1 in colon 
suspension as analyzed by HPLC followed by diode array detection. Retention 
time is expressed in minutes. 
 
Limits of detection and recovery of analytes 
The limits of detection (LOD) for the PAH hydroxylates,  based on a signal to noise 
ratio of 3:1 was 0.26 to 6.9 µg L-1 when determined in MilliQ® water and 0.6 to 31.3 µg 
L-1 for most hydroxylated PAHs when determined in colon suspension (Table 4.1). The 
LODs for 45OHBaP and 78OHBaP in colon suspension were however much higher 
compared to the other analytes, reflecting residual interference from background 
signals (Table 4.1). In general, the LODs are higher than those reported for 1OHP, 4 
ng L-1, and 3OH BaP, 51 ng L-1, in urine samples (Hollender et al., 2001). Also for urine 
samples, Chetiyanukornkul et al. (2002) reported a LOD of 0.1 µg L-1 for 1OHP, 
compared to the value of 0.6 µg L-1  observed for the colon suspension in the current 
investigation. However, the colon suspension can be considered as a more complex 
matrix with more hydrophobic microbial metabolites, compared to the hydrophilic 
properties of urinary metabolites. Galceran and Moyano (1996), who also used an LC-
MS method for PAH hydroxylate analysis, arrived at higher LOD values of 500 µg L-1. 
Considering the LOD from these related studies and the matrix complexity from this 
study, the presented LC-ESI-MS method offers comparable or improved detection of 
the PAH hydroxylates in colon suspensions. 
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Table 4.1  Limits of detection (µg L-1) for the PAH hydroxylates. Injection volume was 10 
µl for each standard. 
 LOD (water)  
µg L-1 
LOD (Colon) 
µg L-1 
1-hydroxy naphthalene 3.5 1.9 
2-phenylphenol 1.4 6.0 
9-hydroxy fluorene 7.0 17.9 
9-hydroxy phenanthrene 1.0 2.1 
1-hydroxy pyrene 0.2 0.6 
7-hydroxy benzo(a)pyrene 1.2 4.0 
4,5-dihydroxy benzo(a)pyrene 3.6 31.3 
7,8-dihydroxy benzo(a)pyrene 2.7 21.5 
 
 
The recovery of the PAH hydroxylates was determined in MilliQ® water (clean 
matrix) at 0.5 mg L-1 and in centrifuged colon suspension (complex matrix) at two 
concentrations, 0.5 and 0.05 mg L-1. Table 4.2 shows that the recoveries from the MQ 
water matrix were quite good with values between 82 and 94%.  These values are 
comparable to the recovery values of 80-91% for 1OHP from human urine samples (Li 
et al., 2002; Ferrari et al., 2003). The relative standard deviation (RSD) values for 
within-day precision studies (n=3) ranged from 1 to 8%. Only 7OHBaP had a lower 
recovery percentage of 58%, but the low standard deviation of 4.2% indicates that the 
results were reproducible. The lower recovery suggests that the solid phase extraction 
method with methanol as eluting solvent is less selective for the more hydrophobic 
hydroxylates. The recovery of the pair of dihydroxylates of benzo(a)pyrene gave a high 
recovery of 121%, reflecting uncertainties associated with calibration and recovery of 
these two analytes. 
For the colon matrix containing 0.5 mg L-1 PAH hydroxylates, recoveries ranging 
from 55 to 89% were obtained. Again, the two dihydroxylates of benzo(a)pyrene were 
calculated as a non-resolved pair, leading to a recovery of 107%. At lower 
concentrations of 0.05 mg L-1, the PAH hydroxylate recoveries ranged between 56 and 
83% with one lower recovery of 45% for 9OHF (Table 4.2). The lower recoveries of the 
monohydroxylates, especially at lower concentrations, may be explained by the 
complexity of the colon matrix itself, which consists of a wide variety of hydrophobic 
compounds that are not fully removed during sample clean-up. These components 
easily bind to the packing material of the C18 columns and thus compete with the PAH 
hydroxylate or parent compounds investigated. Both at concentrations of 0.5 and 0.05 
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mg L-1, the more hydrophilic PAH hydroxylates – 1OHN, 2PP and 9OHF – appear to 
have lower recoveries than the more hydrophobic compounds (Table 4.2).  
 
Table 4.2 Recovery (%) and RSD values (%) of PAH hydroxylates fortified in MQ water 
and SHIME matrix (fortification concentration in parenthesis). (n=3) 
 MQ water  
(0.5 mg L-1) 
RSD 
 
SHIME matrix 
(0.5 mg L-1) 
RSD 
 
SHIME matrix  
(0.05 mg L-1) 
RSD 
 
1-hydroxy naphthalene 94 ± 5.6 6 63 ± 3.1 5 67 ± 3.1 5 
2-phenylphenol 91 ± 7.0 8 61 ± 3.2 5 56 ± 8.0 14 
9-hydroxy fluorene 87 ± 6.9 8 55 ± 6.1 11 45 ± 7.6 17 
9-hydroxy phenanthrene 82 ± 6.2 7 89 ± 6.1 7 83 ± 9.3 11 
1-hydroxy pyrene 94 ± 5.6 6 72 ± 4.3 6 57 ± 5.8 10 
7-hydroxy benzo(a)pyrene 58 ± 4.2 7 87 ± 12.2 14 74 ± 6.8 9 
4,5- and 7,8-  
dihydroxy benzo(a)pyrene  
121 ± 1.8 1 107 ± 13.4 12 83 ± 7 8 
 
 
It is therefore possible that some loss of the more hydrophylic compounds occurred 
when the extraction column was rinsed with MQ water after sample loading. Likewise, 
the loading capacity may have been compromised by the complex nature of the colon 
suspensions.  Further refinement of the procedure may thus require the use of less 
hydrophobic column material such as C8 packing material. Despite the general low 
recoveries, however, the reproducibility was acceptable at 0.5 mg L-1. The within-day 
precision RSD value (n=3) ranged from 5 to 11%, showing moderate reproducibility. 
For example, the within-day precision (n=3) showed a good reproducibility with RSD 
values between 5 and 11% values for 1OHN, 2PP and 9OHF. At a concentration of 
0.05 mg L-1, the reproducibility was good with RSD values between 5 and 11%. For 
2PP and 9OHF, the reproducibility was lower with RSD values of 14% and 17% at 0.05 
mg L-1. These numbers indicate the usefulness of the presented method to quantify 
PAH hydroxylates in the intestinal suspension. 
The corresponding recoveries for the parent PAHs are given in Table 4.3. For 0.75 
mg L-1 fortified MQ water, the recoveries were between 114 and 55% with RSD values 
ranging from 1 to 13.9%. For the more complex SHIME matrix, as expected the 
recovery was generally lower than those measured for the relatively clean MQ water. 
Recovery values (obtained from two fortification levels) ranged from 39 to 60% were 
obtained for the least hydrophobic PAHs, whereas values of 19 to 42% were obtained 
for the most hydrophobic PAHs, fluoranthene, pyrene, benzo(a)anthracene, chrysene 
and benzo(a)pyrene. The RSD values (1.1 to 15.2%) (n=3) indicate good to moderate 
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reproducibility. Besides quantifying PAH hydroxylates in the intestinal suspension, the 
presented method can thus also be applied for quantification of their respective parent 
PAHs. 
 
Table 4.3 Recovery (%) and RSD values (%) of PAHs fortified in MQ water and SHIME 
matrix (fortification concentration in parenthesis) (n=3) 
 MQ water 
(0.75 mg l-1) 
RSD 
SHIME matrix 
(1.0 mg l-1) 
RSD 
SHIME matrix  
(0.10 mg l-1) 
RSD 
naphthalene 108 ± 2.1 3 47 ± 3.6 7.7 49 ± 1.7 4.0 
acenaphthylene 94 ± 3.0 3.2 60 ± 3.8 6.3 50 ± 2.7 5.1 
fluorene 87 ± 1.0 1.2 43 ± 1.1 2.5 51 ± 1.5 3.3 
phenanthrene 91 ± 2.3 2.5 42 ± 0.6 1.3 49 ± 1.2 2.4 
anthracene 79 ± 9.3 11.7 39 ± 0.4 1.1 46 ± 2.5 6.0 
fluoranthene 114 ± 2.5 2.2 41 ± 1.0 2.4 42 ± 3.6 9.3 
pyrene 107 ± 1.1 1.0 40 ± 5.1 1.3 38 ± 2.5 7.1 
benzo(a)anthracene 55 ± 7.6 13.9 19 ± 2.1 11.3 23 ± 3.5 15.2 
chrysene 78 ± 7.3 9.3 26 ± 0.1 4.4 30 ± 1.1 4.5 
benzo(a)pyrene 70 ± 9.3 13.3 31 ± 1.9 6.0 40 ± 2.9 7.0 
 
Analysis of hydroxylated PAHs in intestinal suspensions 
The proposed method was applied to analyze colon suspension in which PAHs at 
a 5 mg L-1 concentration had been incubated for 24 h at 37°C. This suspension 
contained a complex microbial community that was comparable to in vivo colon 
conditions (Molly et al., 1993). No hydroxylated PAHs were recovered from centrifuged 
colon suspension from which the majority of microorganisms was removed. This 
showed that no extracellular enzymes were involved in the formation of hydroxylated 
PAHs. As indicated in Figure 4.3, no hydroxylated PAHs were measured in undosed 
colon samples which served as a negative control. PAHs that had been incubated in a 
stomach and small intestinal digestion did not lead to a detection of hydroxylated PAHs 
either. 
In contrast to the negative controls, 1 of the 8 target PAH hydroxylates was 
detected after 24 h of incubation in colon suspension, namely 1OHP at a concentration 
of 2.5 µg L-1 (Figure 4.5). A small peak was observed for 9OHF, however below the 
limit of quantification. After incubation of a 1 m aliquot of the sample in glucuronidase 
and aryl sulfatase, a concentration of 4.4 µg L-1 was obtained for 1OHP, suggesting 
that conjugated metabolites had also been formed. Some of the other PAH 
hydroxylates investigated were also found but at trace level. 7OHBaP was found at a 
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1.9 µg L-1 concentration, whereas shoulder peaks corresponding to the retention time 
and m/z ratios for 1OHN and 9OHF were observed but not quantified as they were 
below the detection limit. 
 
Figure 4.5  Chromatogram for internal standards and 1-hydroxypyrene in colon digests of 
pyrene at a concentration of 4.05 mg L-1: before (upper 2 chromatograms) and 
after (lower 2 chromatograms) incubation with β-glucuronidase and 
arylsulfatase as deconjugation enzymes. The m/z 217.2 peak at retention times 
of the internal standard probably is a water adduct MI.S.+18 ; (199.2+18=217.2) 
 
Conclusion 
In general, the LC-ESI-MS procedure provided relatively low detection limits for 
PAH hydroxylates in colon suspensions.  Low recoveries were observed for some 
analytes with overall good precision for the analytes investigated. The practical 
application of the method for study of complex colon suspensions was demonstrated to 
reveal that PAHs may be transformed by colon microbiota to hydroxyl derivatives. 
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 Human colon microbiota transform polycyclic aromatic 
hydrocarbons to estrogenic metabolites 
Abstract 
Ingestion is an important exposure route for polycyclic aromatic hydrocarbons 
(PAH) to enter the human body. Although the formation of hazardous PAH metabolites 
by human biotransformation enzymes is well documented, nothing is known about the 
PAH transformation potency of human intestinal microbiota. Using a gastrointestinal 
simulator, we show that human intestinal microbiota can also bioactivate PAHs, more 
in particular to estrogenic metabolites. PAH compounds are not estrogenic and indeed, 
stomach and small intestine digestions of 62.5 nmol naphthalene, phenanthrene, 
pyrene and benzo(a)pyrene showed no estrogenic effects in the human estrogen 
receptor bioassay. In contrast, colon digests of these PAH compounds displayed 
estrogenicity, equivalent to 0.31, 2.14, 2.70 and 1.48 nmol 17α-ethynylestradiol (EE2), 
respectively. Inactivating the colon microbiota eliminated these estrogenic effects. 
Liquid chromatography – mass spectrometry (LC-MS) analysis confirmed the microbial 
PAH transformation by the detection of PAH metabolites 1-hydroxypyrene and 7-
hydroxybenzo(a)pyrene in colon digests of pyrene and benzo(a)pyrene. Furthermore, 
we show that colon digests of a PAH contaminated soil displayed estrogenic activity, 
equivalent to 0.58 nmol EE2, whereas stomach or small intestine digests did not. 
Although the matrix in which PAHs are ingested, may lower the exposure 
concentrations in the gut, our results imply that the PAH bioactivation potency of colon 
microbiota is not eliminated by the presence of soil. Moreover, since PAH toxicity is 
also linked to their estrogenicity, the PAH bioactivation potency of colon microbiota 
suggests that current risk assessment may underestimate the risk from ingested 
PAHs. 
 
 
Redrafted after Van de Wiele T, Vanhaecke L, Boeckaert C, Peru K, Headley J, Verstraete W, 
Siciliano S. 2004. Human colon microbiota transform polycyclic aromatic hydrocarbons to 
estrogenic metabolites. Environmental Health Perspectives. In press. doi:10.1289/ehp.7259 
(available at http://dx.doi.org/) 
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Introduction 
Polycyclic aromatic hydrocarbons (PAH) are high priority environmental 
contaminants because of their toxic, carcinogenic and putative estrogenic or anti-
estrogenic properties in the human body. Human exposure to high molecular weight 
PAHs mainly occurs through oral uptake of charcoil-broiled, grilled and smoked meats 
(van Maanen et al., 1994) and through ingestion of soil or poorly cleaned vegetables, 
resulting in exposed doses about an order of magnitude higher than exposure by 
inhalation (Heisterkamp and van Veen, 1997). The hazardous effects of ingested 
PAHs come from this PAH fraction that releases from the nutrition, soil or associated 
organic matter in the intestinal lumen and which, upon intestinal absorption, reaches 
the intestine enterocytes and liver hepatocytes. In these cells, PAHs may act as 
ligands to the human aryl hydrocarbon (Ah) receptor, which plays a central role in the 
toxic response of specific aromatic hydrocarbons by the regulation of typical human 
biotransformation enzymes (reviewed by Hankinson, 1995). 
The risk from orally ingested PAHs is currently thought to be reduced when co-
ingested soil or fibres decrease the intestinal PAH absorption and hence, bioavailability 
(De Kok and van Maanen, 1992). The majority of ingested PAHs would pass 
harmlessly through the gastrointestinal (GI) tract without being transformed by human 
enzymes to hazardous metabolites. However, this assumes that no microbial 
biotransformation of PAHs occurs. The human GI tract harbors an incredibly diverse 
microbial community, which typically performs fermentative processes, but which is 
also capable of transforming xenobiotic compounds (Macdonald et al., 1983; Ilett et al., 
1990; Aura et al., 2002). Hence, if microbial PAH biotransformation in the human colon 
is possible, the susceptibility of the colon epithelium to bioactive PAH metabolites may 
increase the health risks that are associated with non-absorbed PAHs that reach the 
colon. To date, no information is available on the PAH bioactivation potency from 
human colon microbiota. To evaluate this, we looked in this study at PAH estrogenicity, 
since several PAH metabolites structurally resemble steroidal hormones that bind the 
human estrogen receptor (Ariese et al., 2001), which could thus lead to estrogenic or 
anti-estrogenic activity in vivo. 
We opted for an in vitro approach to specifically look for microbial 
biotransformations and thus avoid possible interference from colon epithelium 
enzymes that would be present in an in vivo approach. Pure PAH compounds and a 
PAH contaminated urban soil were incubated in the stomach, small intestine and colon 
suspensions from a simulator of the human GI tract. Given the aromaticity of PAHs, we 
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used a modified aryl hydrocarbon (Ah) receptor yeast assay (Miller, 1997) to 
investigate whether the PAHs in the different digests could activate the human Ah 
receptor and subsequently induce signal transduction. Besides this, we investigated 
the estrogenicity of the PAH incubated digests by monitoring activation of the human 
estrogen receptor in a modified estrogen receptor yeast assay (Routledge and 
Sumpter, 1996). In addition, we applied a newly optimized liquid chromatography – 
mass spectrometry (LC-MS) protocol to detect whether PAH metabolites were formed 
during incubation. 
 
Materials and Methods 
Chemicals 
PAH parent compounds napthalene, phenanthrene, pyrene and benzo(a)pyrene 
were reagent grade and obtained from Sigma-Aldrich (Bornem, Belgium). To avoid 
solubility problems in the incubation tests, PAHs were first dissolved in ethanol prior to 
digestion. All stock solutions were prepared in amber glass bottles and stored in the 
dark at 4 °C. Hydroxy-PAH metabolites 1-OH naphthalene, 9-OH phenanthrene, 1-OH 
pyrene and 7-OH benzo(a)pyrene were reagent grade and also obtained from Sigma-
Aldrich. 
 
Incubations 
Incubations of PAHs and soils were performed in batch by sampling 
gastrointestinal suspension from the Simulator of the Human Intestinal Microbial 
Ecosystem (SHIME). This dynamic model of the gastrointestinal tract consists of 5 
compartments representing the stomach, small intestine, colon ascendens, 
transversum and descendens, respectively (Figure 5.1). The colon suspension 
contains in vitro cultured microbiota which were isolated from human feces and which 
are representative for the in vivo colon microbial ecology after a growth stabilization 
period in the different colon compartments (Molly et al. 1993). A typical stomach 
digestion consists of an incubation of PAHs or PAH contaminated soil samples for 3 
hours at pH 1.5 at 37°C. A small intestine digestion consists of an incubation for 5 
hours at pH 7 at 37°C in the presence of bile salts (0.2 mmol L-1) and pancreatic 
enzymes supplemented as pancreatic powder from porcine origin (0.4 g L-1). A colon 
digestion consists of an incubation with colon microbiota for 48 h at 37°C, withdrawn 
from the colon vessels of the SHIME reactor. Some samples were incubated with 
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inactive colon microbiota. For this, colon microbiota were autoclaved for 30 minutes 
(121°C, 1 bar overpressure). Incubation of PAH standard compounds in stomach, 
small intestine and colon digests occurred at a concentration of 20 µmol L-1. This 
concentration is normally not encountered in the gastrointestinal tract, but gave us 
more possibilities to study microbial PAH metabolism in depth. Gastrointestinal 
digestion experiments on soil samples were done as previously described (Van de 
Wiele et al., 2004) to simulate a hypothetical soil ingestion of 5 g d-1 by children 
(stomach 50mL, small intestine 60mL and colon 100mL). To avoid photocatalytic 
effects, all digestions were performed in amber flasks. After the respective incubations, 
samples were centrifuged at 3000×g for a duration of 10 minutes to remove most of 
the particulates and biomass. The supernatants were subsequently stored at -20°C 
prior to analysis. 
 
 
Figure 5.1 Schematic representation of the Simulator of the Human Intestinal Microbial 
Ecosystem (SHIME). Vessels 1 to 5 respectively simulate conditions from the 
stomach, small intestine, colon ascendens, colon transversum and colon 
descendens. 
 
Sample treatment 
PAH parent components and PAH metabolites were extracted from the digests by 
performing a liquid/liquid extraction in which the digest and ethylacetate were mixed in 
a 1:1 ratio. The ethylacetate fraction was subsequently put in a rotavapor to remove 
most of the solvent. The remainder of the solvent was removed under a gentle stream 
of nitrogen gas and finally replaced by dimethylsulfoxide which is a suitable solvent to 
use in bioassay tests. For chemical analysis of the samples using LC-MS, sample 
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aliquots were subjected to a solid phase extraction using PrepSepTM C18 (250 mg) 
(Fisher Scientific, Edmonton, Canada). PAH hydroxylates were eluted with methanol. 
PAH conjugate analysis 
To check whether conjugated PAH metabolites were formed in the different 
digests, samples were also incubated in the presence of β-glucuronidase and aryl 
sulfatase, both obtained from Sigma–Adrich (Belgium). After the PAH parent 
compounds had been incubated in SHIME suspension, a 1 mL aliquot of these 
samples were diluted in 1mL 0.1 M acetate buffer and the pH was adjusted to 5 with 
sodium hydroxide. A volume of 400 µl β-glucuronidase (100U mL−1) and 250 µl aryl 
sulfatase (60U mL−1) were added and the mixture was incubated for 6 h at 37 °C to 
hydrolyze the PAH conjugates.   
Bioassays 
For the bioassays, we used a modified protocol from De Boever et al. (2001) that 
was based on the protocol developed by Routledge and Sumpter (1996) for the yeast 
estrogen bioassay and Miller (1997) for the yeast Ah bioassay. Details on the yeast Ah 
bioassay, the yeast estrogen bioassay and the preparation of the medium compounds 
have been described before (Routledge and Sumpter, 1996; Miller, 1997). In brief, 
these researchers transformed Saccharomyces cerevisiae with the human Ah receptor 
gene and the human estrogen receptor (ERα) gene, together with expression plasmids 
containing responsive elements and the lacZ reporter gene (encoding the enzyme β-
galactosidase). The expression of β-galactosidase is triggered by test chemicals, 
which upon binding to the respective receptors induce the conformational change 
necessary for binding of the receptor/ligand dimer to the responsive elements. This β-
galactosidase activity is quantified at 540 nm by the conversion of the chromogenic 
substance chlorophenol red-β-D-galactopyranoside into chlorophenol red. The 
bioassay response is expressed as the absorbance at 540 nm divided by the optical 
density at 630 nm (A540/A 630)net. Positive signals in the Ah receptor assay were 
typically expressed as percentage equivalence to 200 nM benzo(a)pyrene which 
arbitrarily corresponded to a bioassay response of 100 %. Similarly, estrogenic activity 
of the samples was expressed as percentage equivalence to 6.96 nM 17α-ethynyl 
estradiol which elicited a 100 % response in the estrogen receptor bioassay (De 
Boever et al., 2001). To make sure that background signals from gastrointestinal 
suspensions of soil or food matrices did not interfere with the detection of estrogenic 
signals in the bioassays, corrections were made in a set of negative control 
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experiments by subtracting the response of a PAH containing digest with that from a 
blank digest without PAHs (see supplemental material). The bioassays were 
performed in 96-well plates in which 10 µL of the test compounds were tested and 
incubated with 240 µL of the genetically modified yeast (optical density of 0.25 at 
610nm). Serial dilutions of the test compounds were made in dimethylsulfoxide which 
allowed to generate dose-response curves for doses (ordinate) versus activity 
(abscissa). The data were fitted by a 4 parametric logistic model using the Marquardt-
Levenberg algorithm (Sigmaplot 4.0, SPSS Inc., Chicago, Illinois, USA) (De Boever et 
al., 2001). 
 
Negative controls 
Since we specifically examined the effect of gastrointestinal digestion processes on 
the production of estrogenic PAH metabolites, we corrected for background signals 
coming from the digestion matrix as such. Therefore we tested blank digest 
suspensions, which are typically the stomach, small intestinal or colon suspension 
from the SHIME reactor to which no PAHs had been added. No positive responses 
were expected from the blank stomach or small intestinal digests, but the colon 
suspension from the SHIME reactor is a complex mixture of microbiota and hundreds 
of different metabolites among which some compounds may posses pseudo-
estrogenic properties. The latter may be capable of binding the human estrogen 
receptor in the bioassay test and hence lead to a small, yet positive response. Blank 
stomach and small intestine digests indeed did not induce a significant response in the 
yeast estrogen bioassay (Figure 5.2a), hence no corrections for these digests were 
performed in later experiments. We noted however an inhibition in yeast growth when 
the bioassay was performed on blank small intestine digests. This inhibtion was 
previously explained by the presence of bile salts (De Boever et al., 2001). These 
compounds are present in the small intestine digests at 0.2 mmol/L and may disrupt 
the membrane integrity of the yeast cell wall. In contrast to the stomach and small 
intestine digests, the blank colon digest elicited a positive response of 28% EE2 
equivalence at the highest concentration (Figure 5.2a), thus making corrections on 
experimental data necessary. This value may seem high, but mainly originated from 
low absorbance values at 630 nm, which increases the final response, calculated as 
(A540/A630)net. All dose-response curves of colon digests were hence corrected for 
this matrix background signal. 
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Figure 5.2  Dose-response curves in the estrogen yeast assay for negative control samples. 
Values are averages of 4 replicates. Error bars represent standard deviation and 
may disappear in the datapoint if too small.  
a. blank stomach, small intestine and colon digests to which no PAHs had been 
dosed, were screened for estrogenic effects in the bioassay.  
b. stomach, small intestine and colon digests on a clover soil, rich in 
phytoestrogens were tested for their estrogenic response in the yeast estrogen 
bioassay. The estrogen response for the colon digest has been corrected for the 
matrix background response coming from colon suspension (Figure 5.2a). 
 
PAH contaminated soil samples were also included in this research and they too 
were subjected to the digests from the SHIME model. Besides PAHs and their possible 
metabolites, these soils may also contain pseudo-estrogenic compounds, 
phytoestrogens for instance. We examined whether the presence of phytoestrogens in 
b 
a 
 113
Chapter 5 
 
a soil sample could be of any concern in the yeast estrogen bioassay. We therefore 
incubated a clover (Family Leguminosae) soil, putatively rich in phytoestrogens to a 
stomach, duodenal and colon digest and analyzed these samples in the bioassay. 
Very low estrogenic signals of 5.6% EE2 equivalence were observed for stomach or 
duodenal digests on this soil (Figure 5.2b). A colon digestion on this leguminosae soil 
did lead to a slightly positive response in the lower 21 to 24 dilution range, however not 
significantly different from the blank colon suspension. After correction for this colon 
background signal, a maximal estrogen response of 4.5% was obtained (Figure 5.2b). 
We therefore concluded that no corrections for possible phytoestrogens in the PAH 
contaminated soil were needed, since on the latter soil there was primarily growth of 
Poaceae, which produce phytoestrogens at much lower concentrations than 
Leguminosae (Grippo et al., 1999). 
 
PAH analysis (GC-MS) 
etermination of PAHs were performed by the 
Env
Hydroxy-PAH analysis (LC-MS) 
PAHs was performed according to Van 
de 
Sample treatment for and d
ironmental Research Centre (Erembodegem, Belgium). Briefly, PAHs from pellets 
were extracted by a 1:1 aceton/hexane mixture using an ASE® 200 (Accelerated 
Solvent Extractor, Dionex, Sunnyvale, CA, USA). PAHs from supernatants were 
extracted with dichloromethane. Analysis of the PAH content in the extracts was 
performed according to a standardized method (Method EPA8270, Environmental 
Protection Agency, USA) by gas chromatography coupled with mass spectrometry 
(GC–MS). The MS detector used was a quadrupole mass spectrometer (Trace-MS, 
Fisons/Thermoquest, Belgium). The detection limit for the different PAH components 
was 0.2 µg L-1. The quantification limit was 0.4 µg L-1. The extraction efficiency of the 
sample preparation step prior to PAH analysis was between 80 and 110%, as 
determined with the reference soil CRM535. 
 
LC-MS analysis of the samples for hydroxy-
Wiele et al. (2004b). The identity of hydroxy-PAH metabolites in the samples was 
confirmed by using synthetic standards of these metabolites and compare the HPLC 
profiles from the colon digests with those from the standards. Briefly, all samples for 
LC-MS analysis were subjected to solid phase extraction using PrepSepTM C18 
columns (250 mg) (Fisher Scientific, Edmonton, Canada). Sample volumes of 5ml 
were loaded on the columns and washed with 10 mL of Milli-Q ® water and 
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subsequently, the target analytes were eluted with 10 mL of methanol. One mL 
aliquots were subsampled and stored in amber vials at 4°C prior to LC-MS analysis. 
HPLC analysis was performed using a Waters 2695 (Milford, MA, USA) separation 
module. The selected column was a 2.1 mm×100 mm, 3.5 µm particle size, Waters 
XTerra MS C18 column (Milford, MA, USA) which was kept at a constant temperature 
of 26 °C. The binary eluent system consisted of methanol:water 90:10 v/v (eluent A) 
and methanol:water 10:90 v/v (eluent B). Mass spectrometry analysis was performed 
with a Quattro Ultima Mass spectrometer (Micromass Technologies, Manchester, UK) 
that was equipped with an electrospray interface operating in the negative ion mode. 
Instrumental control and data acquisition was performed with MassLynx software 
version 3.5. The electrospray ionization source was operated at 90°C, desolvation 
temperature 200 °C, cone voltage 61 V, and a capillary voltage of 2.74 kV. Nitrogen 
gas served as the cone gas (flow rate of 159 L h-1), desolvation gas (490 L h-1) and 
nebulizer gas (set to maximum). The detector multiplier voltage was set to 650V. 
Selected ion monitoring was employed for quantitative analysis monitoring the (M-H)- 
of m/z for the PAH hydroxylates. 
 
Results and Discussion 
Bioactivation of pure PAHs 
f aromaticity, we expected pure solutions of 
nap
Due to their moderate to high degree o
hthalene, phenanthrene, pyrene and benzo(a)pyrene to test positive in the Ah 
bioassay. Naphthalene, 200 nM, displayed 0.4 % benzo(a)pyrene equivalence 
whereas 200 nM phenanthrene and 200 nM pyrene displayed 15.1 % and 48.2 % 
benzo(a)pyrene equivalence. PAH compounds are not estrogenic and up to 16 µM of 
the four pure PAHs indeed did not induce an estrogenic response in the estrogen 
bioassay. Similarly, separate stomach and small intestine digests of the four PAHs did 
not show a significant estrogen response (Figure 5.3). In contrast, PAHs from colon 
digests became estrogenic. Conversion of the % EE2 equivalence values, depicted in 
Figure 5.3, to equivalent EE2 concentrations resulted for colon digests of 62.5 nM 
pyrene, into 2.70 nM EE2 equivalence, for phenanthrene, 2.14 nM EE2 equivalence, 
for benzo(a)pyrene, 1.48 nM EE2 equivalence and for naphthalene 0.31 nM EE2 
equivalence. This PAH bioactivation was only evident upon the colon digestion. This 
shows the selectivity of the colon digestion towards an increase in estrogenicity 
whereas no increased aryl hydrocarbon response was detected, compared to stomach 
or small intestine digests. To make sure that the observed effects were not coming 
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from the matrix background of the colon interacting with PAHs, we incubated PAHs in 
a heat inactivated colon suspension. The removal of microbial activity markedly 
reduced the increase in estrogenic activity (Figure 5.3). This finding indicates that the 
risk for PAH bioactivation along the gastrointestinal tract is not exclusively associated 
with human biotransformation enzymes from the enterocytes in the small intestine 
epithelium and colonocytes in the large intestine epithelium (Autrup et al., 1978; De 
Kok and van Maanen, 2002; Doherty and Charman, 2002), but that colon microbiota 
can also bioactivate PAHs. 
 
 
Figure 5.3 Estrogen response of naphthalene, phenanthrene, pyrene and benzo(a)pyrene 
 
Bioactivation of soil-bound PAHs 
rocess using lower, more realistic 
con
incubated at 62.5 nmol/L in stomach, small intestine, colon digests and digests 
with inactivated colon microbiota. Error bars represent standard deviation values 
of 4 replicates. * none of the stomach digestions gave a significant response in 
the estrogen bioassay. 
We then evaluated the significance of this p
centrations obtained from a former urban playground soil, contaminated with 
49±1.5 mg PAH kg-1 soil DW by years of atmospheric deposition. Children form the 
largest risk group for soil ingestion due to their typical hand-mouth behaviour and small 
body weight. Hence, we simulated the GI tract of a child, hypothetically ingesting 5 g 
soil d-1. GC-MS analysis previously showed that the released PAH fraction from the 
soil matrix was highest in the stomach digest (18±5.3 µg L-1), followed by the small 
intestine digest (3±1.1 µg L-1) and the colon digest (2±0.3 µg L-1) (Van de Wiele et al., 
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2004d). This corresponded to a maximal Ah bioassay response for the stomach digest 
of 41±2.9 % benzo(a)pyrene equivalence, the small intestine 27±1.4 % and the colon 
22±2.6 % (Figure 5.4).  
 
 
Figure 5.4  Dose-response curve of stomach, small intestine and colon digests of a PAH 
 
ased on the role of the human Ah receptor in the toxicity of specific aromatic 
hyd
contaminated playground soil in the Ah receptor yeast bioassay, expressed as 
percentage benzo(a)pyrene equivalence in function of released PAH 
concentration in the respective digests. Values are averages of 4 replicates. Error 
bars represent standard deviation and may disappear in the datapoint if too 
small. 
B
rocarbons, these findings would normally indicate that the colon digest represents 
the lowest risk for PAH bioactivation. Surprisingly, the trend in estrogenic activity was 
the inverse of observed PAH release or Ah bioassay response. Similar to the estrogen 
bioassay results on pure PAHs, there was negligable induction of estrogenic activity 
upon the stomach and small intestine digestion (Figure 5.5). However, an average 
value of 20.1±0.84 % EE2 equivalence was observed upon a colon digestion of the 
contaminated soil (Figure 5.5). We infer that the PAH bioactivation potency from colon 
microbiota also occurs at lower and relevant concentrations for human exposure and 
that the presence of soil does not eliminate this potency. To bring these numbers in 
perspective, it is interesting to note that the observed estrogenicity is quite 
considerable, in comparison to the intestinal digestion of soy germ powder at relevant 
adult concentrations as performed by De Boever et al. (2001). De Boever et al. (2001) 
noted that the presence of soy isoflavones genistein, glycitein and daidzein resulted in 
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an estrogenic response of 35 ± 13.8% equivalence to 6.96 nM EE2. Taking into 
account these numbers, it can be concluded that the microbial PAH bioactivation to 
compounds with estrogenic properties may be physiologically important. 
 
 
Figure 5.5  Released concentrations of PAHs and estrogen response upon stoma all 
 
oil organic matter or nutritional fibres are known to lower the fraction of a 
con
compared to pure PAHs.  
ch, sm
intestine and large intestine digests on PAH contaminated soil samples. Error 
bars represent standard deviation values of 4 replicates. 
S
taminant that can be absorbed by the intestine (van Schooten et al., 1990; O’Neill 
et al., 1991; Oomen et al., 2000). This would theoretically lower the risk from ingested 
contaminants since bioactivation by human biotransformation enzymes will be reduced 
due to a lower bioavailability. To test this hypothesis, we compared the estrogenicity 
from colon incubated PAHs in the presence and absence of soil by calculating the 
bioactivation potency of the digests as estrogenicity / aromaticity. We divided – at 
equimolar concentrations – the % EE2 equivalence of the different digests by their 
respective % benzo(a)pyrene equivalence. At equimolar concentrations of 8.03 nmol 
PAH L-1, this ratio was for naphthalene, 0.93, for phenanthrene, 2.16, for pyrene, 0.98 
and for benzo(a)pyrene, 0.12, whereas the colon digest of the PAH contaminated soil 
gave a ratio of 0.88, the same order of magnitude as the ratios for pure PAH 
compounds and significantly higher than the ratios for the stomach soil digest, 0.016, 
or small intestine soil digest, 0.077. These findings provide further evidence that the 
presence of a soil matrix does not eliminate the PAH bioactivation by colon microbiota 
and that the estrogenic potency of soil derived PAHs does not significantly decrease if 
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Analytical detection of PAH metabolites 
PAH metabolites that typically have estrogenic properties, are hydroxylated 
der ogens (Hirose et al., 2001; 
Fer xt step of the research, we 
scr
AH bioactivation 
he formation of hydroxylated PAH metabolites and especially the increased 
est ved 
tran ent 
can
1). 
Additionally, microbial glucuronidase activity in the intestine sometimes cleaves off 
ivatives, due to their structural similarity to natural estr
tuck et al., 2001a; Fertuck et al., 2001b). Hence, in a ne
eened with LC-MS for the presence of hydroxy-PAHs by analyzing the respective 
colon digests of 20 µmol L-1 pure PAH compounds. The identity of PAH metabolites 
was confirmed by comparing the HPLC profiles and MS spectra of the colon digests 
with those from chromatographic synthetic standards of several hydroxy-PAHs. The 
developed protocol had reasonably low detection limits for 1-hydroxy napthalene, 9-
hydroxy phenanthrene, 1-hydroxy pyrene and 7-hydroxy benzo(a)pyrene (Table 4.1) 
(Van de Wiele et al., 2004b). From all colon digests, only the pyrene digest tested 
positive for a hydroxylated PAH metabolite with 1-OH pyrene at a concentration of 2.5 
µg L-1. Hydroxylated PAHs were not found in the stomach and small intestine digests. 
Glucuronidated or sulfated PAH conjugates are also typical biotransformation products 
from eukaryotic organisms (Cajthaml et al., 2002). Since the concentration of fungi and 
yeasts in the colon suspension amounted to 4.3±0.6 log CFU mL-1, we tested whether 
PAH conjugates were present in colon digests of pure PAH compounds. 
Glucuronidase and arylsulfatase typically cleave off glucuronic acid or sulfate groups 
from conjugated PAHs, regenerating the hydroxylated PAH metabolites (Cajthaml et 
al., 2002). After incubating the extracts of the colon digests in the presence of 
glucuronidase (100 U mL-1) and arylsulfatase (60 U mL-1) for 6 hours at 37°C, we 
found higher concentrations of 1-OH pyrene (4.4 µg L-1) and a new metabolite, 7-OH 
benzo(a)pyrene (1.9 µg L-1). No hydroxylated PAHs were retrieved from inactivated 
colon samples. Although other PAH hydroxylates may have formed than those tested 
during LC-MS analysis, these analytical data show that PAH bioactivation by colon 
microbiota may result from hydroxylated PAH metabolites. 
 
Biological plausibility and relevance of P
T
rogenicity by human colon microbiota bring up two questions. Are the obser
sformations plausible for the in vivo human gastrointestinal tract and to what ext
 bioactive PAH metabolites contribute to the total risk from oral PAH exposure?  
 
To answer the first question, literature shows that resident gut microbiota may 
influence xenobiotic metabolism from the intestinal epithelium (Hooper et al., 200
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glu
tential values from the colon 
sus
 
PAH bioactivation to estrogenic metabolites may constitute an increased health risk 
whe
curonic acid groups from excreted human conjugated metabolites, thus 
regenerating the more bioactive hydroxylated intermediates (Aura et al., 2002). These 
reports describe indirect effects of intestinal microbiota towards xenobiotic metabolism. 
However, our findings indicate a direct metabolism effect of human colon microbiota 
towards PAH parent compounds, since the in vitro approach used in the current study 
eliminated possible interferences by intestinal epithelium enzymes. The observed 
biotransformation and bioactivation reactions originate from a microbial community 
which resembles that of the in vivo intestinal lumen both in composition and in 
metabolic activity. Rather than containing the less active microbiota from fecal matter, 
the microbial community from the used in vitro method is more representative of the 
different parts of the human colon (Molly et al., 1993).  
As suggested by the LC-MS results, the colon microbiota formed hydroxylated 
PAH metabolites, which may seem uncommon since this oxidative step would occur in 
an anaerobic environment as shown by redox po
pension that varied between -180 mV and -230 mV. The latter values are well 
within the range of -145 mV to -250 mV reported for the colon in vivo (Bowler et al., 
2001; Chourasia and Jain, 2003). Yet, oxidative reactions by intestinal bacteria from 
humans, mice and rats have been described for the conversion of 2-amino-3-
methylimidazo[4,5-f] quinoline (IQ) to its reportedly mutagenic 7-keto derivative (7-
OHIQ) (Rumney et al., 1993). Additionally, Enterococcus faecalis even performs 
aromatic hydroxylation reactions in the intestine in vivo (Huycke and Moore, 2002). It is 
therefore not unlikely that intestinal microbiota may hydroxylate PAHs, also given the 
fact that anaerobic PAH hydroxylation has been reported by microorganisms, beit in 
sediments (Karthikeyan and Bhandari, 2001). These studies on oxidative reactions by 
intestinal microbiota and anaerobic PAH biotransformations may thus support our 
findings, which need further study to identify which microorganisms bioactivate PAHs.  
 
To answer the second question concerning the contribution of the observed effects 
to the total risk from PAH ingestion, further research is warranted. Yet, the microbial
n the human body is orally exposed to contaminated soils. The human colon 
epithelium is 20% more permeable to 17α-estradiol than the human small intestine 
epithelium (van der Bijl and van Eyck, 2003) and also has a higher permeability to 
hydrophobic compounds in general (Ungell et al., 1998). PAH metabolites with 
structures resembling steroidal hormones may thus exhibit weak estrogenic or 
antiestrogenic activity in vivo (Ariese et al., 2001). Since PAHs that reach the colon will 
be biotransformed by colon microbiota, we conclude that, in the in vivo situation, the 
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colonic epithelium – which has estrogen receptors – may be subjected to hazardous 
effects from microbial PAH metabolites. The equivalent EE2 response of 20 % for the 
colon incubated environmental sample (Figure 5.5) indicates that the observed 
activation of the human estrogen receptor is significant. Still, it must be kept in mind 
that a positive response in ER-reporter gene assays such as that from the present 
study, does not necessarily predict endogenous transcription (Gozgit et al., 2004). 
Gozgit et al. (2004) noted that several PAHs induced activity in ER-reporter gene 
assays but that these PAHs did not upregulate estrogen-responsive genes. The 
authors conclude that the ER-reporter gene assays may detect concentrations of 
toxicants that are not physiologically active. In light of these recent findings, the 
estrogenic response from microbial PAH bioactivation in this study needs careful 
interpretation. However, the finding of 1-OH pyrene and 7-OH benzo(a)pyrene as 
metabolites from human colon microbiota is something that is not anticipated from 
current scientific knowledge or risk assessment studies. Comparison of our findings 
from active to those from inactivated colon microbiota shows us that the microbial 
bioactivation potency is a factor 12 higher than would be currently expected in risk 
calculations. Moreover, the time during which bioactive hydroxy-PAHs could react with 
colonocytes is also considerably longer (up to 72 hours) than the residence time in 
human enterocytes or hepatocytes (8 hours). Additionally, if taken up by colonocytes, 
the hydroxy-PAHs are typical metabolites that are more easily metabolized by human 
biotransformation enzymes to for example potent carcinogens such as b(a)p-r7,t8-
dihydrodiol-t9,10-epoxide (Kim et al., 1998).  Clearly, these literature reports on human 
PAH metabolism and our findings of PAH bioactivation by colon microbiota indicate the 
importance of conducting future work in which the relative importance of the human 
bioactivation processes versus the microbial bioactivation processes should be 
compared. 
 
Conclusion 
 summary, our results reveal that human colon microbiota can directly bioactivate 
PAHs, a potency that has not been reported before. As indicated by the analysis of a 
PAH contaminated environmental sample, we also show that the presence of soil does 
not
In
 eliminate this microbial bioactivation potency. We therefore conclude that risk 
calculations that are solely based on human biotransformation enzymes, may 
underestimate the risk from ingested aromatic contaminants because it does not 
consider the bioactivation processes described here. 
 121
Chapter 5 
 
ACKNOWLEDGMENTS 
The authors wish to thank FWO (Fund for Scientic Research) for funding this 
research. We appreciate the help of Nico Boon, Sylvie Seurinck, Karel Decroos, Kristof 
Verthé and Sofie Dobbelaere for critically reading the manuscript. 
 
 
 122
 CHAPTER 6 
 
Prebiotic chicory inulin exerts chemopreventive activity 
towards bioactivation of polycyclic aromatic hydrocarbons by 
intestinal microbiota 
Abstract 
Inulin is frequently studied for its prebiotic activity as it stimulates health-promoting 
bacteria in the human colon. Inulin is also hypothesized to exert chemopreventive 
effects towards hazardous biotransformation reactions from the resident colon 
microbiota towards potential toxicants in the gut lumen. Using a Simulator of the 
Human Intestinal Microbial Ecosystem (SHIME), we investigated whether inulin 
addition inhibited the conversion of polycyclic aromatic hydrocarbons (PAH) to 
estrogenic metabolites by human colon microbiota. Additionally, prebiotic effects were 
evaluated by monitoring the microbial community from the colon compartments in 
terms of metabolic activity and community structure. Yeast estrogen bioassay data 
revealed that inulin addition significantly decreased the estrogenicity of PAH incubated 
samples from the ascending (39% decrease) and transverse (14% decrease) colon 
compartment, whereas inulin did not exert chemopreventive effects in the descending 
colon. Interestingly, this colon-specificity showed parallels with the prebiotic effects. 
Conventional culture-based techniques and PCR-DGGE analysis on the SHIME colon 
suspension revealed significant bifidogenic effects during inulin treatment in the 
ascending colon whereas the overall microbial community kept relatively unchanged. 
Additionally, short chain fatty acid production increased with 44%, 23% and 33% in the 
ascending, transverse and descending colon while ammonia concentrations 
significantly decreased in the ascending colon. This indicates that the prebiotic effects 
from inulin may also purport inhibitory effects towards PAH bioactivaiton. From the real 
time PCR data, which showed bifidogenic effects (> 1 log CFU mL-1) throughout the 
entire colon, we infer that specific conditions from the proximal colon region promote 
the chemopreventive effects from inulin the most.  
  
Redrafted after: Van de Wiele T, Boon N, Possemiers S, Jacobs H and Verstraete W. 2004. 
Prebiotic effects from native chicory inulin in the Simulator of the Human Intestinal Microbial 
Ecosystem. FEMS Microbiology Ecology. In press. 
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Introduction 
Human exposure studies reveal that polycyclic aromatic hydrocarbons (PAH) are 
more likely to be ingested than inhaled by the incidental uptake of contaminated soils 
or the consumption of processed foods such as charcoal-broiled, grilled and smoked 
meat (De Kok and van Maanen, 2000). Dietary exposure in particular significantly 
contributes to total PAH exposure and depending on the individual life style, the total 
daily PAH-intake may vary between 25 and 300 µg d-1 (van Maanen et al., 1994). The 
oral bioavailability is assumed to be quite low, below 10% (van Schooten et al., 1997), 
because of complexation effects with the soil matrix or dietary constituents that limit 
the available fraction for intestinal absorption (Chapter 3; Van de Wiele et al. 2004d). 
Hence, a substantial part of the ingested PAHs reaches the colon and rectum, thus 
presenting a putative target for PAH-induced carcinogenicity. In order to exert toxic 
effects in colon and rectum, PAHs need to be bioactivated (De Kok and van Maanen, 
2000). It has been demonstrated that colonic tissue is able to metabolize PAHs 
similarly as found in other tissues (Autrup et al., 1978), but interestingly, the research 
results from Chapter 5 show that colon microbiota can also convert PAHs to bioactive 
components (Van de Wiele et al., 2004c), more specifically metabolites with estrogenic 
properties.  
The bioactivation potency was illustrated previously by several studies that show 
that colon microbiota are involved in colorectal cancer by the production of 
carcinogenic metabolites (Hirayama et al., 2000; Hughes and Rowland, 2000; Aura et 
al., 2002; Gill and Rowland, 2002). As an example, intestinal microbiota from humans, 
mice or rats were responsible for the conversion of 2-amino-3-methylimidazo[4,5-f] 
quinoline (IQ) to the mutagenic 7-keto derivative (7-OHIQ) (Rumney et al., 1993; 
Kassie et al., 2001). These reports and the newly discovered PAH bioactivation by 
colon microbiota from Chapter 5, indicate that more attention should be given to the 
metabolic potency of specific microbial groups in the colon lumen towards 
contaminants. Of course, colon microbiota are not solely presenting health risks 
towards their host. There are also microbial groups that exert beneficial effects such as 
the synthesis of fermentation products that provide energy to the colon epithelium 
(Cummings and Englyst, 1987), the stimulation of the gut immune system (Salminen et 
al., 1998), the synthesis of vitamins K and B (Conly and Stein, 1992) and the 
colonisation resistance against exogenous pathogens (Hopkins and Macfarlane, 
2003).  
 124
Inulin as chemopreventive agent against PAH bioactivation 
The balance between these health-promoting and hazardous microbial groups and 
their metabolic reactions is rather delicate. Research suggests that the GI microbiota 
can be beneficially affected by means of a well-balanced diet and consumption of 
functional foods such as pro- and prebiotics (Gibson and Roberfroid, 1995; Collins and 
Gibson, 1999; Gibson and Williams, 1999). Probiotic food products contain live lactic 
acid producing bacteria such as lactobacilli, bifidobacteria and streptococci. If these 
health-promoting bacteria are still active when reaching the large intestine, they may 
support the growth of indigenous beneficial bacteria from the gut and suppress the 
colonization of pathogens by lowering the intestinal pH and producing bacteriotoxins 
(Fooks et al., 1999). A successful proliferation of probiotic bacteria in the human colon 
however depends on their survival through the acidic stomach environment, the 
membrane damaging effects from small intestinal bile salts and substrate- and niche 
competition with other intestinal microorganisms. Therefore, the concept of prebiotics 
has been developed.  
Prebiotics are indigestible food ingredients that beneficially affect the host by 
selectively stimulating the growth and/or activity of one or a number of health-
promoting colon bacteria such as lactobacilli and bifidobacteria (Gibson and 
Roberfroid, 1995). Of all the possible prebiotics, the effects of inulin type 
fructooligosaccharides (FOS) have been investigated the most. FOS are a mixture of 
indigestible but fermentable β-D-fructans with variable degree of polymerization. The 
average dietary intake of inulin by humans is estimated to be 1-4 g d-1 (Van Loo et al., 
1995). Inulin would typically alter the composition of the human colon microbiota 
towards a predominance of bifidobacteria which can readily metabolise inulin, by which 
they have a nutritional advantage over other colon microbiota (Gibson et al., 1995; 
Brighenti et al., 1999; Hopkins and Macfarlane, 2003). In this way, the production of 
hazardous metabolites from bacteroides, clostridia or coliforms would decrease 
through the addition of inulin. 
It this study, we investigated the prebiotic effects from native chicory inulin in 
combination with its inhibitory properties towards the microbial bioactivation of PAHs 
towards metabolites with estrogenic properties. Molecular analysis techniques and 
conventional methods were used to evaluate how inulin affects the composition and 
fermentation activity of in vitro cultured colon microbiota. The estrogen receptor 
bioassay was used to study the influence of inulin addition towards the microbial 
bioactivation potency of PAHs. The Simulator of the Human Intestinal Microbial 
Ecosystem (SHIME), which harbours a microbial community resembling that from the 
human colon both in fermentation activity as in composition (Molly et al., 1993), was 
operated at full scale.  
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Materials and methods 
SHIME run at full scale – inulin supplementation 
The Simulator of the Human Intestinal Microbial Ecosystem (SHIME) is a dynamic 
model of the human gastrointestinal tract (Molly et al., 1993; De Boever et al., 2000). It 
consists of 5 double-jacketed vessels maintained at a temperature of 37 °C, 
respectively simulating the stomach, small intestine, ascending colon, transverse colon 
and descending colon, with a total retention time of 76 h (Figure 6.1). The colon 
vessels harbour a mixed microbial community and pH controllers (pH controller R301, 
Consort, Turnhout, Belgium) maintain the pH in the range 5.6-5.9, 6.2-6.5 and 6.6-6.9 
in the ascending colon, transverse colon and descending colon, respectively. There is 
no gas exchange between the different vessels and the headspace of the culture 
system was flushed twice a day for 15 min with N2 to ensure anaerobic conditions. 
The growth medium for the microbial inoculum consisted of a carbohydrate-based 
medium containing arabinogalactan (1 g.L-1), pectin (2 g.L-1), xylan (1 g.L-1), starch (4.2 
g.L-1), glucose (0.4 g.L-1), yeast extract (3 g.L-1), peptone (1 g.L-1), mucin (4 g.L-1) and 
cysteine (0.5 g.L-1). The pH of the medium was 5.5. Detailed information on the 
medium can be found in Molly et al. (1993). 
 
 
Figure 6.1  Schematic representation of the Simulator of the Human Intestinal Microbial 
Ecosystem (SHIME). Vessels 1 to 5 respectively simulate conditions from the 
stomach, small intestine, colon ascendens, colon transversum and colon 
descendens. (Source: De Boever et al., 2000) 
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At the beginning of the experiment, the last three vessels were inoculated with a 
pooled fecal sample of three adult volunteers who had no history of antibiotic treatment 
in the last year. During the start-up period, the normal nutritional medium was 
supplemented to the reactor, which enabled the microbial community to adapt 
themselves to the nutritional and physicochemical conditions that prevail in the 
different colon vessels (Molly et al., 1993). After two weeks, the treatment period was 
initiated, which lasted for five weeks. The nutrition for the treatment period consisted of 
the normal compounds as described above, except that the amount of starch in the 
medium was completely replaced by native chicory inulin (Fibruline Instant, 
COSUCRA, Warcoing, Belgium). This commercial inulin product has a dry matter of 
96% and contains, on dry matter, 92% FOS with an average polymerisation degree of 
10 and 8% free sugars. The dose of inulin to the SHIME reactor was 2.5 g d-1, which 
was equivalent to a human dose of 5 g inulin d-1. As the inulin replaced the starch 
concentration in the medium, the amount of available carbohydrates for the 
microorganisms stayed the same throughout the entire SHIME run. After the treatment 
period, a final control period concluded the run, to see whether the metabolic 
parameters and/or microbial concentrations evolved towards their initial values from 
the start-up period. This period lasted for 2 weeks and the inulin compound was again 
replaced by starch in the medium. 
 
Chemical analysis 
Short chain fatty acids (SCFA). Liquid samples were collected and frozen at -20 
°C for subsequent analysis. The SCFA were extracted from the samples with diethyl 
ether and determined with a Di200 gas chromatograph (GC; Shimadzu, 's-
Hertogenbosch, The Netherlands). The GC was equipped with a capillary free fatty 
acid packed column (EC-1000 Econo-Cap column (Alltech, Laarne, Belgium), 25 
m×0.53 mm; film thickness 1.2 µm), a flame ionization detector and a Delsi Nermag 31 
integrator (Thermo Separation Products, Wilrijk, Belgium). Nitrogen was used as 
carrier gas at a flow rate of 20 mL min-1. The column temperature and the temperature 
of the injector and detector were set at 130 °C and 195 °C, respectively. 
Ammonia. Using a 1026 Kjeltec Auto Distillation (FOSS Benelux, Amersfoort, The 
Netherlands), ammonium in the sample was liberated as ammonia by the addition of 
an alkali (MgO). The released ammonia was distilled from the sample into a boric acid 
solution. The solution was back-titrated using a 665 Dosimat (Metrohm, Berchem, 
Belgium) and 686 Titroprocessor (Metrohm). 
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Lactate. Lactate concentrations were measured by dissolving 10 µL of sample in 
990 µL lactate reagent (Sigma, Bornem, Belgium). Absorbance at 540 nm after 10 min 
incubation was read with an UVIKON 930 spectrophotometer. 
Enzyme analysis. The samples were centrifuged at 10 000×g for 10 min. Cell free 
supernatant (100 µL) was pipetted into a 96-well plate, with 100 µL of a 5.0 mM 
solution of substrate, prepared in a 0.1 mM phosphate buffer (pH 6.5). The substrates 
(Sigma, Bornem, Belgium) used were p-nitrophenyl-β-galactopyranoside, p-
nitrophenyl-β-glucuronide for β-galactosidase and β-glucuronidase. The plates were 
incubated at 37°C and the absorbance at 405 nm was read after 30 min with a 
Biokinetics EL312e multi-well reader (Bio-Tek Instruments Europe, Spijkenisse, The 
Netherlands). The amount of p-nitrophenol released was measured based on a 
standard curve of p-nitrophenol. The results were expressed in µmol p-nitrophenol 
released (mL min)-1.   
 
Microbial analysis 
Plate counting. The analysed bacterial groups and the used media, purchased 
from Oxoid (Hampshire, UK), are indicated in Table 6.1. Liquid samples were 
withdrawn from the culture system and serially diluted in saline solution (8.5 g NaCl    
L-1). Three plates were inoculated with 0.1 mL sample of three dilutions, and incubated 
at 37°C (43°C for E. coli) using conditions given in Table 6.1. Anaerobic incubation of 
plates was performed in jars with a gas atmosphere (84% N2, 8% CO2, and 8% H2) 
adjusted by the Anoxomat 8000 system (Mart, Sint-Genesius-Rode, Belgium). 
 
Table 6.1. Analyzed microbial groups together with the isolation media used and the 
incubation conditions 
Bacterial group Medium Condition Time 
   h 
Total aerobes Brain Heart Infusion agar Aerobic 24 
Total anaerobes Brain Heart Infusion agar Anaerobic 72 
Bifidobacteria Raffinose Bifidobacterium agar Anaerobic 72 
Lactibacilli Rogosa agar Anaerobic 72 
Fecal coliforms Mc. Conkey agar Aerobic 24 
Enterococci Enterococcus agar Aerobic 48 
Staphylococci Mannitol Salt agar Aerobic 48 
Clostridia Tryptose Sulfite Cycloserine agar Anaerobic 24 
Fungi Martin agar Aerobic 72 
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PCR-DGGE. The protocol for total DNA extraction from the SHIME samples was 
based on Boon et al. (2000). Three microbial groups of the colon were analysed: 
general bacteria, bifidobacteria and lactobacilli. A nested PCR approach (Boon et al., 
2002) was used to amplify the 16S ribosomal RNA genes of the bifidobacteria and 
lactobacilli. In brief, one µl of the DNA was amplified using the primers BIF164f-
BIF662r (Satokari et al., 2001) and SGLAB0158f-SGLAB0667 (Heilig et al., 2002), 
respectively for bifidobacteria and lactobacilli. When the first PCR round gave a clearly 
visible band, a second amplification round with forward primer P338F (with a GC-
clamp of 40 bp) and reverse primer P518r was used (Muyzer et al., 1993). The 16S 
rDNA of all bacteria was amplified by applying primers P338F with GC-clamp and 
P518r on total extracted DNA. 
DGGE (Denaturing Gradient Gel Electrophoresis) based on the protocol of Muyzer 
et al. was performed using the Bio-Rad D Gene System (Bio-Rad, Hercules, CA, 
USA). PCR fragments were loaded onto 8% (w/v) polyacrylamide gels in 1 × TAE (20 
mM Tris, 10 mM acetate, 0.5 mM EDTA pH 7.4). On each gel, a home made marker of 
different PCR fragments was loaded, which was required for processing and 
comparing the different gels (Boon et al., 2002). The polyacrylamide gels were made 
with denaturing gradient ranging from 45 to 60 % (Boon et al., 2000). The 
electrophoresis was run for 16 hours at 60°C and 38 V. Staining and analysis of the 
gels was performed as described previously (Boon et al., 2000). The normalization and 
analysis of DGGE gel patterns was done with the BioNumerics software 2.0 (Applied 
Maths, Kortrijk, Belgium). The statistical comparison of the DGGE patterns on the 
same gel was done with the GelCompar software 4.1 (Applied Maths, Kortrijk, 
Belgium). The calculation of the similarity matrix was based on the Pearson correlation 
coefficient. Clustering algorithm of Ward was used to calculate dendrograms (Ward, 
1963). 
DNA sequencing. 16S rDNA gene fragments were cut out of the DGGE gel with a 
clean scalpel and added to 50 µl of PCR water. After 12 hours of incubation at 4°C, 1 
µl of the PCR water  was reamplified with primer set P338F and P518r. Five µl of the 
PCR product was loaded on a DGGE gel (see above) and if the DGGE pattern only 
showed 1 band, it was sent out for sequencing. DNA sequencing of the ca. 180 bp 
fragments was carried out by ITT Biotech-Bioservice (Bielefeld, Germany). Analysis of 
DNA sequences and homology searches were completed with standard DNA 
sequencing programs and the BLAST server of the National Center for Biotechnology 
Information (NCBI) using the BLAST algorithm (Boon et al., 2002). 
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Nucleotide sequence accession numbers. Nucleotide sequences for bands Bif1, 
2 and 3 and Bac1 have been deposited in GenBank database under accession 
numbers AY647970, AY647971, AY647972 and AY647973, respectively. 
Real-time PCR. The real-time PCR was based on the principle of Heid et al. 
(1996). For quantification of bifidobacteria by real-time PCR, amplification was 
performed in 25-µl reaction mixtures by using buffers supplied with the qPCR™ Core 
Kit for Sybr™ Green I as described by the suppliers (Eurogentec, Liège, Belgium) in 
MicroAmp Optical 96-well reaction plates with optical caps (PE Applied Biosystems, 
Nieuwerkerk a/d Ijssel, The Netherlands). Primers BIF164f-BIF163r (Satokari et al., 
2001) for 16S ribosomal RNA genes were used for the quantification of bifidobacteria 
at a concentration of 1 µM. PCR temperature program was as follows: 50°C for 2 min, 
95°C for 10 min, followed by 40 cycles of 94°C for 1 min, 62°C for 1 min and 60°C for 1 
min. The template DNA in the reaction mixtures was amplified (n=3) and monitored 
with an ABI Prism SDS 7000 instrument (PE Applied Biosystems, Nieuwerkerk a/d 
Ijssel, The Netherlands). DNA was extracted from a 6.4 x 107 CFU mL-1 culture of 
Bifidobacterium breve (LMG11042) (Kowalchuk et al., 1998). Standard curves were 
constructed after real-time PCR amplification of four different DNA concentrations 
(n=4) ranging from 1.28 x 107 to 1.28 x 104 cell equivalents/well. The standard curve 
had a R2 value of 0.99 and the slope was -4.3. 
 
Microbial PAH bioactivation  
PAH incubation. During the start-up period and the treatment period of the SHIME 
run, weekly samples of 50 mL were taken from the different colon compartments of the 
SHIME reactor to perform incubation experiments in batch with benzo(a)pyrene as 
model PAH compound. Benzo(a)pyrene (40 µM) was incubated in the colon 
suspension (O2=0.12 mg L-1; Eh = -180 mV) at 37 °C for 72 h. No samples were 
incubated from the control period after inulin supplementation was stopped. 
Sample treatment. Upon incubation, the digest mixtures were extracted using 
liquid/liquid extraction with ethylacetate in a 1:1 ratio. The ethylacetate fraction was 
subsequently put in a rotavapor to remove most of the solvent. The remainder of the 
solvent was removed under a gentle stream of nitrogen gas and finally replaced by 
dimethylsulfoxide (DMSO) which is a suitable solvent to use in the estrogen receptor 
bioassay.  
Bioassay. The estrogen receptor test was used as previously described (Van de 
Wiele et al., 2004c). Basically, this test follows a modified protocol from De Boever et 
al. (2001) that was based on the protocol developed by Routledge and Sumpter 
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(1996). The latter researchers transformed Saccharomyces cerevisiae with the human 
estrogen receptor (ERα) gene, together with an expression plasmid containing 
estrogen responsive elements and the lacZ reporter gene (encoding the enzyme β-
galactosidase). The expression of β-galactosidase is triggered by test chemicals, 
which upon binding to the estrogen receptor induce the conformational change 
necessary for binding of the receptor/ligand dimer to the responsive elements. This β-
galactosidase activity is quantified at 540 nm by the conversion of the chromogenic 
substance chlorophenol red-β-D-galactopyranoside into chlorophenol red. The 
bioassay response is calculated as the absorbance at 540 nm divided by the optical 
density at 630 nm (A540/A630)net. Estrogenic activity of the samples was expressed as 
percentage equivalence to 6.96 nM 17α-ethynyl-estradiol (EE2) which elicited a 100 % 
response in the estrogen receptor bioassay (De Boever et al. 2001). To make sure that 
background signals from the gastrointestinal suspension as such did not interfere with 
the detection of estrogenic signals in the bioassays, corrections were made in a set of 
negative control experiments as previously described (Van de Wiele et al., 2004c). 
 
Statistical analysis 
Statistical analysis of the fermentation and microbial parameters was performed on 
samples taken over time once stable conditions during the subseqent start-up, 
treatment and control periods were obtained. It was not feasible to perform replicate 
SHIME runs since one run with the SHIME reactor takes more than 3 months. An 
unpaired 2-tailed t-test was used to compare averages.  
 
Results 
Inhibitory effects from inulin towards PAH bioactivation 
To evaluate the effects from inulin towards the microbial conversion of PAHs to 
estrogenic metabolites, the bioactivation potency of the colon microbiota was checked 
by incubating benzo(a)pyrene at a concentration of 40 µM in mixed microbial 
suspensions retrieved from the different colon compartments of the SHIME reactor. 
Bioactivation was evaluated by measuring the estrogenicity of the samples using the 
yeast estrogen assay. Incubated samples from the start-up period were compared with 
incubated samples from the inulin treatment period (Figures 6.2, 6.3 and 6.4).  
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Figure 6.2 Estrogen response of benzo(a)pyrene incubated microbial suspension, 
sampled from the ascending colon compartment (n = 4) 
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Figure 6.3 Estrogen response of benzo(a)pyrene incubated microbial suspension, 
sampled from the transverse colon compartment (n = 4) 
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Figure 6.4 Estrogen response of benzo(a)pyrene incubated microbial suspension, 
sampled from the descending colon compartment (n = 4) 
 
Confirming the results from Chapter 5, benzo(a)pyrene incubated colon samples 
elicited an estrogenic response after 72 h, whereas non-incubated samples elicited no 
positive response (data not shown). The highest estrogenicity was observed in the 
ascending colon (86±3.4% EE2 equivalence), followed by the transverse (78±5.2%) 
and descending colon (67±2.5%). Interestingly, incubation of benzo(a)pyrene with 
samples that were taken during the period of inulin supplementation showed a 
significantly lower estrogen response. The difference with the start-up period was most 
obvious in the ascending colon samples (47±4.3%), followed by the transverse colon 
samples (64±4.3%). No difference in estrogen response was seen in the descending 
colon samples, indicating the specificity of the chemopreventive effect of inulin in the 
ascending colon. The effect from inulin supplementation towards the estrogenicity of 
the samples was also evidenced by shifts in the EC50-values when inulin was added.  
The estrogen bioassay results clearly indicate the effect from inulin 
supplementation towards the estrogenic response of samples from the respective 
colon compartments that were incubated with benzo(a)pyrene. To explain these 
inhibitory effects from inulin, a possible relationship with the well-known prebiotic 
effects from inulin was evaluated. Therefore, both the metabolic activity from the 
microbiota in the respective colon compartments of the SHIME reactor, as the 
microbial community composition were investigated.  
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Metabolic activity 
Replacement of starch by a metabolic equivalent amount of chicory inulin in the 
nutrition of the gastrointestinal simulator changed the microbial fermentation pattern in 
all colon vessels towards a more saccharolytic metabolism. This metabolic shift was 
already observed after 1 week of inulin supplementation (data not shown) and 
eventually resulted in a significant (p<0.01) increase in short chain fatty acid (SCFA) 
production with 44, 23 and 33% in the ascending, transverse and descending colon at 
the end of the 5 week treatment period (Table 6.2). The higher SCFA concentrations 
primarily originated from an increased production of propionate and butyrate, whereas 
no significant changes in concentrations of acetate or branced fatty acids were 
observed. During inulin administration, ammonia concentrations significantly 
decreased in the ascending colon vessel, whereas no significant changes in ammonia 
production were observed in the other colon vessels. As for lactate production, no 
significant changes were detected upon administration of inulin. In the control period, 
inulin was removed from the nutrition for the SHIME reactor and again replaced by the 
original amount of starch (4.2 g L-1). SCFA production again decreased with 26%, 30% 
and 28% in the ascending, transverse and descending colon and approached the initial 
levels from the start-up period (Table 6.2). This was primarily due to lower levels 
(p<0.01) of propionate and butyrate. The metabolic shift during the control period was 
also apparent from a higher ammonia production (33%) and a decrease in lactate 
production in the ascending colon vessel and the increase in lactate concentrations in 
the transverse colon vessel. Enzymatic activities of β-galactosidase and β-
glucuronidase were monitored in the respective colon compartments and did not 
change significantly during the entire SHIME run (data not shown). 
 
Microbial community analysis 
Plate counting. Using selective growth media, analysis of the microbial 
suspension from the SHIME colon compartments revealed that inulin administration 
had limited effects on the overall composition of the microbial community. 
Concentrations of the beneficial microbial groups, bifidobacteria and lactobacilli, 
increased in all colon vessels during the first weeks of inulin supplementation (data not 
shown), yet this increase only became significant during the last two weeks of the 
treatment period. For the transverse and descending colon compartments, lactobacilli 
concentrations were 1.5 log CFU higher (p<0.01) than the initial levels from the start-
up period (Table 6.3). Significantly higher bifidobacteria concentrations (p<0.05) were 
observed in the ascending colon after 5 weeks of inulin supplementation. A limited 
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decrease in staphylococci concentrations (p<0.05) was observed in the descending 
colon whereas fecal coliforms were inhibited both in the transverse colon (p<0.05) and 
descending colon (p<0.01) (Table 6.3). During the control period, starch again 
replaced inulin in the nutrition of the SHIME reactor. This resulted in lower lactobacilli 
concentrations in the transverse colon and lower bifidobacteria concentrations in the 
ascending colon, whereas no other significant changes compared to the startup period 
were found. 
 
Table 6.2 Concentration of short-chain fatty acids, NH4+ and lactate measured in vessels 
3, 4 and 5 of the SHIME during the start-up (n = 14), treatment (n = 13) period 
with inulin after 5 weeks and control period (n = 6). Data are means ± SD, 
 Parameter Asc. Colon Trans. Colon Desc. Colon. 
  µmol/mL suspension 
Start-up Acetic acid 21.2 ± 5.4 30.4 ± 2.5 32.7 ± 3.6 
 Propionic acid 7.0 ± 2.1 10.6 ± 0.5 10.3 ± 1.3 
 Butyric acid 7.7 ± 4.3 14.5 ± 3.4 12.9 ± 5.3 
 Other acids 1.1 ± 0.6 1.9 ± 0.2 2.3 ± 0.7 
 Total SCFA 36.9 ± 5.9 57.4 ± 2.8 58.2 ± 9.4 
 Ammonium 15.6 ± 0.9 23.4 ± 2.9 26.2 ± 3.5 
 Lactate 1.35 ± 0.49 0.13 ± 0.04 0.10 ± 0.02 
Treatment Acetic acid 19,9 ± 2,9 28,1 ± 4,5 33,9 ± 4,0 
 Propionic acid 17,6 ± 1,7** 21,3 ± 2,2** 21,6 ± 2,1** 
 Butyric acid 14,3 ± 2,1** 19,3 ± 1,7** 19,3 ± 1,2** 
 Other acids 1,4 ± 0,3 2,0 ± 0,4 2,9 ± 0,4 
 Total SCFA 53,3 ± 4,9** 70,7 ± 5,6** 77,6 ± 4,1** 
 Ammonium 11,5 ± 1,7** 21,1 ± 2,7 24,3 ± 1,9 
 Lactate 0,71 ± 0,19 0,13 ± 0,03 0,13 ± 0,05 
Control Acetic acid 19.1 ± 9.5 25.3 ± 2.1** 30.5 ± 3.0 
 Propionic acid 7.6 ± 2.3°° 11.9 ± 1.8°° 12.2 ± 2.6°° 
 Butyric acid 11.5 ± 5.3°° 10.8 ± 4.3°° 10.7 ± 4.0°° 
 Other acids 1.4 ± 0.6 1.5 ± 0.5 2.5 ± 0.6 
 Total SCFA 39.6 ± 3.8°° 49.6 ± 4.5°°** 55.9 ± 9.4°° 
 Ammonium 15.3 ± 0.8°° 21.8 ± 3.0 23.9 ± 4.4 
 Lactate 0.12 ± 0.02°° 0.40 ± 0.01°°** 0.12 ± 0.03 
* Significantly different from the start-up period, p ≤ 0.05; ** p ≤ 0.01,  
° Significantly different from treatment period, p ≤ 0.05; °° p ≤ 0.01 
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Table 6.3 Microbial counts in the colon vessels of the SHIME reactor during 2 weeks of 
start-up (n = 5), 5 weeks of treatment with inulin at normal concentration (n = 5) 
and 2 weeks of control period (n = 3). Data are means ± SD, 
 Microbial group 
Ascending 
Colon 
Transverse 
Colon 
Descending Colon 
  Log CFU/mL 
Start-up Aerobe 8,27 ± 0,15 8,34 ± 0,13 8,31 ± 0,52 
 Anaerobe 8,18 ± 0,14 7,79 ± 0,81 7,55 ± 0,75 
 Lactobacilli 5,57 ± 0,69 5,42 ± 0,75 5,01 ± 0,83 
 Enterococci 6,98 ± 0,25 6,91 ± 0,20 6,81 ± 0,14 
 Fecal coliforms 6,66 ± 0,40 7,00 ± 0,40 7,32 ± 0,28 
 Bifidobacteria 6,26 ± 0,22 6,83 ± 0,84 6,75 ± 0,62 
 Staphylococci 7,15 ± 0,17 6,59 ± 0,42 6,75 ± 0,08 
 Fungi 3,43 ± 0,22 3,20 ± 0,60 2,80 ± 0,14 
 Clostridia 8,12 ± 0,22 8,13 ± 0,24 7,72 ± 0,29 
Treatment Aerobe 7,82 ± 0,96 8,40 ± 0,58 7,62 ± 0,26 
 Anaerobe 7,98 ± 0,45 8,15 ± 0,33 8,35 ± 0,34 
 Lactobacilli 6,39 ± 0,21 6,91 ± 0,13** 6,64 ± 0,05** 
 Enterococci 6,58 ± 0,23 6,68 ± 0,22 6,57 ± 0,25 
 Fecal coliforms 6,28 ± 0,30 6,29 ± 0,29* 6,33 ± 0,37** 
 Bifidobacteria 6,93 ± 0,29* 6,57 ± 0,24 6,75 ± 0,56 
 Staphylococci 6,70 ± 0,28 6,53 ± 0,05 6,43 ± 0,20* 
 Fungi 3,36 ± 0,44 2,40 ± 0,14 2,40 ± 0,14 
 Clostridia  7,53 ± 0,53 8,20 ± 0,94 8,01 ± 0,61 
Control Aerobe 8,01 ± 0,53 8,06 ± 0,42 8,08 ± 0,48 
 Anaerobe 8,18 ± 0,47 7,80 ± 0,65 7,66 ± 0,93 
 Lactobacilli 6,77 ± 0,18 6,48 ± 0,04° 6,68 ± 0,14 
 Enterococci 6,78 ± 0,61 6,21 ± 0,89 6,47 ± 0,06* 
 Fecal coliforms 6,45 ± 0,47 6,54 ± 0,22 6,56 ± 0,40* 
 Bifidobacteria 5,69 ± 0,22° 5,57 ± 0,56 5,39 ± 0,34 
 Staphylococci 6,56 ± 0,69 6,40 ± 0,53 6,12 ± 0,71 
 Fungi 3,15 ± 0,40 - ± - - ± - 
 Clostridia 7,81 ± 0,52 7,23 ± 1,07 7,71 ± 0,05 
* Significantly different from the start-up period, p ≤ 0.05; ** p ≤ 0.01,  
° Significantly different from treatment period, p ≤ 0.05; °° p ≤ 0.01 
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Microbial fingerprinting. PCR-DGGE was used as a molecular fingerprinting 
technique to monitor qualitative changes in the composition of the microbial community 
from the three colon compartments throughout the SHIME run. Samples from the start-
up period were taken at day 14, just before the supplementation of inulin began. 
Samples from the treatment period were taken at day 35 and day 49, respectively after 
3 and 5 weeks of inulin supplementation. Finally, samples from the control period, 
during which no inulin was supplemented, were taken at day 54 and 61. Thus, for the 
three colon compartments, a total of 15 samples was collected and DGGE analysis 
was performed for general bacteria, bifidobacteria and lactobacilli. 
The global fingerprint for general bacteria showed that all samples from the 
ascending colon clustered in a separate group and that most samples from the 
transverse and descending colon clustered together in another group (Figure 6.5). 
Both within the ascending colon group as the transverse/descending colon group, the 
influence of inulin addition was observed by the separate clustering of the treatment 
samples d35 and d49 and the control samples d54 and d61 (Figure 6.5). Although this 
inulin effect was slightly apparent within each colon compartment, the dominant factor 
for clustering was the colon compartment itself, from which the samples were taken. 
This roughly corresponds to the limited variations in microbial populations that were 
observed using conventional plating techniques. This was in contrast to clustering 
analysis of DGGE patterns for the bifidobacteria. For this bacterial group, samples did 
not cluster according to the colon compartment of origin, but to the time point at which 
they were taken (Figure 6.5). All colon samples from the treatment period (d35 and 
d49) clustered together with the first colon samples from the control period (d54). For 
all three colon vessels, a new band strongly appeared at day 35, after three weeks of 
inulin supplementation. 
Samples from the start-up period (d14) and the second control sample from the 
descending colon formed a second cluster, whereas the control samples at d61 for the 
ascending and transverse colon clustered separately. For lactobacilli, the clustering 
pattern was roughly comparable to that for bifidobacteria. All samples from the start-up 
period (d14) formed a first cluster together with several samples from the control 
period (d54 or d61), whereas all samples from the treatment period (d35 and d49) and 
some of the control period were grouped in a second cluster. At higher similarity 
values, two additional clusters were distinguished, a first one formed by ascending 
colon samples from the treatment (d35 and d49) and control period (d54 and d61) and 
a second one formed by several samples from the transverse and descending colon 
for the treatment and control period. 
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Sequencing. Based on the DGGE fingerprint analysis of the colon microbial 
community, several shifts in bands or changes in band intensity were observed. To 
identify the bacterial species that were responsible for those changes, DNA fragments 
from bands of interest were excised from the DGGE gel, isolated and finally 
sequenced. Four bands were succesfully sequenced. DNA fragment bands marked 
“bif1” on the bifidobacteria DGGE gel showed 95% similarity (141 out 147 bases) to an 
uncultured bacterium isolated from mucosa associated bifidobacteria (AY267921). 
These bands strongly appeared during the first weeks of inulin supplementation, but 
then declined again in intensity. Two other bands – marked “bif2” and “bif3” – also got 
more intense during inulin supplementation and these bands respectively revealed 
similarity to Bifidobacterium infantis (96% similarity, 169 out of 176 bases, 
AY166531.1) and Bifidobacterium longum (96% similarity, 170 out of 177 bases, 
AY166538.1). For the bacterial DGGE pattern too, a remarkable change was observed 
during inulin administration, with one band marked “bac1” getting more intense in all 
colon vessels. The DNA sequence of this band showed 93% similarity (178 out 192 
bases, AF371889) to an uncultured bacterium from the GI tract, belonging to the genus 
of Prevotella and was much less intense during the start-up and control period. 
 
 
 
 
 
 
 
 
 
 
Figure 6.5  DGGE fingerprint patterns for general bacteria, bifidobacteria and lactobacilli. 
“M” indicates marker lanes on the gel. Between the markers, samples are 
organized as follows: colon ascendens - d14, d35, d49, d54, d61; colon 
transversum - d14, d35, d49, d54, d61; colon descendens - d14, d35, d49, d54, 
d61. Samples d14 were taken during the start-up period, samples d35 and d49 
were taken during the treatment period, whereas samples d54 and d61 were 
taken during the control period. Samples from the ascending colon d54 and 
transverse colon d14 were not taken up in the clustering analysis since the 
amount of loaded PCR product on the gel was too little. 
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Real-time PCR. From the conventional culture based techniques, we observed a 
significant bifidogenic effect upon inulin supplementation. However, this effect was only 
seen in the ascending colon (0.7 log CFU increase). Yet, DGGE analysis showed that 
samples from all colon vessels clustered together during the treatment period. 
Therefore, we used real-time PCR as a cultivation independent method to quantify the 
number of bifidobacteria in samples from all colon compartments at the end of the 
start-up, treatment and control periods. We noted an overall higher bifidobacteria 
concentration with real-time PCR compared to those obtained using conventional 
plating techniques. The real-time PCR data showed a strong bifidogenic effect in all 
three colon vessels (p<0.01), whereas conventional plate count data only showed this 
effect in the ascending colon (Table 6.4). The observed increase in bifidobacteria 
concentrations was not maintained till the end of the control period during which no 
inulin was supplemented (p<0.01). 
 
 
Table 6.4  Bifidobacteria concentrations in the intestinal suspension from the colon 
vessels during start-up (n = 5), 5 weeks of treatment with inulin at doses of 2.5 
g d-1(n = 5) and control period (n = 3) a 
  
Plate count 
(log CFU/mL) 
Real-time PCR 
(log CFU/mL) b 
Asc. Colon Start-up 6.26 ± 0.22 7.45 ± 0.12 
 Treatment  6.93 ± 0.29* 8.05 ± 0.07** 
 Control  5.69± 0.22 7.41 ± 0.04°° 
    
Trans. Colon Start-up 6.83 ± 0.84 7.34 ± 0.16 
 Treatment  6.57 ± 0.24 8.46 ± 0.11** 
 Control  5.57 ± 0.56 7.21 ± 0.02°° 
    
Desc. Colon. Start-up 6.75 ± 0.62 7.14 ± 0.29 
 Treatment  6.75 ± 0.56 8.01 ± 0.08** 
 Control  5.39 ± 0.34 7.60 ± 0.03*°° 
a Data are means ± SD,  
* Significantly different from the start-up period, p ≤ 0.05; ** p ≤ 0.01, ° Significantly different 
from treatment period, p ≤ 0.05; °° p ≤ 0.01 
b Real-time PCR values are averages of 3 replicates 
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Discussion 
In this study, we have shown that inulin may purport not only prebiotic effects 
towards an in vitro cultured microbial community of the human colon, but also that it 
acts as a chemopreventive agent towards the microbial bioactivation of PAHs to 
compounds with estrogenic properties. The latter was evidenced by a lower 
estrogenicity from colon suspensions that were sampled from the SHIME reactor after 
3 weeks of inulin treatment and that had been incubated with benzo(a)pyrene for 72 h. 
The chemopreventive effect from inulin was most apparent from ascending colon 
samples, whereas descending colon samples were not affected by inulin addition. 
These in vitro observations are the first for inulin as inhibitory compound towards PAH 
bioactivation by intestinal microbiota. The chemopreventive effects occurred after three 
weeks of inulin addition to the SHIME reactor at a dose of 2.5 g d-1, which corresponds 
to an equivalent human dose of 5 g d-1. This is a feasible human daily intake and well 
within the range of earlier reports testing the effects of inulin in vitro and in vivo 
Macfarlane et al., 1998; Rao, 2001). Similar inhibitory effects from inulin were 
previously reported for the microbial formation of hazardous heterocyclic aromatic 
amines (HAA), which resulted in a decreased mutagenicity (Shin et al., 2003). The 
chemopreventive effect of inulin can be quite strong as it significantly decreases the 
number of aberrant crypt foci, precursors from adenomas or carcinomas, in the rat 
colon (Reddy et al., 1997; Rowland et al., 1998). The chemopreventive effects from 
inulin towards overall mutagenicity in the colon, or in this study, the bioactivation of 
PAHs, can be explained by the prebiotic properties of inulin in the lumen of the GI 
tract.  
In fact, successful application of inulin as prebiotic agent may have several 
consequences that are all related to health-promoting effects. Prebiotics promote the 
growth of  health-beneficial microbial groups such as Bifidobacteria, thus keeping 
concentrations of bacteriodes, clostridia or coliforms at low levels (Gibson and 
Roberfoid, 1995) by the production of bacteriotoxins (Fooks et al., 1999). Also, the 
promotion of lactic acid producing bacteria in general is beneficial since these 
organisms possess antimutagenic and anticarcinogenic properties (Bodana and Rao, 
1990). As a direct outcome of the stimulation of beneficial microbial groups, the 
increased production of SCFA by colon microbiota and the decreased production of 
ammonia and β-glucuronidase have direct health consequences as will be further 
discussed. An analysis of the prebiotic effects from inulin supplementation in this study 
may help explain the decreased estrogenicity of PAH incubated samples with inulin. 
 141
Chapter 6 
Moreover, the prebiotic effects may be related to the inhibition of hazardous health 
effects when toxic PAH metabolites make contact with the colon epithelium.  
 
Firstly, administration of inulin to the nutrition of the SHIME reactor beneficially 
influenced the fermentation pattern of the colon microbiota towards a more 
saccharolytic environment with a significantly higher SCFA production, more in 
particular propionate and butyrate, and a lower ammonia production (Table 6.2). The 
44% increase in SCFA production in the ascending colon seems uncommon since the 
treatment period entailed a replacement of starch by an equivalent amount of inulin 
and not an addition. The inulin degrading capacity from bifidobacteria would normally 
result in SCFA production levels that are comparable to the start-up period when an 
equivalent amount of starch was added. The additional SCFA production may possibly 
be explained by the additional bifidobacterial biomass, created by the bifidogenic effect 
from inulin. Additionally, other microbial groups in the colon suspension that are used 
to starch breakdown, may ferment alternative carbon sources from the nutrition 
medium to SCFA. This extra SCFA production needs clarification in further research. 
The shift towards propionate and butyrate corresponds to earlier observations by 
Uehara et al. (2001), who supplemented FOS to rats and saw a significant increase in 
concentration for these two SCFA. These observations do not directly point towards 
bifidogenic effects since bifidobacteria are acetate and lactate producers. Maybe other 
microbial groups such as Megasphaera elsdenii or Roseburia sp. can convert lactate 
or acetate to butyrate (Duncan et al., 2002; Hashizume et al., 2003). Similar processes 
in the SHIME reactor may explain the constant lactate and acetate concentrations 
during inulin treatment, whereas specific increases in bifidobacteria concentrations 
were seen. This needs to be addressed in further research. In general, increased 
SCFA synthesis creates a more acidic environment in the gut which is important in vivo 
in terms of colonization resistance against pathogens. Moreover, SCFA are important 
energy sources for the colonocytes and influence colonic function by stimulating water 
and sodium absorption and modulating motility (Cherbut et al., 1997). More 
specifically, butyrate also induces differentiation and together with propionate, it 
stimulates apoptosis of cancerous cells in vitro (Scheppach et al., 1995; Jan et al., 
2002). In relation to the microbial bioactivation of benzo(a)pyrene in this study or for 
example mutagenic HCA formation in other studies (Shin et al., 2003), an increase in 
SCFA production is thus beneficial since it may decrease the risk of cancer 
development in the colon or rectum. Moreover, inulin administration also resulted in a 
significant decrease of ammonia levels in the ascending colon. This is important since 
ammonia can alter the morphology and intermediary metabolism of intestinal cells, 
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increase DNA synthesis and promote tumorigenesis (Ichikawa and Sakata, 1998). 
Lower proteolytic activities are therefore related to health-promoting effects. 
SCFA and lactate analyses are important measures for intestinal metabolism, but 
in this research, they gave no direct information on bifidogenic effects. Therefore, we 
monitored β-galactosidase in the colon suspension of the SHIME reactor, since this 
enzyme is often related to the presence of bifidobacteria (Van Laere et al., 2000). Due 
to a large variability in the measurements, no significant changes in β-galactosidase 
levels were found in the colon compartments during inulin administration. We also 
monitored β-glucuronidase production, since the latter is often associated to hazardous 
processes in the gut. The reason for this is that microbial β-glucuronidase is involved in 
the intestinal hydrolysis of conjugated xenobiotics and may delay the excretion of 
harmful exogenous compounds (Weisburger, 1971). With respect to oral PAH 
exposure, as discussed in this dissertation, this may be important since a decreased β-
glucuronidase production would increase the excretion of phase II PAH metabolites 
from the enterocytes or hepatocytes. However, no significant changes were detected 
in the absence or presence of inulin. Hence, from the metabolic perspective of inulin 
administration, we concluded that inulin administration had beneficial effects towards 
more SCFA production, but no direct evidence of bifidogenic effects was obtained. 
With regards to effects towards the microbial community, Bifidobacteria have a 
nutritional advantage over other intestinal microorganisms due to their β-1,2-
glycosidase activity, allowing them to metabolize FOS compounds from the inulin. 
Significant changes in microbial community composition were only observed after two 
weeks of inulin supplementation whereas metabolic changes were found within days. 
This can be explained by the faster adaptation of a microbial population towards their 
metabolism (RNA-based) than towards their community structure (DNA-based) (Boon 
et al., 2003). Plate count analysis of the microbial community structure revealed that 
bifidogenic effects in the ascending colon vessel and the increase in lactobacilli in the 
other colon vessels only became significant after three weeks of supplementation. This 
shows that the lower dose of 2.5 g d-1 from this study needs to be administered over a 
longer time frame to effectively induce and maintain beneficial effects. Single doses of 
inulin are therefore of no use. Besides the nutritional advantage that bifidobacteria may 
have from inulin over other intestinal microbiota, bifidobacteria together with lactobacilli 
also create a more acidic environment by the production of lactic acid, thus inhibiting 
the excessive growth of pathogens. Plate count data may support this hypothesis by 
the decreased concentration of opportunistic pathogens as E. coli and staphylococci 
(Table 6.3). Comparable inhibitory effects of inulin towards other pathogens as 
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Clostridium difficile were previously described (Macfarlane et al., 1998). The 
bifidogenic effect from inulin was however only observed in the ascending colon 
vessel. Interestingly, the chemopreventive effects of inulin treatment towards PAH 
bioactivation were also most apparent in the proximal colon compartments (Figure 6.3 
and 6.4). This could be explained by the fact that the larger prebiotic effects towards 
bifidobacteria and lactobacilli in this colon compartment also result in a larger 
suppression of hazardous microbial groups such as Bacteriodes, Clostridia or 
coliforms. This would also decrease the number of hazardous metabolic reactions that 
these groups perform, including for instance the hazardous production of estrogenic 
PAH compounds. Moreover, sorption of hazardous compounds by lactic acid 
producing bacteria has been reported by Bolognani et al. (1997), thus reducing the 
mutagenicity in the gastrointestinal tract. Similar sorption phenomena by an increased 
number of Bifidobacteria may have affected the estrogenicity of the PAH incubated 
intestinal suspensions from the SHIME reactor.  
 
Structural analysis of the colon microbiota using PCR-DGGE showed that 
administration of inulin during the treatment period significantly affected Bifidobacteria 
and Lactobacilli populations, whereas the overall microbial community kept relatively 
unchanged (Figure 6.5). Clustering of the Eubacteria DGGE patterns according to the 
colon vessel shows that the SHIME reactor harbours different microbial communities in 
the different colon vessels and that these populations are relatively unaffected by 
inulin. In contrast, clustering of the Bifidobacteria and Lactobacilli DGGE patterns 
showed that samples from the treatment period were grouped together. This confirms 
the data obtained with selective growth media and indicates the selectivity of inulin 
towards these health-promoting bacteria. The sequencing of the more intense DNA 
fragment bands on the DGGE gels pointed towards a previously uncultured 
Bifidobacterium species, B. longum and B. infantis. The latter organisms have been 
described to be beneficially affected by inulin derived substrates (Wang and Gibson, 
1993; Mayer et al., 2003; Hopkis and Macfarlane, 2003) and are also used as 
probiotics. In contrast to the plate count data, the DGGE and sequencing analysis also 
showed that the bifidogenic effect was not restricted to the ascending colon alone, but 
was also visible in the distal colon vessels. To get a more precise idea of the 
bifidogenic effect in the different colon vessels, we used real-time PCR to quantify 
bifidobacteria. 
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In general, the higher bifidobacteria concentrations from real-time PCR analysis 
compared to plate count analysis (Table 6.4) may be explained by the fact that real-
time PCR takes into acount all bifidobacteria including viable but non culturable 
organisms and inactive organisms. The bifidogenic effect of inulin in the SHIME reactor 
was strongly supported by real-time PCR data that showed a more pronounced 
increase in bifidobacteria, not only in the ascending colon vessel, but also in the other 
colon vessels. With conventional plating techniques, no significant bifidogenic effects 
were observed in the distal colon compartments. Analysis of real-time PCR results 
needs to carefully consider that changes in data may be attributed to stimulation of 
bacterial species with different copy number. However, the rrndb (ribosomal RNA 
operon copy number database) (Klapperbach et al., 2001) indicates that the copy 
number of the different bifidobacterial species is fairly constant, 3 or 4. Even if inulin 
promotes the growth of a species with a copy number more than the already present 
bifidobacteria, the difference attributed to this increase in copy number would be 
negligable to the difference of 1 log CFU mL-1 as observed in our study. To our 
knowledge, this is the first report indicating that real-time PCR is a more precise 
method by which more subtle differences in bifidobacteria populations can be 
detected, this in contrast to more variable results from conventional plate count 
techniques. This general bifidogenic effect from inulin did not correspond to the 
specific chemopreventive effect of inulin in the ascending colon. It is possible that an 
increased number of Bifidobacteria is able to successfully decrease PAH bioactivation 
reactions in the ascending colon by the inhibition of hazardous microbial groups. 
However, conditions in the distal colon compartments are less favourable to 
Bifidobacteria due to a higher pH and lower substrate availability. This would decrease 
its inhibitory effect towards pathogens and their associated hazardous metabolic 
activity. 
 
In summary, our study showed beneficial effects from inulin treatment towards 
microbial metabolism and community composition. The inhibition of estrogenic PAH 
metabolite formation in the ascending colon can be considered as beneficial, since this 
would reduce the risks that bioactive PAHs may pose towards the colon epithelium. A 
complete elucidation of how this chemopreventive effect relates to the observed 
prebiotic effects requires further investigation of the responsible microbial groups and 
their associated metabolism. It is however interesting to remember that even at a fairly 
low dose of 2.5 g d-1, significant chemopreventive effects were observed. Additionally, 
benefical metabolic effects were rapidly seen with an increase in SCFA synthesis 
towards butyrate and propionate and a decreased ammonia production. It should be 
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noted though that a prolonged supplementation period is needed to also observe 
beneficial effects at the microbial community level. Moreover, we found that the 
prebiotic effects from inulin were limited to the period of supplementation. In order to 
maintain these prebiotic effects and support the growth of beneficial bacteria, inulin 
should thus be continuously dosed. This study indicates the usefulness of advanced in 
vitro methods that mimick both the proximal as distal region of the colon, this in 
contrast to in vivo studies that often investigate fecal microbiota that are less 
representative of the colon lumen microorganisms. 
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General Discussion and Perspectives 
Relevance of this research 
Importance of soil ingestion in HHRA 
The potential exposure of soil contaminants to human or ecological receptors leads 
to significant health risks or ecological consequences that need careful monitoring in 
risk management processes. As discussed in Chapter 1, the latter are designed to 
remediate any adverse effects where impairment of the environment occurs and to 
minimize potential threats for human health. For human exposure, this necessitates an 
accurate and reliable human health risk assessment study which investigates the 
different exposure routes of the contaminants to the human body and the toxic effects 
of the bioavailable fraction. Human exposure to soil contaminants can be multiple and 
complex comprising several exposure pathways and exposure routes.  
As part of the human health risk assessment process for these contaminated sites, 
exposure to contaminants via ingestion of soil is routinely estimated. Contaminated 
soils constitute a ubiquitous source of environmental pollutants and may be ingested 
as a result of recreation, gardening, consumption of locally grown foods and the 
ingestion of airborne contaminated dust (Swartjes, 2002). Children are normally 
thought to experience the highest risk due to their typical hand-to-mouth behavior 
which often leads to soil ingestion rates of 200, 500 mg and even several g d-1 (van 
Wijnen et al., 1990; Calabrese et al., 1997a; Calabrese et al. 1997b). However, also 
adults, more in particular construction workers, are often exposed to soil contaminants 
via the ingestion exposure route (Stanek et al., 1997). Reported soil ingestion rates for 
adults vary from 1 to 124 mg d-1 (Brunekreef et al., 1987; Calabrese et al., 1990). In 
brief, the default oral exposure factors that are proposed by EPA when performing site-
specific soil screening evaluations are for adults and children 100 and 200 mg d-1 
respectively (EPA, 1997).  
To what extent the ingestion pathway contributes to the actual exposure of the 
human body to soil contaminants, is illustrated in Figure 7.1. Several European 
institutes have developed human exposure models which allow to estimate the extent 
of human exposure to soil contaminants, to predict associated toxicity levels and, if 
applicable, to indicate soil quality standards and e.g. treshold limit values (TLV). 
Comparison of the different models with one another for different model compounds 
reveals that soil ingestion is one of the predominant exposure routes to soil 
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contaminants (Swartjes, 2002). Only for benzene, as model compound for aromatic 
chemicals, direct soil ingestion is insignificant. Yet, the ingestion pathway is still well 
represented with 17% exposure due to crop consumption. Human exposure to soil-
borne cadmium and benzo(a)pyrene, model compounds for heavy metals and PAHs 
respectively, primarily occurs through soil ingestion, whereas soil ingestion (37.2%) for 
atrazine as model compound for pesticides is equally important as crop consumption 
(38%).  
These values indicate the need to perform research on the oral exposure to soil 
contaminants. When carrying out site-specific risk assessment studies, it needs to be 
taken into account that soil ingestion is an important contributor to the total risk from 
contaminated sites. 
Figure 7.1 Contribution of the separate exposure pathways to total exposure of human 
adults to cadmium, atrazine, benzene and benzo(a)pyrene. Values are 
averages from seven European exposure models (%). (Source: Swartjes, 
2002).  soil ingestion ;  crop consumption ;  indoor air inhalation ;  
other exposure pathways 
Benzo(a)pyrene
48.9%
33.8%
0.0%
17.2%
Atrazine
37.2%
38.0%
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Bioavailability processes in oral contaminant exposure 
Carrying out site-specific risk assessment studies to evaluate human health risks 
from contaminated sites requires an evaluation of the hazardous effects of soil 
contaminants when taken up by the human body. Toxicity values of the contaminant as 
such are in many cases available, but they are often based on the external dose of the 
chemical to test animals, rather than the actual internal dose which is generally not 
known. Therefore, the term “absolute bioavailability” is introduced giving a direct link 
between the external dose and the internal dose and indicating the fraction of an orally 
ingested contaminant that reaches systemic circulation. For example, ingestion of 10 
mg Pb will thus result in a 50% bioavailable fraction if 5 mg is taken up in the systemic 
tract. However, these absolute bioavailability values are useless when considering 
ingestion of contaminated matrices. The bioavailable fraction of contaminants in soil is 
generally lower than the contaminants that are used in the toxicity for deriving toxicity 
values.  Hence, the term “relative bioavailability” needs to be introduced which takes 
into account the differences between bioavailability in the soil matrix and bioavailability 
in the toxicity test matrix. Briefly, the relative bioavailability is the ratio between the 
amount of a contaminant reaching systemic circulation when ingested with soil and the 
same amount obtained when ingested in the toxicity experiment (Grøn and Andersen, 
2004). Following from the above example: if 10 mg soil-bound Pb is ingested and the 
relative bioavailability is 20%, then the Pb bioavailability is: 10mg * 50% * 20% = 1mg. 
The current assumption that a soil contaminant has a relative bioavailability factor 
of 100% compared to the toxicity study significantly impacts the outcome of a risk 
assessment. The limited knowledge concerning the gastrointestinal parameters which 
govern the releas of a soil contaminant, respectively the complexation adds to the 
uncertainty of the risk assessment in general. Additionally, the calculated risks and 
deduced soil quality guidelines may be too conservative leading to unrealistically high 
exposure levels which would unnecessarily raise the economical costs associated to 
soil remediation initiatives. Moreover, the current approach does not allow placing 
remediation priority on one contaminated site or another, since the calculated 
exposure dose is always the same (NRC, 2003). Hence, risk assessments of 
contaminated soils would be more accurate when the luminal processes that 
determine the contaminant bioavailability are clarified and better understood. This 
would improve the development of better in vitro methods that allow to study the 
gastrointestinal tract. These methods can then be used in site-specific risk assessment 
studies in which the bioavailable fraction of a toxicant is assessed under relevant 
conditions.  
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Metabolic potency of colon microbiota  
Cancer of the colon is typically a disease of the economically "developed" world. In 
Europe, cancer of the colon and rectum is the second most common cancer for both 
men and women (Ferlay et al., 2000) (Table 7.1). Scientific studies suggest that diet 
plays a significant role in the aetiology of colorectal cancer (Gill and Rowland, 2002; 
WHO, 2002). The colon microbiota are thought to play a fundamental role in the 
general health status of a human subject, both positively e.g. by the production of short 
chain fatty acids (SCFA) which provide energy to colonocytes or by stimulating the 
host’s immune system, but also negatively e.g. by the production of hazardous 
metabolites or colonization of pathogenic bacteria. Especially the involvement of the 
colon microbiota in colorectal cancer by the production of carcinogenic metabolites 
from dietary constituents has been intensively investigated and discussed (Ilett et al. 
1990; Rumney et al. 1993; Gill and Rowland 1998; Hughes and Rowland, 2000; 
Hirayama et al., 2000; Aura et al. 2002; Humblot et al. 2004a). Several enzymes and 
metabolites have been identified that are directly or indirectly related to colorectal 
carcinogenesis (Ilett et al., 1990; McBain and Macfarlane, 1998; Hughes and Rowland, 
2000). Yet, there are only limited data on the potency of the colon microbiota to directly 
bioactivate environmental xenobiotics. If the gut microbiota are able to bioactivate 
chemicals that are normally inactive and if the bioactivated metabolites significantly 
contribute to the total risk of a contaminated sample, this could have consequences for 
current human health risk assessment. Chemicals that are not absorbed in the small 
intestine but that are available to microbial biotransformation may become as yet 
hazardous to the colonocytes in an activated form. This hypothesis requires further 
investigation and is of relevance to the aetiology of colorectal cancer in general.  
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Table 7.1 Incidence of most common cancers in 2000. (Source: Ferlay et al., 2000) 
  Males   Females  
 Rank Cancer New cases 
(thousands) 
Rank Cancer New cases 
(thousands) 
World 1 Lung 902 1 Breast 1050 
 2 Stomach 558 2 Cervix 471 
 3 Prostate 543 3 Colon/rectum 446 
 4 Colon/rectum 499 4 Lung 337 
 5 Liver 398 5 Stomach 318 
Developed 
countries 
1 Lung 471 1 Breast 579 
 2 Prostate 416 2 Colon/rectum 292 
 3 Colon/rectum 319 3 Lung 175 
 4 Stomach 208 4 Stomach 125 
 5 Bladder 164 5 Corpus uteri 114 
Developing 
Countries 
1 Lung 431 1 Breast 471 
 2 Stomach 350 2 Cervix 379 
 3 Liver 325 3 Stomach 193 
 4 Oesophagus 224 4 Lung 162 
 5 Colon/rectum 180 5 Colon/rectum 154 
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Research findings 
The most important findings from this research can be located in two different 
aspects of oral exposure to soil contaminants. The different research chapters and 
most important findings are schematized in Figure 7.2. 
 
I. Firstly, assessing the risks from ingested contaminated soil largely depends on the 
correct measurement of the bioavailable fraction of the compound, whereas the 
toxicity of the compound as such is usually well known. The contaminant release and 
complexation reactions that are part of the bioaccessibility process in the intestinal 
lumen play a decisive role in the bioavailability process, prior to absorption and 
biotransformation, but there is currently no consensus how to measure it.  
 In Chapter 2, a unique comparison study of five in vitro methods of the human 
gastrointestinal tract was conducted to identify the most crucial parameters 
that influence the bioaccessibility of lead in a contaminated soil. 
 In Chapter 3, luminal desorption and complexation processes were studied in 
detail for a PAH contaminated soil. The research conclusions from this chapter, 
together with the knowledge obtained from Chapter 2 give the required 
indications of how to interpret and measure the bioaccessible fraction of 
an ingested contaminant.  
II. Secondly, ingested contaminants that are not transported across the intestinal wall 
may partly become available to intestinal microorganisms. The role of metabolic 
activities of the gut microbiota in relation to cancer has been investigated before, but 
more research is needed to find out to what extent these microbiota can directly 
transform ingested environmental contaminants.  
 In Chapter 4, an analytical method was developed to detect microbial PAH 
metabolites in the complexity of an in vitro cultured intestinal suspension. 
 In Chapter 5, it was shown for the first time that the colon microbiota have 
the potency to convert PAHs to bioactive compounds, more in particular 
metabolites with estrogenic properties. Such processes are as yet not 
considered in risk assessment practice.  
 In Chapter 6, a potential added value of chicory inulin was explored. Inulin 
exerted strong inhibitory effects towards microbial PAH bioactivation 
which opens new perspectives for dealing with ingested contaminants from the 
environment or food. 
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Figure 7.2 Schematic research overview for locating the different research chapters 
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General discussion 
Bioaccessibility: reviewing research data 
The first two research chapters of this dissertation, Chapter 2 and 3 specifically 
dealt with luminal processes of soil-bound contaminants in the in vitro gastrointestinal 
tract and how to obtain bioaccessibility data from these digestions. Chapter 2 
describes the research conducted with BARGE (BioAccessibility Research Group 
Europe). Five in vitro models were used to determine the bioaccessible fraction of soil-
borne lead under fed and fasted conditions. The models were compared against each 
other and it was investigated how well they relate to the oral bioavailability values of 
lead from the same soil, as obtained by Maddaloni et al. (1998). An important 
observation is that under fed conditions, all models yielded bioaccessibility data that 
were significantly higher than the bioavailable fraction. This shows that the generated 
bioaccessibility values are conservative estimators of bioavailability. The 
underestimation of bioavailability of the SHIME, PBET and DIN models under fasted 
conditions is more problematic. The fact that all models except TIM used digestion 
parameters for small children may be a possible explanation for this discrepancy. To 
illustrate, the SHIME model assumes a hypothetical child soil ingestion of 1 g d-1 
leading to low liquid to soil ratios (L/S) of 25. This may hinder the lead mobilization 
from the soil matrix.  
However, a more important feature to remember from Chapter 2 was the general 
difference between fed and fasted bioaccessibility. Although the variability between the 
different models was still fairly high, almost every model showed higher bioaccessibility 
values under fed conditions, this in contrast to the in vivo bioavailability data which 
were lower under fed conditions (2.5% versus 26.2% under fasted conditions). The 
TIM model followed the latter trend and had bioaccessibility values that closely 
approached the in vivo bioavailability results. Also the RIVM method followed the same 
trend, but had bioaccessibility values that were much higher than the in vivo 
bioavailability values. The positive influence of food compounds towards an increase in 
bioaccessibility values was already observed and discussed in the previous 
comparison study from BARGE (Oomen et al., 2002) and it was also proposed by 
Hack and Selenka (1996). It is however in sharp contrast with the observations of 
Maddaloni et al. (1998) and other researchers who found lower contaminant 
bioavailability values under fed conditions (James et al., 1985; Blake et al., 1983). 
Maddaloni et al. (1998) explain this in vivo trend by the fact that nutritional components 
such as calcium, iron, and other cations interact strongly as competitors of Pb uptake 
so that Pb absorption generally increases as dietary levels of these nutrients decrease 
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(Muschak, 1991). However, this explanation specifically refers to the intestinal 
absorption process, whereas in vitro models only simulate luminal processes, not 
intestinal transport nor biotransformation. It is much more likeley that the presence of 
fibres and lipids plays a key role in the release of lead from its soil matrix. The 
difference in bioaccessibility values between models and the influence of fed 
conditions towards contaminant bioaccessibility needs further discussion. 
 
Before addressing bioaccessibility further, a closer look will be taken at some of the 
results of Chapter 3, because additional clues are given here to help elucidate the 
luminal processes to which ingested contaminants are subjected. Here, a PAH 
contaminated soil was subjected to stomach, small intestine and colon conditions and 
the PAH release from the soil matrix was monitored. It was not the purpose of this 
research chapter to calculate the bioaccessible fraction, but to specifically focus on 
typical luminal processes such as contaminant mobilization from a matrix and 
complexation to other compounds in the intestinal suspension. A mathematical model 
was also developed to verify some of the observed trends and thus get a better 
understanding of these effects. Although Chapter 3 dealt with an organic chemical, 
PAH, instead of a metal, Pb, in Chapter 2, a similar effect from food components was 
observed towards the bioaccessible fraction. Adding nutrition to a stomach digest of 
the PAH contaminated soil significantly raised the released PAH fraction with 65% 
compared to fasted conditions without food compounds. The explanation is that 
nutrition contains higher concentrations of organic matter under the form of fibres, 
polysaccharides, fats or other compounds. This organic matter in the gastrointestinal 
solution provides more complexation niches for PAHs in solution as was already 
indicated for other organics by Hack and Selenka (1996) and Oomen et al. (2002). If 
the complexation is considerable, this might affect some of the PAH compounds 
present in soil, by shifting the equilibrium towards desorption from the soil matrix. The 
signifant effects from bile salts towards PAH desorption and complexation confirm 
earlier observations of Oomen et al. (2000).  
An important aspect to remember from Chapter 3 is that the mathematical model 
aided in confirming the modulating effect of food compounds and bile towards PAH 
desorption from the soil matrix and the formation of novel complexes with bile. The 
latter phenomenon occurred with bile as such or bile in combination with organic 
matter (including microbial biomass when present in the colon). The mathematical 
model showed that there is a dual effect from organic compounds in the intestinal 
suspension. On the one hand, desorption of PAHs from the soil matrix may be 
enhanced due to the provision of complexation niches. On the other hand, complexes 
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may be formed that are too large to come into consideration for getting absorbed 
across the intestinal epithelium. This directly affects the bioaccessible fraction of the 
PAH contaminant. It is important to note that the mathematical model was specifically 
developed using parameters from the different digest conditions and the PAH 
contaminated soil. It can thus not be extended to and applied for other situations or 
contaminated sites. 
 
Bioaccessibility: towards a better interpretation 
Bringing together the different observations and conclusions made from Chapter 2 
and 3, we can now try to find an explanation for the differences in bioaccessibility 
values between the different in vitro models and why the TIM model obtained 
bioaccessibility values that were lower under fed than under fasted conditions. Soil-
borne contaminants that enter the gastrointestinal tract will be subjected to various 
mechanical (grinding, kneeding), physico-chemical (dissolution, sorption) and 
enzymatic (protease, amylase…) processes. Microbial interactions are only 
predominant in the colon, and are not considered in this discussion of bioaccessibility. 
The different processes that bring an ingested contaminant from soil-bound to 
bioavailable are depicted in Figure 7.3.  
Upon ingestion of a soil-bound contaminant (i) an equilibrium of sorption and 
mobilization from the soil matrix may partly dissolve the contaminant in the 
gastrointestinal lumen. The freely solubilized contaminant fraction may then interact 
with (ii) particulate organic matter, (iii) dissolved organic matter or (iv) it may be taken 
up in bile salt micelles. Bile salts and even lipids and certain proteins may act as a 
carrier vehicle for apolar and cationic contaminants towards the surface of the 
intestinal epithelium.  
 
Figure 7.3  Processes towards bioavailability of ingested soil-borne contaminants:  
1. bioaccessibity, 2. intestinal absorption, 3. human metabolism. 
 i) contaminant desorption 
ii) interaction with particulate organic matter  
iii) interaction with dissolved organic matter  
iv) uptake in bile salt micelles  
v) biotransformation to conjugated metabolites. 
vi) fraction that passes the liver, vii) uptake in lymph duct.  
viii) interaction with colon microbiota 
 ix) microbial conversion to bioactive metabolites 
 x) microbial deconjugation 
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At the surface of the enterocytes, a micro-acidic environment prevails which 
destabilizes micelles causing fatty acids to release and become available for intestinal 
transport (NRC, 2003). For hydrophobic contaminants specifically, co-transport with 
fatty acids is thus made possible. If absorption takes place, the contaminant may (v) 
undergo biotransformation processes and may be excreted in a conjugated form back 
into the intestinal lumen. Biotransformation takes place in the enterocytes and/or liver, 
the latter may produce conjugates for both biliary as urinary excretion. The 
contaminant fraction that (vi) passes the liver or that is (vii) transported to the lymph 
ducts upon absorption are taken up in the systemic circulation and are bioavailable. 
Hence, the oral bioavailability of a chemical depends on three crucial steps: 1) 
bioaccessibility, 2) intestinal absorption and 3) metabolism by human biotransformation 
enzymes and is calculated as:  
F = FBAcc * FAbs *  FMet  (1) 
 
with F the bioavailable fraction, FBAcc being the bioaccessible fraction, FAbs being 
the fraction absorbed and FMet being the fraction which escapes human metabolism. 
To accurately predict oral bioavailability, it should be assessed what the sensitivity is of 
these 3 factors to matrix effects. Clearly, the metabolism factor FMet is insensitive to 
luminal matrix effects, whereas the bioaccessible fraction FBAcc is highly sensitive since 
matrix effects determine the luminal processes of mobilization, complexation, 
desorption…  From the above description of Figure 7.3, the intestinal absorption FAbs 
can not be influenced by matrix effects since chemicals must be present in a free form 
at the surface of the intestinal epithelium to be considered for absorption. This 
interpretation contrasts the previous assumption that the intestinal absorption process 
is sensitive to matrix effects such as bile salts or organic matter (Hack & Selenka, 
1996; Reynolds et al., 1998; Weber and Lanno; 2001; Grøn and Andersen, 2003). 
Only the chemical form and chemical properties of the contaminant will determine 
whether it is absorbed or not. Absorption is thus clearly separated from the luminal 
matrix effects which are part of the bioaccessibility process. (note: there are some 
exceptions with regards to pinocytosis where particulates may be absorbed. This 
transport process is however less common). 
 
This discussion immediately falls back to the definition of bioaccessibility: 
bioaccessibility describes the fraction of the chemical that desorbs from the soil 
matrix and is available for intestinal absorption (Ruby et al., 1999). Although this 
definition is generally agreed upon, it is remarkable to see that there are so many 
approaches to separate the bioaccessible fraction from the non-bioaccessible fraction: 
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3000×g, 3500×g or 7000×g centrifugation, 0.45µm filtration, 5 kDa ultrafiltration... 
(Ruby et al., 1996; Hack and Selenka, 1996; Oomen et al. 2002; Waisberg et al., 2004; 
Arkbåge et al. 2004). As inferred from the definition, a bioaccessible contaminant is 
available for intestinal absorption. Hence, it should be present as a free compound at 
the surface of the intestinal wall and released from micelles or other complexes. This 
means that a stringent method is needed to separate this fraction. The currently 
applied separation methods of centrifugation, microfiltration, 5 kDa ultrafiltration pertain 
to the different sizes of the carrier-contaminant complex that will be left in the 
supernatant or filtrate (Figure 7.3). The distinction between the different complexes by 
different separation methods in this figure should not be literally interpreted, but merely 
gives an indication of the different fractions that exist. To show that the separation 
method is indeed very crucial, the RIVM institute recently performed experiments in 
which the bioaccessibility of lead from the Bunker Hill soil was measured under fed 
conditions with the same breakfast formulation as the one used in the in vivo study 
from Maddaloni et al. (1998) and that used with the TIM model (Chapter 2). Different 
separation methods were compared to one another and had a significant influence on 
the outcome of the tests (Table 7.2).  
 
Table 7.2  Differences in bioaccessibility of lead in Bunker Hill soil under fed conditions 
depending on the separation method 
Separation method Bioaccessibility (%) 
Centrifugation (3000×g) 31.5 
Microfiltration (0.45 µm) 22 
Ultrafiltration (5 kDa) 3.5 
 
From these data and the previous discussion, it can be concluded that the 
separation method is a crucial parameter to consider when interpreting 
bioaccessibility results. This also has consequences when comparing lead 
bioaccessibility to oral bioavailability data using equation 1. For lead as a heavy metal, 
liver metabolism is not relevant, so a FMet value of 100% is assumed. The intestinal 
transport of lead is inherent to the intestinal epithelium and is a constant, hence 
FAbs=constant. Since the separation method is not part of the digestion process, the 
bioaccessible fraction FBacc should also be a constant under well-defined 
circumstances. Assuming that ultrafiltration is the closest approach to bioaccessibility, 
FBAcc is 3.5% and 7% for the RIVM and TIM method, respectively. Remaining 
differences between the 2 models can be explained by the different digestion 
characteristics. The other (milder) separation methods generate values that 
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overestimate the actual bioaccessible fraction in various degrees, necessitating the 
use of larger correction factors to calculate oral bioavailability. This adds to the 
uncertainty of the risk assessment process. However, it should be kept in mind that 
using more stringent separation methods such as ultrafiltration will also decrease the 
level of conservacy, which is something that needs careful consideration, especially for 
human health risk assessment where safety factors must always be included. 
 
In summary, the different sizes and types of the carrier-contaminant complex that 
are related to different separation methods cause the fundamental difference in the 
current bioaccessibility measurements of chemicals. Besides that, there are still 
methodological differences due to other digestion characteristics between in vitro 
methods of the gastrointestinal tract. The different bioaccessibility data from Chapter 2 
can partially be explained by the difference in the digestion characteristics such as L/S 
ratios, stomach pH, bile content and presence of food compounds (Hack and Selenka, 
1996; Hamel et al., 1998). Further research from BARGE will focus on both digestion 
characteristics as the separation methods, which will allow to give additional 
recommendations to researcher and risk assessers that want to develop a protocol to 
test the bioaccessible fraction of ingested soil contaminants. This will allow to give a 
conservative estimate of the orally bioavailable fraction.  
 
 
Colon microbiota and ingested contaminants 
From Figure 7.3, it can be inferred that a certain amount of ingested chemicals will 
reach the colon region of the human GI tract. This fraction incorporates compounds 
that are not transported across the intestinal epithelium, compounds that are excreted 
by the P-glycoprotein efflux metabolism from the enterocytes and compounds that are 
secreted as conjugated metabolites from biotransformation processes in the 
enterocytes or hepatocytes. Besides this, the colon suspension, or colon chyme, also 
contains undigested food components, plant chemicals, microbial fermentation 
products, microbial metabolites and secreted compounds from the intestinal 
epithelium. Several of these colon chyme constituents may present a health risk by 
exposing the colorectal mucosa with mutagenic compounds in the chyme. To illustrate, 
fecal mutagenicity studies have indicated that environmental rather than genetic 
factors determine the risk of colorectal cancer in a population (reviewed by De Kok and 
van Maanen, 2000). In addition, intestinal microorganisms are significantly associated 
with cancer development both in a negative way by the production of toxic 
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components, as in a positive way by the suppression of hazardous microbial groups 
and the inhibition of (pro-)carcinogen production (reviewed by Hughes and Rowland, 
2000). Within the context of this doctoral research, the importance of studying colon 
processes, both physico-chemical as microbiological, is illustrated by the interaction of 
the colon matrix and colon microbiota with PAHs that reach the colon region.  
 
As toxic effects towards the intestinal epithelium are most probably attributed to 
soluble reactive substances in the intestinal suspension, the aqueous phase of human 
faeces (fecal water) is used to assess the toxicity and genotoxicity of harmful 
substances in the colon chyme (Gill and Rowland, 2002). In this respect, it is important 
to better understand how contaminants in the colon suspension interact with 
substances from the colon matrix. Chapter 3 showed how PAHs in the colon may 
adsorb to microbial biomass, besides the soil matrix, residual food compounds and 
other intestinal components (Figure 7.3 (viii)). These additional complexation sites in 
the colon suspension will affect the fraction of contaminants that is bioaccessible. 
Chapter 3 only addressed some of the complexation processes in the colon 
suspension. Further investigations should therefore focus on actual bioaccessibility 
measurements as outlined in the previous discussion. Such research may be 
particularly interesting when studying the absorption of persistent organic pollutants 
(POP) by the colon wall. Although the lower surface area of the colon epithelium and 
its increased tightness generally lowers colon absorption compared to small intestine 
absorption, it seems that some hydrophobic compounds, such as POPs, are better 
absorbed in the colon region of the GI tract (Ungell et al., 1998). This is important since 
the contact of hazardous compounds with the colon epithelium and subseqent 
absorption may give detrimental health effects. In general, not much research has 
been performed to study the bioavailability of ingested environmental contaminants in 
the colon region. Yet, some results are available from the pharmaceutical sector. 
Certain drugs are unstable under the low pH of the stomach or high enzymatical or bile 
content of the small intestine. Since this sensitivity (partly) decreases their activity, 
there is much interest to specifically deliver drugs to the colon where absorption can 
take place under less stringent conditions (Yokoe et al., 2003; Nykanen et al., 2001). 
The principle of the so called slow-release systems for colon-targeted drug delivery are 
often microbially triggered (Sinha and Kumria, 2003) and allow the intestinal absorption 
of hydrophobic compounds in the colon region of the human GI tract.  
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Where Chapter 3 targeted the complexation of contaminants in the colon region 
and the process towards bioaccessibility, Chapters 4 and 5 addressed the presence of 
bioactive contaminants in colon suspension. The current focus of risk assessment for 
the oral exposure to environmental contaminants lies on the human bioactivation 
processes by cytochrome P450 complexes in enterocytes and hepatocytes. There are 
however many indications that the intestinal microbiota can inactivate or bioactivate a 
wide variety of chemical agents from diet, biliary excretion or microbial metabolites 
(McBain and Macfarlane, 1998). Since it is very much conceivable that the intestinal 
microbiota may purport similar effects towards ingested contaminants, the metabolic 
potency of colon microbiota to convert PAHs to bioactive transformation products was 
assessed (Figure 7.3 (ix)). In Chapter 4, an analytical methodology using LC-MS was 
developed to detect microbial hydroxy-PAH metabolites in the complex colon 
suspension. For these experiments, it was important to consider the interference of the 
chyme matrix background with the analysis of hydroxy-PAHs which may suffer from 
poor limits of detection or low reproducibility. Future research efforts to analyze 
microbial biotransformation products, biliary excreted metabolites or food chemicals in 
the chyme should therefore spend enough time to optimize the chemical analysis 
method and get rid of the background interference. The detection of 1-OH pyrene and 
7-OH benzo(a)pyrene upon incubation of parent PAHs with colon microbiota reveals 
that intestinal microorganisms indeed have a metabolic potency towards organic 
chemicals.  
Moreover, the bioassay experiments conducted in Chapter 5 showed that the 
colon microbiota are able to convert PAHs towards compounds that show an affinity for 
the human estrogen receptor. Although a positive response in the estrogen receptor 
bioassay does not necessarily predict endogenous transcription (Gozgit et al., 2004), 
these microbial bioactivation phenomena may not be neglected. Microbial bioactivation 
is not covered in current risk assessment practice, but it has already been extensively 
discussed when reviewing the relationships between diet and cancer and the role of 
intestinal microorganisms (Ilett et al., 1990; McBaine and Macfarlane, 1998; Hughes 
and Rowland, 2000; Gill and Rowland, 2002). The type of microbial metabolic 
processes are highly diverse and usually reductive (Ilett et al., 1990). Yet, the 
hydroxylation of PAHs as discussed in Chapter 4 and 5 is not an isolated case of 
oxidative reactions. The hydroxylation of IQ to 7-OH IQ by intestinal Eubacterium and 
Clostridium species have been reported several times (Van Tassel et al., 1990; 
Rumney et al., 1993; Kassie et al., 2001) and advanced analytical techniques such as 
Nuclear Magnetic Resonance (NMR) are being used for the identification and isolation 
process of microbial metabolites in the complex matrix of the intestinal suspension 
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(Humblot et al. 2004b; Rabot, 2004). The conclusions from Chapter 5 show that for 
oral exposure to environmental contaminants, further research should focus on the 
microbial bioactivation potency in the intestinal lumen. It should also be assessed to 
what extent microbially bioactivated contaminants may contribute to the total risk that 
environmental contaminants pose towards human health. 
 
From Figure 7.3 (x), it should also be kept in mind that there is an indirect 
bioactivation route of intestinal microorganisms towards contaminants. Conjugated 
metabolites of contaminants can enter the colon lumen as a result of biotransformation 
processes in the enterocytes or in the hepatocytes, followed by secretion into the 
intestinal lumen. These more hydrophilic conjugates are normally not available for 
intestinal absorption allowing them to be removed from the body with the feces. 
However, the colon microbiota possess several enzymes that may deconjugate the 
phase II metabolites, regenerating the more hydrophobic parent compound or phase I 
metabolite which is then again more available to absorption (Gill and Rowland, 2002). 
In this way for instance, bacterial β-glucuronidase activities can hydrolyze 
glucuronidated conjugates and may thus delay the excretion of harmful exogenous 
compounds (Weisburger, 1971). This was also demonstrated by Takada et al. (1982) 
who observed a reduced number of azoxymethane induced tumours in the rat colon 
upon administration of β-glucuronidase inhibitors.  
The microbial bioactivation of ingested PAHs in Chapters 4 and 5 and the indirect 
bioactivation through microbial deconjugation enzymes, indicate the important role of 
the colon microbiota in the generation of toxic compounds. Since such bacterial 
enzymatic activities are often diet related, it would be interesting to modulate the 
bioactivation potency through dietary factors. Several studies have shown that the diet 
strongly modulates the metabolic activity from intestinal microbiota (Hambly et al., 
1997) and changes in the microbial community composition have been observed to 
influence the metabolism of DNA-reactive carcinogens (Chadwick et al., 1992). It has 
been demonstrated that oligosaccharides such as FOS, GOS, or inulin inhibited the 
formation of heterocyclic aromatic amines (HCA) (Shin et al., 2003), while probiotic 
bacteria as dietary supplements exerted detoxifying properties towards hazardous 
chemicals in the GI tract (Rowland et al., 1998).  
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This formed the starting point for the research described in Chapter 6, in which the 
use of native chicory inulin as inhibitory compound for PAH bioactivation was explored. 
The results from the estrogen bioassay showed that inulin administration significantly 
decreased the formation of estrogenic compounds in PAH incubated colon samples, 
specifically in the ascending colon and to a lesser extent also the transverse colon. 
The most important effect from inulin administration towards the microbial community 
was the significant increase in Bifidobacteria, as indicated by plate counts, realtime 
PCR and DGGE. Inulin-type fructans are composed of β-D-fructofuranoses attached 
by β-2Æ1 linkages (Roberfoid, 1999) that can be broken by Bifidobacteria specifically, 
thus giving a nutritional advantage over other microbial groups in the gut (Roberfoid, 
2001). This may suppress microbial groups that are for instance responsible for the 
production of bioactive PAH metabolites, other carcinogens or toxins. This prebiotic 
effect was accompanied by a significant increase in short chain fatty acid production, 
primarily butyrate and propionate and a decrease in ammonia production which can be 
considered as general indicators of a lower incidence of cancer (Jan et al., 2002; 
Scheppach et al., 1995). Additionally, the hazardous β-glucuronidase production was 
significantly decreased by inulin addition which would increase in vivo the excretion of 
PAH conjugates with the fecal material.  
These observations indicate that the prebiotic effect of inulin addition acts on 
several aspects which may all be related to toxic PAH metabolites in the colon. Future 
research should further elucidate which organisms are probably suppressed and it may 
be investigated whether these are also responsible for the production of hazardous 
PAH metabolites. Additionally, other dietary factors and the influence of human age 
and/or physiology towards contaminant bioactivation in general needs to be further 
addressed.  
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In summary of this general discussion, some take home messages can be 
formulated. 
1. In vitro methods of the human GI tract allow mechanistic studies and high-
throughput screenings of many environmental samples in a cost-efficient 
way. This makes bioaccessibility measurements an important tool when 
performing site-specific risk evaluations. 
2. Bioaccessbility measurements always generate conservative estimators 
of the oral bioavailabiltiy, provided that the bioaccessible fraction is 
accurately measured.  
3. The separation method is one of the most crucial parameters to consider 
when interpreting bioaccessibility data and when identifying correction 
factors that relate bioaccessibility to oral bioavailability. Ultrafiltration 
seems to give the closest estimate of the actual bioaccessible fraction, but it 
should be kept in mind that the level of conservacy is lower with more 
stringent separation methods. 
4. Human colon microbiota are able to directly convert PAHs into 
estrogenic metabolites. This direct bioactivation of PAHs by colon 
microbiota has not been observed before and further research should 
investigate what microbial groups are responsible for the conversion and to 
what extent bioactivated PAHs contribute to the total health risk from 
ingested PAHs.  
5. If significant, microbial conversion of ingested contaminants should be 
considered in risk assessment.  
6. Prebiotic inulin has an added-value by its chemopreventive properties 
towards the bioactivation of PAHs. Inulin elicits strong bifidogenic effects 
and further research should focus on which microorganisms are suppressed 
by inulin supplementation and if these are related to the observed 
conversion of PAHs to estrogenic metabolites.  
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Research perspectives 
From the framework of this research – oral exposure to environmental 
contaminants – several future research topics can be identified that are directly or 
indirectly related to human health risk assessment (HHRA). These can be situated in 
the increasing importance and relevance of rapid and adequate screening tests for the  
site-specific risk evaluation of an increasing number of contaminated areas and the 
risk evaluation from new and existing chemicals that are brought on the market and 
reach the environmental compartments. Additionally, the influence of intestinal 
microorganisms on the bioactivation of ingested compounds, both environmental 
contaminants as dietary constituents, is a field of research which is largely unexplored.  
 
Soil contaminants 
The world economy has experienced an exponential increase since the Industrial 
Revolution and in the last couple of decades it has been constantly increasing with 30 
billion € every year, putting it at roughly 43.75 trillion € in 2002 (Nationmaster, 2004). It 
is remarkable that the developed countries, which represent only 18% of the world’s 
population, are responsible for 60% of the world gross domestic product (GDP) (Figure 
7.4).  
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Figure 7.4 Comparison of the global GDP and ecological footprint between developed and 
developing countries. 
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The ecological footprint from the developed countries is a factor 4 larger than that 
from the developing countries and in numerous “developed” regions, the environmental 
buffer capacitiy to adsorb and convert contaminants has been exceeded for several 
decades already. Disturbances in the ecosystem are therefore no longer small and 
quickly restored, but lead to major environmental threats coming from the excessive 
use of the environment as a sink for our pollution and waste streams, thus exceeding 
the environmental capacities to adsorb and convert them. This same capacity for 
contaminant adsorption and conversion can also be allocated to soils.  
Soils are recipients for contaminants from combustion processes, sludge and 
pesticide applications, leakage from industrial sites, landfilling and other waste 
disposal methods (EEA, 1999). In the Europe of the 12 alone, more than 1,500,000 
sites are potentially contaminated (EEA, 1999) (Table 7.3). The majority of these sites 
are located in regions which are heavily industrialized or densely populated. For 
example, in Flanders it is estimated that around 4% of the total surface area is 
potentially contaminated. Moreover, it is assumed that much more areas that are not 
yet registered are also contaminated, since in most countries detailed surveys of soil 
conditions and site-specific risk assessment studies are still in process. The 
remediation costs for those sites that are currently known to have contaminant 
concentrations above the intervention values is estimated to be more than 120 billion 
€, which brings a financial cost of 300 € per European inhabitant for the next 
generation.  
 
Table 7.3 Available data on the number of potentially contaminated sites, for selected 
categories and countries (n.i.: no information). (EEA, 1999) 
 Contaminated sites 
 Identified  
(screening complete) 
Estimated total 
Austria 28000 80000 
Belgium 5528 22500 
Denmark 37000 40000 
Finland 10396 25 000 
France n.i. 800 000 
Germany 202 880 240 000 
Italy 8 873 n.i. 
Netherlands n.i. 120 000 
Sweden 7 000 n.i. 
Switzerland 35000 50000 
United Kingdom n.i. 100000 
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The afore mentioned numbers just include soil contamination from local sources. 
However, diffuse sources also significantly contribute to soil pollution by atmospheric 
deposition of contaminated particles in urban areas (from traffic and industry), farming 
practices (fertilizers and antibiotics), irrigation (wastewater reuse) and pesticide 
treatment. In fact, Western Europe’s anticipated growth in road transport and the 
integration of additional industrial activities in the expanded Europe of 25 countries is 
expected for the next 10 years to increase emission levels of several chemicals such 
as cadmium, mercury, PAH and pesticides, whereas PCB, PCDD, PCDF and lead 
emissions will decrease (Figure 7.4). For example, pesticide application is a major 
diffusive emission source since in many cases less than 5% of the pesticides actually 
reach the soil surface, depending on the weather conditions (Lennartz et al., 1995) and 
the rest is dissipated into the environment. Several reports show that the atmospheric 
deposition of persistent organic pollutants such as PCDF, PCB and PAH is gradually 
increasing over the last century reaching levels for PAHs of 0.07 kg ha-2 yr-1 (Sanders 
et al., 1992; Sanders et al., 1993; Green et al., 2001) which is 1 to 2 orders of 
magnitude lower than the pesticide application in agriculture (1-4 kg ha-2 yr-1). Yet, due 
to their persistence in the environment, this has lead to PAH levels that range between 
0.7 and 40.7 mg kg-1 in urban soils (Mielke et al., 2001) and between 8 and 336 mg kg-
1 in road dust (Menzie et al., 1992).  
 
 
Figure 7.4  Projected percentage changes 1990 to 2010 in emissions of selected 
chemicals (EEA, 1999) 
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Additionally, investigations on the top layer of an alleged non-contaminated site in 
the Black Forest, Germany, revealed PAH soil concentrations between 100 and 500 
µg kg-1 and a leachable PAH fraction of around 0.5 µg L-1 which is higher than the 
European drinking water limit for PAHs (0.2 µg L-1) (Halm and Gratwohl, 2003). It can 
be inferred from these numbers that in the near future, more and more people may 
possibly be exposed to contaminated soils, both in densely populated as more rural 
areas. The importance of human health risk assessment as site-specific assessments 
will therefore only increase. Hence, reliable and accurate high-throughput methods, 
which are also less expensive and less time-consuming than in vivo methods, are 
needed to allow an efficient, fast and accurate site-specific risk assessment.  
 
REACH: registration, evaluation and authorisation of 
chemicals 
The release of manufactured chemical products in the environment by 
anthropogenic activities is ever increasing since 1993 (CEFIC, 2002). Currently, there 
are 20,000 to 70,000 chemical compounds on the European market, many of them 
being hazardous for the environment in general or human health in particular. Several 
of these compounds are not yet completely characterized wih regards to their 
environmental fate and their (eco)toxicity, hence the actual environmental or human 
health risk that they represent is not well known (Figure 7.5).  
Within this scope, the European Union is currently preparing new directives for 
setting up REACH – Registration, Evaluation Authorisation and Restriction of 
Chemicals – a new evaluation system which forces manufacturers and importers of 
chemical compounds to register their products. The endgoal is to better assess the 
impact of chemicals towards public health and the environment. The REACH approach 
thus places a large responsibility with the industry to perform risk assessment studies 
and to comply with the safety standards that are put forward by the EU. Nearly 30,000 
chemical compounds should be documented by the year 2016. To realize the goals of 
the REACH legislation it is of the utmost importance, both practically and scientifically, 
to prioritize which chemicals need to be handled first. The European Chemical Industry 
(CEFIC) and European Center for Ecotoxicology and Toxicology of Chemicals 
(ECETOC) have therefore chosen for a targeted risk assessment approach, improved 
data acquisition, in silico and in vitro methods to evaluate chemicals that will be 
brought onto the market. In parallel, environmental and (eco)toxicological scientists 
and environmental regulators are preparing new recommendations for the OECD in 
setting up new guidelines that make possible a more efficient screening procedure of 
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new chemicals with respect to their Persistent, Bioaccumulative and Toxic properties 
(PBT) (STEP workshop, 2004). It is within this framework that an enormous amount of 
work needs to be undertaken for assessing human health risks from chemicals. With 
regards to human oral exposure, the use of in vitro models would fit in the CEFIC 
strategy of a ‘targeted risk assessment’ which allows faster screening and evaluation. 
Of course, manufactured chemicals are not the only compounds that are hazardous. 
The environment is constantly exposed to a multiplicity of natural compounds and 
compounds that have entered the different environmental compartments by 
anthropogenic activities. 
 
Figure 7.5 Availability of data on 2472 high-production volume chemicals submitted to the 
European Chemicals Bureau (EEA, 1999) 
 
Food contaminants 
Food consumption represents an important pathway for human exposure to 
chemicals from a variety of sources (Dougherty et al., 2000). Not only are there 
chemicals of concern in the natural product (phytoestrogens, plant or animal toxins…), 
there are also hazardous chemicals that are produced during food processing such as 
cooking, broiling or grilling. For instance, the consumption of broiled red meat shows a 
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strong correlation with colon and rectum tumours in particular due to the production of 
potential carcinogens are PAHs and heterocyclic aromatic amines (HCA) during food 
processing (Norat et al., 2002; Murtaugh et al., 2004). Chemicals are also added to 
food for specific technological functions such as food preservation, flavouring or 
colouring. Additionally, chemicals from normal agricultural practice such as pesticides 
or veterinary drugs may be present as residuals in human nutrition. External 
contamination of food by environmental pollutants such as dioxins, PCBs and PAHs 
may be important sources of human exposure. For example, diet is the main source of 
human background exposure to POPs such as PCDD, PCB and HCB 
(hexachlorobenzene) (Schlummer et al. 1998). The best-known example of food 
contamination is probably the presence of PCBs and dioxins in food and livestock 
feedstuffs in Belgium in 1999 and 2000. Given the widespread occurrence or 
production of contaminants in human nutrition and the associated serious health risks, 
prevention of further food contamination must be a national health policy priority in 
every country (Schafer and Kegley, 2002) and efficient procedures should be in place 
to estimate the health risk of food contaminants, taking into account all sources of 
exposure (WHO 2004). Such assessments are based on global toxicological 
evaluations performed by Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) and Joint FAO/WHO Meeting on Pesticide Residues (JMPR) and on 
estimates of exposure to chemicals in the diet. 
As with environmental contaminants, much scientific attention has been payed to 
the metabolization of ingested food contaminants by human biotransformation 
enzymes, whereas many researchers have now pointed out that colon microbiota also 
significantly contribute to the hazardous health effects, for example by the conversion 
of 2-amino-3-methylimidazo[4,5-f] quinoline (IQ) to the mutagenic 7-keto derivative (7-
OHIQ) (Van Tassel et al. 1990; Rumney et al. 1993; Kassie et al. 2001). The intestinal 
microorganisms are generally believed to be strongly involved in the aetiology of 
colorectal cancer not only by the direct conversion of chemicals but also by the 
deconjugation of excreted phase II metabolites in the intestinal lumen (Gill and 
Rowland, 2002). Therefore, the problem of food contaminants and the role of intestinal 
microorganisms in the associated health risks opens several research perspectives 1) 
to further clarify microbial-ecological mechanisms that influence the conversion of food 
chemicals to hazardous metabolites, 2) to identify dietary characteristics that modulate 
these processes and 3) to investigate whether dietary supplements such as prebiotics 
or probiotics may serve as chemopreventive agents as already indicated by Rowland 
et al. (1998). 
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Integrated approach for studying intestinal processes 
To summarize,  the growing awareness of the relationship between general food 
safety, environmental contaminants and human health points out the significance of 
conducting research in the field of human nutrition, gastrointestinal microbiology and 
health relevant biotransformation processes. The recently published global strategy on 
diet, physicial activity and health (WHO, 2004), together with the founding of the 
European Food Safety Authority (EFSA) and the innovation center of the Flemish food 
industry (Flanders’ Food) provides an extra stimulus for the scientific world, 
internationally and nationally, to address human health issues related to general food 
and environmental safety. The demand for demonstrating the safety of a broad group 
of environmental and food chemicals will require a reliable means of assessing 
priorities. It is inconceivable to achieve this by using in-depth toxicological tests and 
costly and time-consuming in vivo methods. Rather, prioritization is much needed and 
should be made possible using high-throughput screening techniques that are still 
reliable with regards to exposure assessment (bioavailability processes) and toxicity 
assessment (biotransformation and toxicity processes). 
This framework provides several research perspectives for the use of in vitro 
models such as the SHIME or other complex models (Minekus et al. 1995) to study the 
GI tract. These studies are quicker and more reproducible than in vivo methods and for 
particular mechanisms, they can be more accurate. Metabolization reactions from 
cultured intestinal microbiota can be studied in a mechanistic way and in much more 
detail. Moreover, the dynamics and metabolism of microbial populations of interest in 
the intestinal lumen can be adequately monitored using a combination of 
physicochemical, microbiological and enzymatical analyses. Further developments in 
the application of non-radiolabelled technology such as nuclear magnetic resonance 
(NMR) spectroscopy, will presumably increase the understanding of toxicokinetics and 
thus improve the process of hazard characterisation (Dybing et al., 2002). In addition, 
molecular fingerprint and quantification techniques such as PCR-DGGE, Fluorescent 
In Situ Hybridization (FISH), realtime PCR and Flow Cytometry now make it possible to 
quantify and characterize an in vitro cultured microbial community in great detail 
(Langendijk et al., 1995; Rigottier-Gois et al., 2003). Moreover, combining in vitro 
digestion technology such as the SHIME with the culture of monolayers of enterocytes 
or colonocytes such as Caco-2 and the culture of mucus secreting HT29 cells opens 
up an additional field of research. It would allow to investigate intestinal transport 
processes (Stein et al., 2000; Oomen et al., 2001), immunological response (Hooper et 
al,. 2001; Cummings et al., 2004), bacterial adhesion to the intestinal epithelium 
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(Drudy et al., 2001; Zarate et al., 2002), and the effects of specific compounds of 
interest at the genetic level of cultured intestinal cells (Granato et al., 2004). 
Additionally, fecal water genotoxicity measurements are possible by Single Cell Gel 
Electrophoresis techniques and are currently investigated with the Comet Assay 
(Venturi et al., 1997; Burns and Rowland, 2004).  
Of course, much attention needs to be payed to the validation of the outcome of in 
vitro studies with in vivo animal studies. Yet, the combination of in vitro gastrointestinal 
digestion technology with cell cultures for measuring host-specific processes allows to 
carry out mechanistic investigations. These can be used to elucidate for example the 
way how intestinal microorganisms interact with the host by producing metabolites, 
adhering to the intestinal epithelium, stimulating immune response and modulating 
carcinogenic effects from dietary or environmental constituents. This will also allow for 
a better interpretation and extrapolation of results to in vivo situations. In this way, a 
combination of novel in vitro techniques with in vivo experiments will provide a better 
understanding of underlying mechanisms in the aetiology of adverse health effects 
from environmental and food contaminants.  
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 SUMMARY 
 
Ingestion is a predominant exposure route for environmental contaminants to enter 
the human body. Common exposure scenarios are the ingestion of contaminated soil 
by small children due to their typical hand-mouth behavior and the direct or indirect 
ingestion of soil and dust particulates by construction workers in contaminated areas. 
Additionally, food consumption is an important exposure pathway by the presence of 
contaminated soil particles on badly cleaned vegetables, the presence of contaminants 
inside the plants due to plant uptake, bioaccumulation of hazardous organic chemicals 
throughout the foodchain or by the production of hazardous compounds during food 
processing. To correctly assess the risks that these ingested chemicals pose towards 
human health, a basic understanding is required of the processes that determine how 
available an ingested chemical is for absorption by the body and the processes that 
determine its possible bioactivation and toxicity. These two aspects of oral uptake of 
environmental contaminants were highlighted in this doctoral research and further 
investigated. 
 
In the first part, processes of bioavailability were investigated. The bioavailability 
process determines what fraction of an ingested contaminant reaches the blood 
compartment. For this, the chemical compound needs desorption from its matrix in the 
gastrointestinal lumen, transport across the intestinal epithelium and passage through 
the liver without being biotransformed and excreted from the body. Although 
pharmacokinetic models and in vivo toxicity studies have generated many useful data 
to elucidate the processes of intestinal absorption and human biotransformation, the 
desorption and complexation processes in the gut lumen are often a black box to risk 
assessers. Therefore, in vitro models of the human gastrointestinal tract have been 
developed which simulate the physicochemical, enzymatic and microbial processes 
occurring in the gut lumen. Studying these luminal processes allow to measure a 
contaminant’s bioaccessibility, which is basically the fraction of the chemical that 
releases from its matrix and becomes available for intestinal absorption. As the 
bioaccessibility process is an important prerequisite to bioavailability, these in vitro 
methods generate a conservative estimator for the bioavailable contaminant fraction, 
which is important to maintain safety factors in risk assessment. Additionally, these 
methods allow a high-throughput, flexible and reproducible screening of many 
samples, which is interesting when conducting site-specific risk assessment studies. 
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Comparison of bioaccessibility data from a lead contaminated soil as generated 
from five European in vitro methods (PBET, DIN, RIVM, SHIME and TIM) of the human 
gastrointestinal tract revealed that a large variability exists between the current 
models, a confirmation of earlier observations where other soil-borne contaminants 
were investigated. Many of the differences could be (partly) explained by the different 
digestion parameters that were applied in a specific in vitro method, such as stomach 
pH, digestion time, the amount of added digestive suspension, what risk group was 
simulated (child, adult)… However, the presence of food compounds had a more 
significant impact on the outcome of the bioaccessibility measurements. Several in 
vitro methods displayed higher bioaccessibility data when fed conditions were 
simulated, whereas the reverse trend was observed from an in vivo study where the 
presence of food compounds lowered the lead bioavailability. Clearly, this brings about 
uncertainty when interpreting the outcome from in vitro bioaccessibility measurements. 
A first clue towards the explanation for this fundamental difference was given by the 
observation that the TIM model, which simulates the human gut in much detail, also 
generated lower bioaccessibility data under fed conditions and that it closely 
approached the in vivo bioavailability of lead. Although the higher complexity of the 
model may explain the more accurate estimates of bioavailability, the most important 
difference of the TIM model with the other in vitro methods is the use of ultrafiltration 
membranes to separate the bioaccessible lead fraction from the intestinal suspension. 
This is a much more stringent method than centrifugation at 3000×g or 0.45 µm 
filtration which are used by the other methods. Ultrafiltration gets rid of larger lead-
complexes which are not available for intestinal absorption. From these data it was 
hypothesized that the presence of food compounds may enhance the release of lead 
from the soil, but that complexation to these food compounds limit the lead 
bioaccessibility.  
To study these release and complexation phenomena in more detail, batch 
experiments according to the principle of the Simulator of the Human Intestinal 
Microbial Ecosystem (SHIME) were conducted on a PAH (polycyclic aromatic 
hydrocarbon) contaminated soil. Although the type of chemical was different, more 
clues were given for elucidating some luminal processes to which ingested 
contaminants are subjected. As expected, specific digestion parameters such as 
stomach pH and liquid to solid ratio influenced the release of PAHs from the soil 
matrix. More importantly, the presence of dissolved and particulate organic matter had 
a dual impact on the soil-borne PAHs. On the one hand, the presence of organic 
matter in the intestinal suspension provides for additional complexation niches, hence 
increasing PAH desorption from the soil. On the other hand, PAH-organic matter 
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complexes limit the fraction of PAHs which is freely available and thus the 
bioaccessibility. These observations were confirmed by data from a mathematical 
model which was developed using standard analogue compounds for PAHs, bile salts 
and organic matter.  
In summary, it can be concluded that in vitro methods of the human gut can be 
used for bioaccessibility measurements only when they reflect as closely as possible 
the digestive parameters of the risk group on a specific contaminated site. Therefore, 
no standard in vitro method exists, but a standard protocol should be developed for 
risk assessers which parameters need to be considered when specific digestion 
experiments need to be performed. This would greatly enhance the predictive power of 
bioaccessibility measurements to the oral bioavailability of ingested contaminants. 
 
In a second part of this doctoral research, the interaction of ingested contaminants 
with in vitro cultured colon microbiota was evaluated using the SHIME method. The 
reason for this is that current risk assessment studies on ingested contaminants 
primarily consider toxification and/or detoxification processes that take place by human 
biotransformation enzymes in the intestine enterocytes or liver hepatocytes. However, 
non-absorbed contaminants or secreted chemical conjugates in the intestinal lumen 
may be transported to the colon region and become available to the vast microbial 
community that resides in the human colon. Thus far, it was not known to what extent 
intestinal microbiota may be able to convert hazardous organic compounds to 
metabolites that are harmless or worse, that possess more toxic properties than the 
parent compound. To study this microbial biotransformation potency, PAHs were 
chosen as model compound, both in pure form as present in a soil matrix.  
Firstly, a LC-MS (liquid chromatography mass spectrometry) method was 
developed and optimized to detect PAH metabolites in colon suspension that was 
sampled from the SHIME and incubated with pure PAH parent compounds. The focus 
was put on hydroxy-PAHs since preliminary experiments with bioassays indicated that 
estrogenic metabolites may be obtained. Several hydroxy-PAH metabolites are known 
for their estrogenic properties. Although the complex nature of the colon suspension 
matrix represented some problems with background interfernce, decent limits of 
detection at ppb level were obtained. Interestingly, analysis of pyrene and 
benzo(a)pyrene incubated colon samples revealed the presence of 1-hydroxypyrene 
and 7-hydroxy benzo(a)pyrene, which is the first analytical evidence that colon 
microbiota are able to convert PAHs without the presence or interference from human 
biotransformation enzymes.  
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Secondly, it was assessed whether these colon suspensions elicited a bioactive 
response in a couple of bioassays. It is known that PAHs as such are not 
estrogenically active. Use of a yeast-based estrogen receptor bioassay revealed that 
colon microbiota were indeed able to convert PAHs to metabolites with estrogenic 
properties. Zero-response data from stomach and small intestine incubated samples 
showed that this microbial bioactivation potency was colon-specific. Moreover, the 
observed estrogenicity was not merely a matrix effect, since inactivation of the colon 
microbiota also took away the estrogenicity of incubated samples. More importantly, 
analysis of PAH contaminated soil indicated that this bioactivation also occurs at 
environmentally relevant concentrations. Further research should focus to what extent 
the bioactive PAHmetabolites contribute to the total risk from ingested PAHs, but 
clearly, absorption of bioactive PAH metabolites may present hazards to both the colon 
and rectum and thus present a health risk that should be taken into consideration. 
Finally, it was investigated whether addition of native chicory inulin could inhibit the 
extent of microbial PAH bioactivation reactions. Inulin is generally agreed to exert 
prebiotic effects as it stimulates health-promoting bacteria in the human gut such as 
Bifidobacteria or Lactobacilli. However, it is also hypothesized that it may exert 
chemopreventive effects by the indirect suppression of microbial groups such as 
certain pathogens that may be responsible for the hazardous conversion of ingested 
chemicals, such as PAHs. Supplementation of inulin during several weeks to a full-
scale SHIME reactor had significant inhibitory effects towards PAH bioactivation to 
estrogenic metabolites, especially in the proximal colon compartments. Interestingly, 
the strongest prebiotic effects were also observed in this region of the colon, indicating 
an indirect relationship with the chemopreventive effects from inulin. This added-value 
aspect of inulin as prebiotic and probably other prebiotics needs further elucidation, for 
example by the identification of the microbial groups that are responsible for the PAH 
bioactivation and those microbial groups that are suppressed during inulin addtion. 
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Ingestie is een belangrijke blootstellingroute waarlangs milieucontaminanten het 
menselijke lichaam binnentreden. Veel voorkomende blootstellingwegen zijn de 
ingestie van gecontamineerde bodem door kinderen via hun typisch hand-mond 
gedrag en de directe of indirecte ingestie van bodem- en stofdeeltjes door arbeiders in 
vervuilde gebieden. Daarbij vormt voedselconsumptie eveneens een belangrijke 
blootstellingweg door de aanwezigheid van vervuilde bodemdeeltjes op slecht 
gereinigde groenten, de opname van contaminanten door de plant zelf, bioaccumulatie 
van organische contaminanten doorheen de voedselketen en de productie van risico-
houdende componenten tijdens de voedselbereiding. Het juist inschatten van de 
risico’s die oraal opgenomen componenten inhouden voor de menselijke gezondheid, 
vergt een basiskennis over deze processen die bepalen hoe beschikbaar een stof is 
voor absorptie door het lichaam en de processen die een eventuele bioactivatie en 
toxiciteit veroorzaken. Deze twee aspecten van orale opname van 
milieucontaminanten werden in dit doctoraal onderzoek toegelicht en verder 
onderzocht. 
 
In een eerste deel werden processen van biobeschikbaarheid bestudeerd. 
Biobeschikbaarheid bepaalt welke fractie van een ingeslikte contaminant de bloedbaan 
bereikt. Hiervoor moet de component eerst vrijgesteld worden van zijn matrix in het 
maag-darm kanaal, getransporteerd worden doorheen het intestinaal epithelium en de 
lever passeren zonder te worden gebiotransformeerd wat kan leiden tot excretie uit het 
lichaam. Niettegenstaande farmacokinetische modellen en in vivo toxiciteitstudies zeer 
bruikbare informatie opleveren voor het ophelderen van processen van intestinale 
absorptie en menselijke biotransformatie, zijn de desorptie- en complexatieprocessen 
in het darmlumen momenteel niet goed gekend bij risico-evaluatie. Daarom werden in 
vitro methodes ontwikkeld die de physicochemische, enzymatische en microbiële 
processen van het menselijke spijsverteringskanaal nabootsen. Het bestuderen van 
deze luminale processen laat toe om de “biotoegankelijkheid” van een contaminant te 
meten, wat in principe de fractie is die in het lumen vrijgesteld wordt van de matrix en 
die beschikbaar is voor intestinaal transport. Aangezien biotoegankelijkheid een 
belangrijke voorwaarde vormt voor biobeschikbaarheid, leveren deze in vitro methodes 
een inschatting op van de biobeschikbare fractie met een veiligheidsmarge, wat 
belangrijk is voor risico-evaluatie. Daarenboven kunnen met deze methodes vrij veel 
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stalen op een snelle, flexibele en reproduceerbare wijze gescreend worden, wat 
interessant is voor plaats-specificieke risico-evaluatiestudies.  
Vergelijking van de biotoegankelijkheidswaarden van een lood-gecontamineerde 
bodem die bekomen werden met vijf Europese in vitro methodes (PBET, DIN, RIVM, 
SHIME en TIM) van het menselijke spijsverteringskanaal, toonden aan dat er een 
grote variabiliteit bestond tussen de verschillende modellen. Dit is een bevestiging van 
vorige studies waarbij andere bodemcontaminanten werden bestudeerd. Veel van de 
verschillen konden (gedeeltelijk) verklaard worden door de verschillende 
digestieparameters die werden toegepast voor een specifieke in vitro methode, zoals 
de maag pH, digestietijd, de hoeveelheid verteringsuspensie of de risicogroep (kind, 
volwassene) die wordt bestudeerd. De aanwezigheid van voedingscomponenten bleek 
echter een meer significante impact te hebben op de biotoegankelijkheid. 
Verschillende in vitro methodes gaven hogere waarden aan indien gevoede 
omstandigheden werden gesimuleerd, dit in tegenstelling tot een in vivo studie op 
dezelfde bodem waar de gevoede omstandigheden leidden tot lagere 
biobeschikbaarheidswaarden. Deze bevindingen brengen onzekerheid teweeg bij de 
interpretatie van in vitro resultaten. Een eerste indicatie om dit fundamentele verschil 
te verklaren werd geleverd door het TIM model dat het maag-darm kanaal vrij 
gedetailleerd nabootst. Hierbij werd vastgesteld dat gevoede omstandigheden 
resulteerden in een lagere biotoegankelijkheid, net zoals de in vivo 
biobeschikbaarheid. Niettegenstaande de hogere graad van complexiteit een 
verklaring kan zijn voor de meer accurate inschattingen van het TIM model, is het 
belangrijkste verschil met de andere modellen de methode die gebruikt worden om de 
biotoegankelijke fractie af te scheiden, nl. ultrafiltratie. Dit is een veel strengere 
methode dan centrifugatie bij 3000×g of 0.45 µm filtratie die bij de andere modellen 
worden gebruikt. Ultrafiltratie houdt geen rekening met complexen van lood met 
organisch materiaal die niet beschikbaar zijn voor intestinaal transport. Uit deze 
resultaten werd besloten dat de aanwezigheid van voedingscomponenten de 
vrijstelling van lood uit de bodem kan verhogen, maar dat complexatie met deze 
voedseldeeltjes de biotoegankelijkheid van lood limiteren. 
Om deze vrijstelling- en complexatieprocessen in meer detail te bestuderen 
werden batchexperimenten volgens het principe van de Simulator van het Humaan 
Intestinaal Microbieel Ecosysteem (SHIME) uitgevoerd op een PAK (polycyclisch 
aromatische koolwaterstoffen) gecontamineerde bodem van een voormalig 
recreatiegebied. Zoals verwacht waren specifieke digestieparameters zoals de maag 
pH van invloed op de PAK vrijstelling uit de bodemmatrix. Heel belangrijk was de 
waarneming dat opgelost en particulair organisch materiaal een tweeledig effect had 
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op de PAKs. Aan de ene kant, vormt organisch materiaal in de intestinale suspensie 
een bron van complexatieniches, waardoor PAK desorptie in de hand wordt gewerkt. 
Langs de andere kant beperken complexen van PAKs met organisch materiaal de 
fractie die vrij in oplossing is en dus ook de biotoegankelijke fractie. Dit werd bevestigd 
door een wiskundig model dat ontwikkeld werd met behulp van 
standaardcomponenten voor PAKs, galzouten en organisch materiaal.  
Samenvattend kan worden besloten dat in vitro methoden voor het menselijke 
maag-darm kanaal enkel gebruikt kunnen worden voor biotoegankelijkheidsmetingen 
indien de digestieparameters zo nauwkeurig mogelijk deze van de risico-groep 
benaderen bij de beoordeling van een gecontamineerde site. Er is dus geen 
standaardmethode voorhanden. Wel kan een standaardprotocol worden opgesteld 
waar risico-inschatters zich aan kunnen houden om te weten welke parameters en 
welke types van digestie-experimenten moeten worden uitgevoerd. Dit zal de 
voorspellende kracht voor biobeschikbaarheidsmetingen voor ingeslikte contaminanten 
sterk verhogen. 
 
In een tweede deel van dit doctoraal onderzoek, werd de interactie van oraal 
opgenomen contaminanten met in vitro gecultiveerde colon microbiota bestudeerd via 
de SHIME methode. Huidige risico-evaluatiestudies houden momenteel voornamelijk 
rekening met toxificatie en/of detoxificatieprocessen die plaatsvinden in de enterocyten 
of hepatocyten door menselijke biotransformatie enzymes. Niet-geabsorbeerde 
contaminanten of gesecreteerde conjugaten ervan in het darmlumen kunnen echter 
getransporteerd worden naar de colon en beschikbaar komen voor de enorme 
microbiële gemeenschap die in de colon verblijft. Tot hier toe was het niet bekend in 
welke mate intestinale microbiota in staat zijn om schadelijke organische componenten 
om te vormen tot metabolieten die in het ergste geval toxischer zijn dan de 
moedercomponent. Om deze microbiële biotransformatie capaciteit te onderzoeken, 
werden PAKs als modelcomponenten gebruikt, zowel in pure vorm als in een 
bodemmatrix. 
Eerst en vooral werd een LC-MS (liquid chromatography mass spectrometry) 
methode ontwikkeld en geoptimalizeerd om PAK metabolieten te detecteren in 
colonsuspensie van de SHIME reactor die werd geïncubeerd met zuivere PAKs. De 
focus werd gelegd op gehydroxyleerde metabolieten, vermits preliminaire 
experimenten aantoonden dat mogelijk estrogene componenten werden verkregen. 
Verschillende hydroxy-PAK metabolieten zijn bekend voor hun estrogene 
eigenschappen. De complexiteit van de colonmatrix leverde aanvankelijk problemen 
met achtergrondinterferentie, maar toch werden detectielimieten op ppb-niveau 
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bereikt. Opmerkelijk was dat pyreen en benzo(a)pyreen geïncubeerde colonstalen 
aanleiding gaven tot de detectie van 1-hydroxypyreen en 7-hydroxy benzo(a)pyreen, 
wat meteen het eerste analytische bewijs vormde dat colon microbiota in staat zijn om 
PAKs om te vormen zonder dat daarvoor menselijke biotransformatie enzymes nodig 
waren. 
Vervolgens werd er nagegaan of PAK geïncubeerde colon suspensies een 
bioactieve respons gaven in een aantal bioassays. PAKs op zich zijn niet estrogeen 
actief, maar gebuik van de de estrogene receptor bioassay toonde aan dat 
colonmicrobiota inderdaad in staat waren om PAKs om te vormen tot metabolieten met 
estrogene eigenschappen. Deze omzetting was colonspecifiek aangezien 
geïncubeerde maag- en dunne darmstalen geen positieve respons gaven in de 
estrogene test. De waargenomen estrogeniciteit was ook niet afkomstig van matrix 
effecten, aangezien inactivatie van de colonmicrobiota geen aanleiding gaf tot stalen 
met estrogene eigenschappen. Meer nog, analyse van de PAK gecontamineerde 
bodem toonde aan dat deze bioactivatie ook optreedt bij milieu-relevante 
concentraties. Verder onderzoek moet uitwijzen in welke mate deze bioactieve PAK 
metabolieten bijdragen tot het totale risico van de oraal opgenomen PAKs. Het is 
echter duidelijk dat absorptie van bioactieve PAKs in het colon of rectum een risico 
vormt naar de gezondheid toe. 
Tenslotte werd onderzocht of toediening van inuline de graad van microbiële PAK 
biotransformaties kon verminderen. Inuline wordt algemeen aangenomen prebiotische 
effecten uit te oefenen door het stimuleren van gezondheidsbevorderende bacteriën, 
zoals Bifidobacteria of Lactobacilli, in de darm. Er wordt echter ook gesteld dat het een 
chemopreventieve werking heeft door de indirecte onderdrukking van microbiële 
groepen, bv. pathogenen, die verantwoordelijk zijn voor de schadelijke omzettingen 
van PAKs. Toevoegen van inuline gedurende een aantal weken aan de SHIME reactor 
had een significant inhiberend effect naar de PAK bioactivatie tot estrogene 
componenten toe, vooral in de proximale coloncompartimenten van de SHIME. Een 
interessante vaststelling was dat de sterkste prebiotische effecten ook in deze regio 
van de colon werden waargenomen, wat wijst op een indirect verband met de 
chemopreventieve effecten van inuline. Deze toegevoegde waarde van inuline als 
prebioticum en tevens van andere prebiotische producten moeten verder bestudeerd 
worden. Verder onderzoek kan uitwijzen welke microbiële groepen worden onderdrukt 
door inuline en of deze eveneens verantwoordelijk zijn voor schadelijke 
omzettingsprocessen in het colon.  
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